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Abstract 
The Tensins are a family of intracellular cytoskeleton-interacting proteins that 
are involved in the regulation of cell motility and migration. Downregulation of 
Tensins has been observed in several cancers, indicating that it may be 
advantageous for tumour progression. In this study, an epigenetic basis for the 
observed downregulation of Tensin3 in human renal cell carcinoma (RCC) has 
been investigated, specifically the methylation state of the TNS3 gene promoter. 
The aims of this study were to: 1. Identify and validate a functional promoter for 
the human TNS3 gene that contains a CpG island within it; 2. quantify the 
methylation level of this region in RCC; 3. determine whether expression of 
Tensin3 could be altered through DNA demethylation treatment.  
Bioinformatic analysis revealed there to be a putative promoter for the human 
TNS3 gene, housing an 826-bp CpG island. A luciferase reporter assay 
demonstrated a functional minimal promoter activity for a 2000 bp sequence 
containing this island. For quantification of methylation in the TNS3 promoter, 
genomic DNA from RCC patients (tumour and adjacent non-tumour) and a 
normal control group were analysed by bisulphite conversion followed by 
pyrosequencing analysis. This enabled quantitative determination of DNA 
methylation of individual CpG dinucleotides within the TNS3 gene promoter, out 
of a total of 43 analysed. Across the entire CpG stretch, RCC DNA showed 
significantly higher methylation level than non-tumour kidney DNA and normal 
control DNA (tumour n=12, non-tumour n=3; normal n=12; P<0.01, tumour vs. 
non-tumour; P<0.0001, tumour vs. normal). Out of the CpGs analysed, two CpG 
dinucleotides, CpGs 2 and 8, showed the most pronounced increases in 
methylation in tumour samples (P<0.0001). Furthermore, CpG 2 methylation 
negatively correlated with Tensin3 gene expression levels in RCC samples 
(P<0.005). In addition, pharmacological demethylation of cultured HK2 kidney 
cells with 5-aza-2’deoxycytidine caused a threefold upregulation of Tensin3 
expression as measured by qRT-PCR. In conclusion, these results reveal a 
differential methylation pattern in the TNS3 promoter region occurring in human 
RCC, suggesting at least in part an epigenetic basis for the observed aberrant 
downregulation of Tensin3 in this disease.   
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Introduction 
1.1. Kidney cancer 
1.1.1 Overview of cancer 
The word “tumour” is usually associated with malignant tumours; however it 
also includes benign tumours, both of which are characterised by abnormal cell 
growth. The term “cancer” is usually ascribed to malignant tumours, which are 
characterised by unrestricted cell growth and the possibility of metastasis. A 
problematic issue with use of the term “cancer” is that it is not one single 
disease, as is often viewed by the public, but a collection of over 100 diseases 
(1). However, despite the great diversity in clinical cancer types, 6 defining 
features common to most, if not all, cancers have been identified, even if these 
are acquired through different mechanisms (Fig. 1) (2).  
 
Fig. 1: The six hallmarks of cancer. Most if not all cancers acquire these traits even if they 
develop them through different mechanisms/mutations (2).  
 
21 
 
The 6 hallmarks of cancer are important features that a cells needs to acquire to 
become cancerous these are: 1. Self-sufficiency in growth signals; a normal cell 
will require external signals, for example from growth factors, in order to divide, 
however cancer cells will not be dependent on these, as they will have acquired 
mutations enabling them to bypass growth factor pathways and thereby grow 
unregulated. 2. Cancerous cells also need to be become insensitive to anti-
growth signals; normal cells will respond to inhibitory signals that prevent them 
dividing randomly. Cancer cells on the other hand, harbour mutations that may 
prevent these signals from being recognised. 3. Cancer cells will also avoid 
apoptotic pathways, as a normal cell that has acquired mutations should 
undergo apoptosis. 4. As cancer cells can grow large in size, they require the 
ability to grow new blood vessels through angiogenesis; whereas in normal cells 
this is required for a supply of oxygen and nutrients, cancer cells require these 
to expand and then survive in their new environment. 5. Cancerous cells also 
require the ability to replicate unlimitedly; a normal cell has a limit on the 
number of times it can replicate, after which it will become senescent due to 
shorting of telomeres located at the end of chromosomes; this occurs at the end 
of each round of DNA replication. However, cancer cells can acquire the ability 
to maintain the ends of the telomeres which will allow them to replicate an 
unlimited number of times. 6. Cancer cells also develop the ability to migrate, 
which allows them to become invasive and metastasise; a mature normal cell 
however does not normally migrate. Cancer cells develop mutations which will 
allow them to excrete enzymes which are involved in the breakdown of the 
extracellular matrix and cell-cell adhesions (1). Once metastasis occurs, it 
becomes difficult to treat and is therefore a major cause of cancer deaths.  
Cancer is the leading cause of death in the UK, with 157,275 deaths from all 
cancer types reported for 2010, with lung cancer making up 22% of this (3). In 
2010, there were 9,639 new cases and 4,062 deaths from kidney cancer; at the 
time these statistics were reported, only approximately 51% of males and 55% 
of female survived for 5 years or more (4).  
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1.1.2 The human kidney 
In humans, kidneys are usually found in a pair, located above the waist between 
the peritoneum and posterior wall of the abdomen. Normally, an adult kidney 
would be 10-12 cm long, 5-7 cm wide and 3 cm thick, and with a mass between 
135-150 g.  
 
Fig. 2: The normal kidney. The kidneys are usually found in a pair and are located above the 
waist in the abdomen A. Diagram of the kidney structure labelled with the main structures. B. A 
human kidney, showing the same view also labelled with the main structures (5).  
The kidney is covered in three layers of tissue: the renal capsule, which helps 
maintain the shape and is a barrier against trauma; an adipose capsule, which 
is a fatty layer above the renal capsule that connects the kidney to the 
abdominal cavity and keeps it in place; followed by the renal fascia, which 
anchors the kidney to the abdominal wall.  
Internally, the kidney has two main sections, the renal cortex and the renal 
medulla (Fig. 2). Within the medulla there are structures called renal pyramids 
which, together with the cortex, form the parenchyma that makes up the 
functional portion of the kidney containing the nephrons.  
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Fig 3: The nephrons of the kidney. The nephrons are the functional unit of kidney. Each 
nephron consists of two parts: a renal corpuscle, where blood is filtered and a renal tubule 
where this fluid then passes. The renal tubule consists of the proximal convoluted tubule, loop 
of Henle and the distal convoluted tubule. Each kidney will have approximately 1 million 
nephrons (6).  
Fig 4: The cells that make up the glomerulus. These include mesangial cells which are 
specialised pericytes that reduce the glomerular surface area and therefore the filtration rate; 
the endothelium cells contain fenestrae (pores) these allow for movement of fluids and protein. 
The foot processes control the movement of proteins from the capillary lumen into Bowman's 
space. The glomerulus is a functional part of the nephron (7).  
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The kidney has many functions including:  
 Excretion of wastes and foreign substances including: 
o metabolites from diet, drugs and toxins 
o ammonia and urea from deamination of amino acids 
o Bilirubin from catabolism of haemoglobin 
o creatinine from the breakdown of creatine phosphate in muscle fibres 
o uric acid from the catabolism of nucleic acids 
 Regulation of blood ionic composition for example, sodium, potassium, 
calcium, chloride and bicarbonate ions.  
 Regulation of blood pH by excreting hydrogen ions and retaining 
bicarbonate ions.  
 Regulation of blood volume and thereby blood pressure.  
 Maintenance of blood osmolarity by regulating the loss of water solutes 
 Production of hormones such as calcitriol (vitamin D3), which helps to 
regulate calcium homeostasis, and erythropoietin, which stimulates red 
blood cell production (6).  
 
1.1.3 Kidney cancer 
1.1.3.1. Incidence and aetiology 
In the United States, 64,770 new cases of renal cancer were predicted to occur 
in 2012, causing an estimated 13,570 deaths (8). Under the umbrella term 
“kidney cancer”, and included in the statistics above, include: renal cell 
carcinoma (RCC), renal pelvis tumours and Wilm’s tumour (a childhood tumour 
type) (9). RCC is the most common kidney cancer, accounting for 
approximately 90%, followed by Wilms' tumour and pelvic tumours accounting 
for 8% (7, 9, 10).  
The incidence of RCC varies depending on location and race; being highest in 
Europe, North America and Australia but lowest in Asia and Africa. Interestingly, 
in the USA, African Americans form the highest risk group for kidney cancer. 
However, it is unclear as to whether this difference is due to racial (genetic 
background) or socioeconomic differences, including differences from the 
general population in frequency of diagnostic imaging, access to healthcare, 
lifestyle or environmental risk factors (10).  
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The gender ratio for RCC is approximately 2:1 male over female (11), while the 
incidence increases with age until 70-75 years, occurring most often in elder 
patients between 60-80 years of age (7, 10). The vast majority of RCC cases 
are sporadic, with heredity RCC accounting for approximately 3-5% of cases 
(12).  
 
1.1.3.1.1 Symptoms and survival  
The majority of cases are asymptomatic until the later stages of disease, and as 
a result, about 20-30% of diagnosed patients present with metastatic disease 
(10). Symptoms can include: pain (back pain and/or abdominal pain), abdominal 
swelling, weight loss and haematuria (9, 13). RCC of all types are graded based 
on the tumour node metastasis model (TNM) (Table 1).  
Table 1. The TNM grading classifications for RCC (12). This is the most common grading type 
in use.  
Primary 
Tumour 
Description 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour 7 cm or less and limited to the kidney 
T1a Tumour 4 cm or less in greatest dimension, limited to the kidney 
T1b Tumour more than 4 cm but less than 7 cm in greatest dimension and limited to the 
kidney 
T2 Tumour greater than 7 cm 
T2a Tumour no more than 7 cm but less than or equal to 10 cm in greatest dimension, 
limited to the kidney 
T2b Tumour more than 10 cm, limited to the kidney  
T3 Tumour extends into major veins/adrenals/perinephric tissue; not beyond Gerota's 
fascia 
T3a Tumour invades into perinephric tissue, renal sinus or renal vein 
T3b Tumour extends into renal vein(s) or vena cava below diaphragm 
T3c Tumour extends into vena cava or into wall of vane cava at any level 
T4  Tumour invades beyond Gerota’s fascia or directly into adrenal gland 
N- Regional Lymph Nodes  
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single regional lymph node 
N2 Metastasis in more than one regional lymph node 
M- Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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The TNM staging is the most commonly used system. It classifies the tumours 
based on how large they are (T), on whether they have spread to the lymph 
nodes (N), and finally whether they have distant metastasis (M). A larger 
number assigned means a worse prognosis (12). The TNM can be further 
simplified into stages based on grouping the sections (Table 2).  
Table 2: Anatomic Staging System/Prognostic Group, the majority of the survival statistics are 
based on this grading (12) 
Anatomic Stage Prognostic Group 
Stage 1 T1, N0, M0 
Stage 2 T2, N0, M0 
Stage 3 T1 or T2, N1, M0            T3, N0 or N1, M0 
Stage 4 T4, any N, M0              Any T, any N, M1 
 
This system allows for easier comparisons between the groups, particularly for 
calculating survival rates, the higher the stage the worse the prognosis, with the 
higher stages having larger tumours which most often have metastasised. 
There is another system, the Fuhrman grading system, is however this most 
applicable to clear cell RCC (ccRCC), and is usually used when correlating to 
prognosis (Table 3). It has been found that nuclear grade was the most 
important in predicting development of metastasis after nephrectomy. This 
grading system is based on the nuclear size, irregularity and nucleolar 
prominence. However, as this system is based on histology, and there can 
therefore be discrepancies between different laboratories (14).  
 
Table 3: The Fuhrman Grading System. This is an older system, which is still in use but often 
alongside the TNM system. 
Grade Description 
Grade 1 Nuclei of the tumour cells are small (<10 µm), hyperchromatic and round 
Grade 2 Nuclei of the tumour cells are slightly larger (15 µm) with finely granular “open” chromatin 
but small inconspicuous nucleoli 
Grade 3 Nuclei of tumour cells are larger (20 µm) and maybe oval in shape with coarsely granular 
chromatin. The nucleoli are easily recognisable  
Grade 4 The nuclei are pleomorphic with open chromatin or hyperchromatic and single or multiple 
macronucleoli 
 
Both systems are commonly in use together for clinical work-ups as they have 
value in prognosis and therapy (15).  
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The 5-year survival rates are: 91% for stage 1, 74% for stage 2, 67% for stage 3 
and 32% for stage 4 (16). As the prognosis for advanced stage disease is and 
remains poor, there is therefore a need to identify novel, more specific, 
molecular markers for each RCC type that can direct more specific and targeted 
therapies.  
 
1.1.3.1.2. Lifestyle risk factors associated with RCC 
Despite research into the risk factors associated with RCC, these are still poorly 
understood. Nevertheless, cigarette smoking and obesity are the two most 
established lifestyle risk factors (10). The link between cigarette smoking and 
RCC has been analysed in a number of studies. Meta-analysis which compared 
many of these studies showed that there was a weak but dose-dependent 
relationship. However, cessation of smoking only appeared to be protective in 
men and was not observed in studies that included women (17). The 
association between RCC and obesity has also been studied; meta-analysis 
showed that a 5kg/m2 in body mass index (BMI) was strongly associated with 
renal cancer in both men and women. Moreover, the association with increase 
in BMI was stronger in women than it was in men (18). Other lifestyle risk 
factors include hypertension and/or the use of anti-hypertensive medication, it is 
very hard to distinguish between the two factors. However, limited data 
indicates that it is the hypertension that is the true risk factor, suggesting that 
better management would reduce the risk (10). Another identified RCC risk 
factor exists in patients with chronic renal failure, particularly those undergoing 
long-term dialysis (7, 9, 11).  
 
1.1.3.2. Classification of RCC and the genetics involved  
RCC accounts for approximately 80-90% of all renal cancers, which can be 
furthered subdivided into: clear cell RCC (ccRCC, 75%), papillary RCC (pRCC, 
15%) and chromophobe RCC (5%) (Fig. 5). Approximately 70% of ccRCC have 
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a mutational defect in the von Hippel-Lindau (VHL) tumour suppressor gene, 
which removes its influence. Of particular note, an extra 13% of VHL-disrupted 
RCC tumours have been shown to have alterations in VHL through 
hypermethylation in the promoter region (19). pRCC, on the other hand, 
commonly have defects in the MET proto-oncogene, where it is overexpressed 
or overactivated (20). Since the discovery of VHL and its role in RCC, 
thousands of other genes have been assessed for frequent mutations in RCC, 
although none of those identified are mutated in more than 15% of tumours. 
However, more than 60 genes have been shown to be epigenetically 
dysregulated in RCC (21).  
 
Fig. 5: The histology of the different subtypes of RCC and the genes which are usually 
dysregulated in the different subtypes. There are clear histological differences between the 
different types; with clear cell (ccRCC) having large cells with transparent bodies due to 
excessive build-up of lipid and glycogen deposits (22).  
 
1.1.3.2.1. Clear cell RCC (ccRCC) 
ccRCC is the most common of the RCCs and is also known as conventional 
RCC. These tumours are made of cells which are clear, hence the name, as 
they are filled with excess glycogen and lipid deposits. They usually arise from 
the proximal tubular epithelium and are usually unilateral, spherical lesions 
which can vary in size and distort the shape of the kidney. The margins of the 
tumour are usually sharply defined and are confined within the renal capsule 
(7).  
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The most common mutation within ccRCC is within the VHL gene, this can be 
familial, sporadic or associated with VHL disease (7). VHL is important in the 
degradation of hypoxia-inducible factor alpha (HIFα). It is normally involved in 
regulating the cell’s response to oxygen in the environment. Under normal 
oxygen conditions, VHL will complex with other proteins, including E3 ubiquitin 
ligase, to cause degradation of the hypoxia-inducible transcription factor HIF1α. 
However, during hypoxia, HIF1α is not degraded but instead binds to HIF1β; 
this heterocomplex can then translocate to the nucleus, where it complexes to 
specific hypoxia response elements that transcriptionally upregulate genes 
including: vascular endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF), transforming growth factor alpha (TGFα), carbonic anhydrase IX, 
erythropoietin, glucose transporter 1 (GLUT-1), among other genes involved in 
cell survival. When VHL is not present because of mutation or promoter 
hypermethylation, then regardless of the oxygen levels, HIF1α will not undergo 
degradation and will activate these proteins, which will become abnormally high 
and lead to development of cancer cells such as those in ccRCC (23) (Fig. 6).  
Fig. 6: The role of VHL in the cells under normal oxygen conditions (left) and its role in hypoxic 
conditions (right). In normal conditions VHL complexes with proteins including E3 ligase and 
degrades HIFα. During hypoxic conditions or if VHL is mutated or not present, HIF1α will 
complex with HIF1β and upregulated genes involved in cell survival (23).  
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1.1.3.2.2. Papillary RCC (pRCC) 
pRCC usually arises from the distal convoluted tubules, and the tumours can be 
multifocal and bilateral, and are typically haemorrhagic and cystic. This is the 
most common RCC tumour type in patients who have cystic disease and are 
undergoing dialysis (7). The most common defect associated with pRCC is 
found in MET, a proto-oncogene that encodes a receptor tyrosine kinase (RTK). 
The MET tyrosine kinase is a receptor for hepatocyte growth factor (HGF), and 
signalling via this receptor stimulates angiogenesis, cellular motility, growth, 
invasion and morphogenetic differentiation (24). Therefore, overactivation of 
MET-triggered processes would be beneficial to the development of a cancer 
phenotype. MET defects are usually associated with familial pRCC rather than 
sporadic cases. Patients with MET mutations display type 1 histological features 
(Fig. 5), although not all type 1 pRCC have MET mutations (13). The majority of 
the mutations occur in the tyrosine kinase domain of the MET protein, that 
results in permanent activation of the kinase (20); there can also be duplication 
and overexpression of these mutant alleles (13). Type 2 pRCC is a particular 
aggressive form of RCC, in which mutations in the enzyme fumarate hydratase 
(FH) have been identified. FH appears to function as a tumour suppressor gene 
(22), where FH gene mutations lead to an increase is fumarate, which in turn 
upregulates HIFα, glucose uptake and lactic acid production (25). As this leads 
to an increase in HIFα, similar to inactivation of VHL, cancerous cells are able to 
survive in low oxygen conditions.  
 
1.1.4 Treatment of kidney cancer  
1.1.4.1. Surgery  
Surgery still offers the best treatment for patients and the best chance for 
survival. There are a number of surgical options and their use depends on 
which stage the patient presents at. Radical nephrectomy involves the removal 
of the tumour-bearing kidney and is common for more advance stage RCC. 
However, there is also the option of nephron-sparing surgery, where only part of 
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the kidney containing the tumour plus a small margin is removed (15). This is 
commonly used in patients with stage 1 RCC or where the patient has bilateral 
RCC, or hereditary forms of RCC where tumours may return in the contralateral 
kidney, or where there may be renal impairment. Nephron-sparing surgery 
would usually only be recommended for patients with tumours that are less than 
4 cm in diameter, in these cases, this technique offers the same long-term 
survival rates as radical nephrectomy. This technique can be carried out in 
tumours of a larger size; however, long-term follow-up surveillance is necessary 
as there is an increased risk of return (15). For patients with stage 1 and 2 
RCC, surgery is often curative and so there is no further need for treatment 
whereas for those with later stage disease and metastasis, additional therapy 
will be necessary (12).  
1.1.4.2. Adjuvant treatment  
Chemotherapy is not recommended in patients with metastatic disease, as RCC 
usually develops from the proximal tubules, where there is usually a high 
expression of P-glycoprotein. This glycoprotein confers multidrug resistance, 
therefore rendering most RCC resistant to traditional chemotherapy (15). The 
role of P-glycoprotein in normal cells is believed to be the protection of cells 
against environmental toxins (26).  
1.1.4.2.1. Interferon-α 
Interferon-α (IFN-α) is the most extensively studied pharmacological therapeutic 
agent for RCC. It is believed to have multiple mechanisms by which it exerts its 
anti-tumour properties, including direct inhibition of tumour cell proliferation, 
increasing the lytic activity of natural killer cells and increasing the expression of 
leukocyte immunoglobulin class-I on the tumour cells, marking the cells for 
recognition and killing by T lymphocytes (27). As a single agent, IFN-α has been 
shown to give response rates in 8-26% of cases; it is normally administered 
after nephrectomy, where it improves survival rates in patients. Stabilisation of 
the disease occurs in approximately 30% of patients, and in very rare cases, 
IFN-α treatment alone leads to long-lasting complete remission (27).  
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 1.1.4.2.2 Multi-kinase and mTOR inhibitors 
Sorafenib is an orally active multiple tyrosine kinase inhibitor (TKI) (also known 
as a “multi-kinase inhibitor”), and is able to effect tumour cell proliferation as 
well as angiogenesis. It is believed to achieve this through inhibition of Raf 
kinase, vascular endothelial growth factor receptors (VEGFR) 1, 2 and 3, 
platelet-derived growth factor receptor (PDGFR) β, FMS-like tyrosine kinase 3, 
and c-Kit and RET RTKs. Until the advent of these new drugs there had been 
no other available treatments for patients who were unable to tolerate or were 
ineligible for IFN-α treatment. In mouse VHL knockout models, Sorafenib was 
able to prevent tumour growth, mainly through inhibiting angiogenesis, it was 
also linked to increased tumour cell apoptosis and necrosis. Furthermore, in 
clinical trials using sorafenib, most patients with ccRCC responded well (28). 
Sunitinib is another multitargeted TKI that is licensed for use in RCC. Its main 
target is VEGF, however it also targets other tyrosine kinases. Promising results 
from clinical trials have shown that sunitinib is better that IFN-α for first line-
treated ccRCC (29). Therefore, such TKIs represent a new generation of 
anticancer drugs with a narrower range of molecular targets that could make 
them more specific and therefore more effective against individual tumours with 
a distinct molecular signature upon diagnosis (Fig. 7).  
Fig. 7: The drug targets involved in the treatment of RCC. TKIs include Sorafenib and Sunitinib, 
while mTOR inhibitors include temsirolimus. The pathways and receptors are shown to be 
targeted by the agents with dotted lines (29).  
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Temsirolimus is an example of a specific mTOR inhibitor, which also represent 
a new class of more specific anticancer agent. mTOR is a kinase, activation of 
which has a number of downstream effects, including increased HIFα activation. 
The mTOR pathway is related to the PI3K/Akt pathway (Fig. 7), mTOR is 
indirectly activated following activation of Akt kinase by PI3K conversion of PIP2 
to PIP3. PI3K activity is inhibited by the tumour suppressor Phosphatase and 
tensin homolog (PTEN), loss of which has also been detected in RCC, leading 
to increased Akt activation and consequently increased cell proliferation. PTEN 
has also been shown to be blocked by derivatives of mTOR inhibitors (30). It 
has been shown that mTOR monotherapy increases overall survival in poor risk 
RCC patients compared to IFN-α, indicating that this therapy would be 
worthwhile to administer, particularly to patients for whom IFN-α is not 
appropriate. Whilst none of these new drugs appear to be a cure, they have 
helped to made significant steps towards stabilising the disease (15).  
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1.2. Epigenetics of cancer  
1.2.1. Epigenetics defined  
The current definition of epigenetics is “the study of heritable changes in gene 
expression that occur independent of changes in the primary DNA sequence” 
(31). These “heritable changes” refer to changes which are established during 
cell differentiation, usually during embryo development, and are maintained 
throughout subsequent cell divisions, meaning that daughter cells in later 
generations continue to carry a distinct identity (31).  
Under the umbrella term of epigenetics includes chromatin modifications, non-
coding RNA (ncRNA) and DNA methylation; however this term is undergoing an 
evolution of its own, its definition being updated as more research is being 
carried out (32).  
1.2.2. The role of chromatin 
Chromatin is a highly ordered structure found in the nucleus of a cell, in which 
the eukaryotic genome is condensed. The main functional unit of the chromatin 
structure is the nucleosome, within which 145-147 bp of DNA are wrapped 
around a histone core. The histone core is made up of two of each of four 
histone protein subunits: H2A, H2B, H3 and H4 (33) (Fig. 8).  
A number of different chemical modifications of histones have been identified 
which, depending on the type of modification and also its location on the 
histone, can have different effects on gene expression. The types of 
modifications include methylation, acetylation, phosphorylation, ribosylation, 
ubiquitination and sumoylation. With histone acetylation being the most studied, 
and histone methylation playing an important role in gene expression, only 
these two histone modification types will be discussed here (31). Furthermore, 
there are also chromatin-remodelling complexes which also play a role in 
affecting transcription (34).  
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Fig. 8: The role of chromatin in the nucleus. A) DNA is tightly wound around histones, this DNA 
can be methylated or unmethylated. This is the further wound into the chromatin structures 
which are themselves wound together in the chromosome structure. B) Histone modifications 
that alternatively promote and repress gene expression H3K4Me3 is associated with promoters, 
H3K6Me3 and H4K12Ac are associated with gene body, while H3K27Ac and H3K4Me are 
associated with enhancers. Promoter repressor marks can include: H3K27Me3, H3K9Me3 and 
5-mC, there are no known repressor marks which have been found in the gene body or 
enhancers (35).  
1.2.2.1. The histone code hypothesis 
Originally, it was believed that histones and histone modifications were static 
and that histones only served a structural role. However, it later became 
apparent that histone modifications were able to affect transcription in a context-
specific manner, with acetylation and methylation as examples of specific 
modifications with distinct outcomes depending on which location on the histone 
they took place (36). Initially, it was believed that these marks affected 
transcription through altering the binding of histones to DNA through altering 
charge, hydrophobicity or basicity. However, it is has become apparent that it is 
a more complex process than this, where these modifications are now believed 
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to act as a language or “histone code” for other proteins or protein complexes, 
which read this code and in turn affect transcription themselves (37).  
1.2.2.2. Histone acetylation 
Histone acetylation modifications are carried out by histone acetyltransferases 
(HAT) and histone deacetylase (HDAC), for addition and removal of the acetyl 
group respectively (37). Chromatin can be described as being in two states: 
euchromatin, where there is a higher amount of active transcription and a higher 
degree of acetylation, and heterochromatin, which is more condensed and with 
a lesser degree of acetylation (33). Acetylation of specific lysine residues at the 
amino termini of histones is associated with a euchromatin state and in this way 
plays a role in transcriptional regulation. In most species, histone H3 possesses 
acetylation sites at lysine residues 9, 14, 18 and 23.  
In some cancers, an overexpression of HDAC has been detected, this removes 
acetylation marks and thereby forces that region into a heterochromatin state, 
consequently leading to downregulation of expression of important genes such 
as tumour suppressor genes. As a result, a number of HDAC inhibitors have 
been designed as pharmacological anti-tumour agents and are currently 
undergoing clinical trials. HDAC inhibitors such as suberoylanilide hydroxamic 
acid (SAHA) has been approved by the FDA for the treatment of cutaneous T-
cell lymphoma (38). These HDAC inhibitors induce cell cycle arrest and cell 
death. Although their mechanisms of action are not completely clear, part of the 
process would be expected to be due to the accumulation of acetylated 
histones and other proteins that are involved in gene expression. . For example, 
vorinostat (SAHA) has been shown to induce cell cycle arrest and cell death by 
activating apoptosis. However, some HDAC inhibitors can also block 
angiogenesis. As normal cells are relatively resistant to their cell death effects, it 
appears that they are able to specifically target a wide range of cancer cell 
types. The extent of the effect of HDAC inhibitors on cancer cells depends on 
the epigenetic changes that are seen in the cell as well as the drug 
concentration and time of exposure to the HDAC inhibitor (38).  
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1.2.2.3. Histone methylation  
Although discovered over 50 years ago by Allfrey et al. (36), histone methylation 
appears more elaborate than acetylation as an epigenetic mark (33). Histone 
methylation can occur on H3 at of lysine residues K4, K9, K27, K36, and K79; 
and on H4 at K20. In addition to lysine methylation, arginine methylation can 
also take place on H3 at R2, R17, and R26 and on H4 at R3. Methylation used 
to be considered a stable mark (33), however , it can be removed by histone 
demethylases (HDM), these HDM such as Lsd1 have started to become 
potential targets in cancer (39). Methylation does not alter the charge of the 
histone tails; however, it can increase the basicity and hydrophobicity, and 
influence the binding to molecules like DNA (33). Methylation appears to be a 
more complex mark, and the effect on transcriptional activity appears to depend 
on where the methylation has occurred on the histone tail and what proteins this 
then recruits (Fig. 9).  
Fig. 9: The effect of methylation of lysine residues on histones H3 (purple) and H4 (blue). The 
functional effect of the methylation is represented as coloured dots, described in the key in the 
bottom left, with the number of dots indicating mono-, di- and trimethylation (40).  
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One of the first marks to be identified was H3K4me (methylation of lysine 4 on 
histone H3). Furthermore, it appears that trimethylation of H3K4me is important 
for transcriptional activation of promoter regions, as well as trimethylation of 
H3K36me being linked with transcriptional elongation (40). These two marks 
appear to be important for marking the promoter region during active 
transcription, though this is only true for trimethylation, lower methylation states 
appearing to have different functions. Trimethylation at other lysines including 
H3K9, H3K27 and H4K20 are usually associated with repression of 
transcription. Methylation at H4K20 has also been shown to be able to recruit 
proteins involved in the DNA damage response pathway (40). In addition, 
studies have shown that methylation of H3K9 is able to control DNA 
methylation, although the mechanism behind this appears to differ in different 
organisms (41).  
 
1.2.2.4. Chromatin epigenetics in RCC 
In a kidney carcinoma study that assessed the levels of histone modifications 
and compared them to survival rates, it was found that patients with low levels 
of the modifications H3K4me2 and H3K18ac had significantly poorer 1-year 
survival probabilities compared with those who had higher levels of histone 
modifications (42). Furthermore, this difference was more prominent in patients 
with stage 1 or 2 cancers. Therefore, this indicates that these histone 
modifications affected expression of genes that are important for cancer 
aggressiveness and consequently survival.  
 
1.2.3 Non-coding RNAs (ncRNA) 
Since the advent of large transcriptome studies, it has been established that 
while approximately 70% of the genome is actually transcribed, protein products 
account for only 1-2% of this activity (43). It is now believed that up to 70% of 
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these transcripts are what is known as ncRNA (44). As these ncRNAs are 
expressed at lower levels than mRNA, it is believed that they have a role in 
regulatory functions, including in development and responses to stress and 
environmental stimuli. Moreover, their own expression can be regulated via 
epigenetic mechanisms. ncRNAs can be further subdivided into two groups: 
those which are infrastructural ncRNAs, including ribosomal, transfer, small 
nuclear and small nucleolar RNAs, and those that are regulatory ncRNAs, 
including microRNA (miRNA), piwi-interacting RNA, small interfering RNA 
(siRNA) and long non-coding RNA (lncRNA). Furthermore, two additional types 
have been discovered: promoter associated RNA (PAR) and enhancer RNA 
(eRNA) (43). The most studied groups within cancer research are microRNAs 
followed by lncRNAs (45).  
 
1.2.3.1. microRNA and RCC 
Changes in miRNA expression have been well documented in cancer, in which 
some individual miRNAs have been shown to be oncogenic whilst others are 
tumour suppressive (44). A number of studies have been conducted into the 
role of miRNAs in RCC. One study found that there were around 100 
differentially expressed miRNAs in RCC tumours compared with adjacent non-
tumour kidney samples (46). Furthermore, expression of different subsets of 
these miRNAs were found to differ between non-recurrent, recurrent and 
metastatic groups of patients; it was therefore suggested that these miRNAs 
could potentially be useful as diagnostic or prognostic markers. Other studies 
focussed on one or more specific miRNAs; Zaman et al. found that miR21 was 
upregulated in ccRCC and that this upregulation correlated with an increase in 
tumour stage and a lower 5-year survival rate (47). Inhibition of miR21 in cells 
caused cell cycle arrest, induction of apoptosis and reduced invasive and 
migratory capabilities. The levels of miRNA in the serum of patients with 
disease such as RCC have also been studied as a possible diagnostic tool. 
Wulfken et al. detected a higher miR1233 level in RCC patients serum as 
compared to healthy control serum (48). miRNAs are therefore an important 
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new class of epigenetic mediator which could be used as a diagnostic tool or 
prognostic marker. Currently, there are no drugs that target these; however, it is 
possible that in the future these will be a therapeutic target or perhaps even a 
therapeutic tool in genetic therapy.  
1.2.3.2. lncRNA and RCC  
lncRNAs are greater than 200 nucleotides in length, and have been implicated 
in gene regulatory roles. It is becoming apparent that mutations within these 
lncRNA genes are linked with disease states including cancer (49). lncRNAs 
can overlap with coding transcripts or be located between coding and non-
coding transcripts (50). A recent bioinformatics study identified 5446 human 
lncRNAs in RCC; along with other studies this brings the current total number of 
identified lncRNA to 6736 (51). The vast majority of these have unknown 
functions. A recent study which compared 6 matched patient samples (tumour 
vs. adjacent non-tumour tissue) found there to be, in 4 of the patients, 3055 
lncRNAs that were up- or downregulated in tumours vs. non-tumour tissues, 
while 1866 lncRNAs were changed in 5 patients and 626 lncRNAs were 
changed in all 6 patients (52). It was also noted that lncRNA downregulation 
was the more common change across the 6 patients. Out of these, the most 
commonly downregulated lncRNA was ENST00000429695 (current build: 
ENST00000441309 (53)), which is located at chromosome 7: 21,259,828-
21,261,047 on the reverse strand. The most commonly upregulated lncRNA 
was ENST00000456816 located at chromosome 3: 194,014,254-194,030,493 
on the reverse strand. As lncRNA ENST00000456816 is located on 3q, even 
though it is located far from the VHL gene, it has not been ruled out that it could 
recruit chromatin-modifying enzymes to target VHL, thus explaining its role in 
the cancer (52).  
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1.2.4. DNA methylation 
DNA methylation in mammals occurs on cytosines, with 5-methylcytosine (5-
mC) being the most common methylation type. This was first properly described 
in 1951 by Wyatt, who identified it as a distinct DNA mark in higher eukaryotes 
(54). It was then further identified by Doskočil in 1962, as specifically occurring 
on cytosines that were located 5’ to guanines, or CpG dinucleotides (55). It was 
later noted by Holliday in 1975 that these modifications might be important in 
gene control during development (56). It was only in the 1980s that it was 
noticed that as a whole the genome has relatively low levels of these CpG 
dinucleotides relative to other combinations, it was further noted that the spread 
of these CpG dinucleotides was not uniform across the genome. Instead, there 
were areas that had high levels of CpGs that were clustered together, and these 
regions became known as “CpG islands” (57). Initially, it was thought that CpG 
islands were only located near to the 5’ end of “housekeeping genes” and were 
associated with their promoters (58). However, it has become apparent that 
they are associated with many more genes, with up to 72% of gene promoters 
now being associated with CpG islands. It has since been postulated that the 
CpG content of promoters can be used to classify the promoters, i.e. those with 
high CpG content and those with low CpG content (approximately 28% of 
promoters). Through this classification, it was noted that the enrichment of 
CpGs peaks around core promoters (59).  
CpG island classification is most commonly based on the criteria set by 
Gardiner-Garden and Frommer (58), where GC content is greater than 50%, 
Observed/Expected (Obs/Exp) is greater than 0.6, and length of the CpG island 
is greater than 200 bp. The ratio of Obs/Exp CpG is calculated as follows (n= 
Total number of nucleotides in the sequence):  
   
   
    
             
                         
   
It has been argued for a more stringent classification where GC content is 
greater 55%, Observed/Expected (Obs/Exp) is greater than 0.65, and length of 
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CpG island is greater than 500 bp; applying this level of stringency will exclude 
repeat sequences such as Alu repeats (60).  
It is believed that the reason behind the overall low levels of CpGs in the 
mammalian genome is methylated cytosines are spontaneously deaminated to 
thymines and as a result there are higher levels of TpG (Fig. 10) (61).  
Fig. 10: Cytosine is methylated by DNA methyltransferase to a 5-methylcytosine. This is 
believed to be toxic and is then spontaneously deaminated to thymidine, leading to overall low 
levels of CpGs in the wider genome (62).  
 
1.2.4.1. The functional role of DNA methylation  
In mammals, DNA methylation is mediated by DNA methyltransferases 
(DNMTs) through the transfer of a methyl group from the donor S-
adenosylmethionine (SAM) to the target cytosine. A number of these DNMTs 
have been identified and these have different roles in developing and 
maintaining methylation (Table 4) (63).  
Table 4. The different DNMT and their roles in methylation-related epigenetics (63).  
DNMT Function 
DNMT1 Maintaining methylation pattern 
Essential for chromosome replication and repair 
Essential for de novo methylation 
DNMT2 Effective in DNA and RNA methylation 
DNMT3a Establishment of de novo methylation pattern especially during gametogenesis 
Maintaining methylation pattern 
DNMT3b Establishment of de novo methylation 
DNMT3L Essential for de novo methylation 
Enhance de novo methylation activity of DNMT3a and DNMT3b 
Establishment of de novo methylation pattern especially during gametogenesis 
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DNMT3L lacks methyltransferase activity itself; however in mice, its association 
with the DNMT3 family is essential for de novo methylation. It also has been 
shown that DNMTs can be regulated by ncRNAs (63).  
 
The vast majority of CpG islands are hypomethylated, yet a small number 
become methylated during normal development and these include genes 
involved in X chromosome inactivation and genomic imprinting (61). These 
features therefore indicate that methylation within a CpG island serves to 
downregulate genes. There have been at least two models of how DNA 
methylation causes downregulation. Firstly, cytosine methylation can prevent 
the binding of certain transcription factors, and second, DNA methylation can 
recruit methyl-CpG-binding proteins (MBP) which indirectly affect chromatin 
state (64). Additionally, further studies have shown that DNA methylation is 
associated with a hypoacetylated chromatin state. Also, methylated DNA is 
usually associated with a closed chromatin state, as evident by digestion of 
methylated and unmethylated DNA, with methylated DNA being less digestible 
by endonucleases (65). 
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1.2.4.2. The role of DNA methylation in RCC  
In RCC, DNA hypermethylation in the promoter region of many genes has been 
shown to cause downregulation of those genes (66).  
Fig. 11: Genes that have been shown to be methylated in RCC and their distribution across the 
genome. There is a concentration of mutated and methylated genes on 3p which are commonly 
reported in RCC (21).  
Around 60 genes have been assessed through gene-specific studies as well as 
microarray studies and have been shown to have methylation in their promoter 
regions (21) (Fig. 11). Specifically, genes that have been implicated in RCC 
through mutation have also been shown to be downregulated by 
hypermethylation in their promoter regions, with VHL and TIMP3 being 
examples (67, 68). In these studies, where VHL has been extensively studied in 
RCC, they were able to show that in a large number of RCC patients there is an 
increase in VHL gene promoter methylation, although this was not the case in 
all patients. Furthermore, VHL gene promoter hypermethylation was not a 
common phenomenon across all RCCs; rather, it occurred preferentially in 
ccRCC (68-70).  
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RASSF1, which is also located on chromosome 3p, has also been identified as 
being frequently methylated in its promoter in RCC, while, interestingly (and in 
contrast to VHL), RASSF1 mutations are rare in RCC. Moreover, RASSF1 
hypermethylation was shown to occur in both ccRCC and pRCC, independently 
of loss of VHL (71). RASSF1 is a RAS effector homolog gene. Re-expression of 
RASSF1A in lung carcinoma cells was shown to reduce colony formation, 
suppress anchorage-independent growth and inhibit tumour formation in mice 
(72). Furthermore, studies showed that RASSF1 promoter methylation was also 
found in the non-tumour adjacent tissue of patients but not in normal tissue 
which came from a more distant site; this indicates that RASSF1 
downregulation plays a role in the early stages of tumourigenesis (21).  
The gene for one of the Tensin family binding partners, DLC1, a tumour 
suppressor gene, has also been shown to be differentially methylated in RCC. 
The study, which used methylation specific PCR (MSP, discussed later), found 
that 35% of tumour samples were methylated whilst only 3% of non-tumour 
adjacent samples were methylated (73). However, DLC1 methylation did not 
correlate with gender, age, tumour site, TNM stage or nuclear grade, indicating 
that DLC1 methylation is an early stage event.  
  
1.2.4.3. Therapy targeting DNA methylation  
As methylation plays an important role in the targeting of tumour suppressor 
genes and other genes which would be unfavourable for cancer cell growth, 
drugs have been designed to target this inappropriate methylation. Decitabine 
(5-aza-2’-deoxycytidine) and azacitidine (5-azacytidine) are the only two 
methylation targeting drugs which have been approved by the FDA for the 
treatment of cancers, specifically myelodysplastic syndrome (74). Both these 
medications are based on similar chemistry and have similar mechanisms of 
action (Fig. 12). 5-azacytidine is able to incorporate into both DNA and RNA, 
which can then lead to the inhibition of DNA, RNA and protein synthesis. Much 
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of this protein synthesis inhibition is believed to be effected via interference with 
tRNA methylation and processing, which leads to defective acceptor function in 
tRNA. 5-aza-2’-deoxcytidine (5-aza), however, is much more cytotoxic than 5-
azacytidine in cultured cells and animal studies, despite the fact it is only 
incorporated into DNA. At low level doses, low enough to avoid causing cell 
death, 5-aza lead to massive loss of DNMT activity as the enzyme becomes 
irreversibly bound to 5-aza. Furthermore, 5-aza replaces methylated sites in the 
daughter cell, leading to further loss of DNMT activity; methylation is then 
passively diminished, due to inhibited DNMT being unable to restore 
methylation. It has been noted that in cells that become resistant to 5-aza and 
5-azacytidine treatment, these are still incorporated into their DNA, but that 
DNMT is less likely to bind them (75).  
Fig. 12: The structure of cytidine and its analogues. R is ribose and DR is deoxyribose. The 
most commonly use analogues are 5-azacytidine and 5-aza-2’-deoxycytidine (75).  
Drug trials with these agents show that they are effective in the treatment of 
myelodysplastic syndromes, which are a wide range of blood cancers that arise 
from the bone marrow and which may develop into leukaemia (76). However, 
the same agents are substandard in treating solid tumours. In clinical trials with 
patients with myelodysplastic syndromes treated with 5-azacytidine, it was 
noted that the complete response rate was around 12%, while haematologic 
improvement was 23% and the median survival for these patients was 14.7 
months compared to control (74). However, toxicities were high and side effects 
included: nausea and vomiting at 63% and dose-limiting myelosuppression at 
33%. In multicentre trials, patients who had 3 cycles of treatment, 60% had a 
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measurable response to the treatment. Median survival was 18 months for 
those who were treated continuously, whilst it was only 11 months for those 
were not treated with the drug. The quality of life for these patients also was 
significantly improved, although there was still a high rate of toxicity. Treatment 
with 5-aza has been trialled in adult and paediatric leukaemia patients showing 
response rates of 33% and 20% for those with acute lymphoblastic leukaemia 
(ALL) and acute myeloid leukaemia (AML) respectively (74). Further analysis 
was conducted in a multicentre trial, grouping patients into two groups, those 
who were treated with 5-aza plus the best treatment care and those who had 
best treatment care alone. For those who were treated with 5-aza, the median 
response to treatment was 3.3 months and the duration of the response was 
10.3 months. Moreover, patients on the 5-aza treatment had a longer median 
time to further development of the disease or death. The primary toxicity was 
also myelosuppression. However, although 5-aza appears to have some effect 
in clinical trials for circulating cancers, there is little evidence that it would be 
beneficial in solid cancers.  
 
 
1.3 The Tensin family 
1.3.1. The human Tensin gene family  
The Tensin family is made up of four proteins, Tensin1, Tensin2 (C1-TEN), 
Tensin3 and Tensin4 (CTEN) (77). The Tensins are homologous to each other 
at both gene and protein levels, furthermore, the N-terminal regions of Tensins 
1-3 also share sequence homology with the tumour suppressor protein PTEN, 
which is often disrupted in cancer. PTEN is a phosphatase that plays a key role 
in the suppression of the phosphatidylinositol 3-kinase (PI3K)-Akt signalling 
pathway (78).  
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Moreover, the four Tensin genes are evolutionarily related to the PTEN gene 
and are likely to have evolved from the same common ancestor gene, as 
revealed by a phylogenetic tree produced from the Ensembl database (Fig. 13).  
Fig. 13: Phylogenetic tree showing the evolutionary relationship between the four Tensin genes 
and the PTEN gene. The length of the branches of the phylogenetic tree represents the relative 
distance from the point at which the genes became evolutionarily distinct (53).  
The phylogenetic tree indicates that TNS1 and PTEN are the most closely 
related, having evolved from the same branch, while TNS2 (TENC1) and TNS4 
became distinct earlier on in evolution (Fig. 13) (53). It is likely that these genes 
have evolved from a duplication event in the genome, and once duplicated, they 
subsequently obtained mutations which eventually sufficiently diverged them 
from one another (79). To further support this, adjacent on the chromosome 
where each of the four Tensin genes are located, lies the genes for at least one 
of the insulin-like growth factor-binding protein (IGFBP) family members (Fig. 
14) (80). Therefore, not only the Tensin genes but also a cluster of neighbouring 
genes within the same regions have been co-duplicated and segregated 
throughout evolution. There are 6 IGFBPs which bind to insulin-like growth 
factors (IGF) and act as carriers, as well as prolonging the half-life of the IGFs. 
The IGF pathway is involved in important processes involving growth and 
differentiation of both normal and cancer cells. Furthermore, IGFBPs have been 
shown to have direct effects in bone cell proliferation and also growth arrest of 
breast and prostate cancer cells (81).  
 
Fig. 14: The location of the Tensin and IGFBP gene families. All four Tensins (red boxes) are located in close proximity to at least one member of the IGFBP 
superfamily (green boxes), modified from the Ensembl database (80).  
 Tensin1 was first identified in 1985 as HA1, a contaminating substance in a 
vinculin preparation made from chicken gizzard extract (82). Further analysis of 
the contaminating molecule showed it to be an as yet undiscovered molecule 
with actin filament-capping properties; this new molecule was subsequently 
named Tensin. Subsequently, after the discovery and cloning of the other 
Tensin genes, the first “Tensin” was then referred to as “Tensin1”. The human 
Tensin1 gene, TNS1, is located on the long arm of chromosome 2 (2q35), on 
the reverse strand (Ensembl accession number: ENSG00000079308 (53)). 
Tensin1 has 19 identified transcripts; however, only 3 appear to be complete 
transcripts. The largest transcript is of 10,311 bp length, being composed of 33 
exons, 28 of which are coding exons, and giving rise to a translated protein 
product of 1735 amino acids length (ENST00000171887.4); this is the only 
current fully curated protein-coding transcript.  
Fig. 15: The different chromosome locations of the human Tensin genes. TheTNS1 gene is 
located on chromosome 2, TENC1 (Tensin2) is located on chromosome 12, TNS3 is located on 
chromosome 7 and TNS4 is located on chromosome 17. The coloured arrows denote the 
different genes’ chromosomal locations (53).  
Tensin2 was first identified in 2002 by two groups, Chen et al. and Hafizi et al. 
(83, 84). In the study by Hafizi et al., the protein was originally designated as 
“C1 domain-containing phosphatase and Tensin homologue (C1-TEN)” due to 
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its homology to PTEN and the fact that it was the first isoform of the protein 
identified to possess a C1 domain, in contrast to that identified by Chen et al. 
Moreover, 2 new C1 domain-containing isoforms were identified by Hafizi et al. 
by real amplification of cDNA ends (RACE) PCR, based on initial analysis of a 
previously identified incomplete transcript called KIAA1075 (84). Therefore, 
Tensin2 is now known to have three isoforms, with different expressions and 
actions, with isoform 3 lacking a C1 domain (84, 85). The human Tensin2 gene, 
TENC1, is located on the long arm of chromosome 12 (12q13.13) on the 
forward strand (ENSG0000011077). There are 7 different predicted Tensin2 
transcripts, three of which have been cloned experimentally. TENC1-001, a 
4737 bp-long transcript containing 29 exons, of which 23 are coding exons, 
giving rise to a protein of 1285 amino acids in length (ENST00000379902); this 
transcript does not code for the C1 domain and gives rise to protein isoform 3. 
Within the gene region of TENC1, there are a number of regulatory elements, 
including Gabp, HNF4A, Nrsf, CTCF, cMyc, Egr1 and YY1; additionally, there is 
a 1004 bp CpG island located within Exon 1 of TENC1-001 and also extending 
upstream of it (EMBOSS CpGPlot, using the Gardiner-Garden and Frommer 
criteria (58)). There are also two other isoforms of Tensin2 which contain a C1 
domain, these are encoded by TENC1-002 (ENST00000314276, codes for 
isoform 1) and TENC1-003 (ENST00000314250, codes for isoform 2). Two of 
the identified transcripts are smaller and, according to Ensembl, would be 
destroyed by nonsense-mediated decay, whilst the others are protein-coding 
and of full length but have not been experimentally verified.  
Tensin3 was first identified in 2004 by Cui et al (86), and is also believed to 
exist as different isoforms. The human Tensin3 gene, TNS3 (also known as 
TENS1, TEM6) is located on the short arm of chromosome 7 (7p12.3) on the 
reverse strand (ENSG00000136205). There are predicted to be 14 different 
transcripts derived from the gene, including 2 which are full length, however 
these are a duplication in the database, one having been identified through the 
Havana prediction team and other through Ensembl genebuild. This study 
focussed on the Tensin3 gene variants TNS3-012 and TNS3-001 due to their 
proximity to the CpG island that is the focus of this thesis. TNS3-001 is a full-
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length transcript of 7618 bp in length, composed of 31 exons, 26 of which are 
coding exons, and gives rise to a protein product of 1445 amino acids 
(ENSP00000312143). TNS3-012, however, is not a full-length transcript, being 
derived from only 7 exons, 6 of which are coding (ENSP00000407464). 
However, there is only one identified experimentally determined transcript, this 
is TNS3-001, the others being incomplete transcripts which lack the 3’ end of 
the gene to different degrees. There is an 826 bp CpG island located within it is 
Exon 1 of TNS3-012 and TNS3-001, it also includes a number of regulatory 
elements including YY1 and E1F2. Furthermore this region contains a CCCTC 
binding factor (CTCF) motif. The CTCF factor usually binds to CTCF insulator 
sequences, which are usually located between an enhancer and promoter to 
prevent the enhancer from incorrectly switching on the promoter or activating 
the wrong promoter (87, 88).  
Tensin4 was first identified in 2002 by Lo & Lo, and is as equally commonly 
referred to as CTEN (COOH-terminal Tensin-like) (89). The human Tensin4 
gene, TNS4, is located on the long arm of chromosome 17 (17q21.2) on the 
reverse strand (ENSG00000131746). There are one full length protein-coding 
transcript, of 4067 bp in length producing a 715 aa-long protein; this transcript 
contains 13 exons, 12 of which are coding exons.  
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Fig. 16: The genomic organisation of the human TNS1 gene and the proteins it codes for. The top half of the figure displays the various transcripts of Tensin1 
identified, while the bottom half shows the bioinformatic determination of what domains these exons code for, through the PROSITE profiles (90) and SMART 
domain databases (91). The full length transcript of TNS1-001 encodes a PTPase/C2 domain as well as the SH2-PTB domain which is located at the C-
terminus. The incomplete transcript TNS1-002 codes for a C1 domain at its N-terminal as well as a PTPase/C2 domain; however this transcript is incomplete 
at its 3’ end.  
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Fig. 17: The genomic organisation of the human TENC1 gene and the proteins it codes for. The top half of the figure displays the various transcripts of 
Tensin2 identified, while the bottom half shows the bioinformatic determination of what domains these exons code for, through the PROSITE profiles (90) and 
SMART domain databases (91). The protein domains of the three different isoforms are shown, TENC1-001 encodes isoform 3, which lacks a C1 domain, 
while TENC1-002 and TENC1-003 encode isoforms 1 and 2 respectively, both of whose protein products possess a C1 domain. Furthermore, all three 
isoforms contain PTPase/C2 domains at the N-terminal and SH2-PTB domains at their C-termini.  
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Fig. 18: The genomic organisation of the human TNS3 gene and the proteins it codes for. The top half of the figure displays the various transcripts of Tensin3 
identified, while the bottom half shows the bioinformatic determination of what domains these exons code for, through the PROSITE profiles (90) and SMART 
domain databases (88). TNS3-001 is the experimentally determined Tensin3 protein, it contains PTPase/C2 domains at its N-terminal and SH2-PTB at its C-
terminal. The hypothetical transcripts TNS3-003, which lacks 3’ end (SH2-PTB C-terminal end) and TNS3-012 encode for a C1 domain, TNS3-003 also 
encodes for the PTPase/C2 domains.  
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Fig. 19: The genomic organisation of the human TNS4 gene and the protein it codes for. The top half of the figure displays the various transcripts of Tensin4 
identified, while the bottom half shows the bioinformatic determination of what domains these exons code for, through the PROSITE profiles (90) and SMART 
domain databases (88). There is only one protein-coding transcript for Tensin4, the protein lacking the N terminal domains of the other Tensins but containing 
the C terminal SH2 and PTB domains common to all Tensins.  
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CLUSTAL 2.1 multiple sequence alignment 
TNS1 -----------------------------------NHELVPITTENAPKNVVDKGEGASRGGN-----------------------------TRKSLEDNGSTRVTPSVQPHLQPIRNMS 56 
TNS2 MKSSGPVERLLRALGRRDSSRAASRPRKAEPHSFREKVFRKKPPVCAVCKVTIDGTGVSCRVCKVATHRKCEAKVTSACQALPPVELRRNTAPVRRIEHLGSTKSLNHSKQRSTLPRSFS 120 
TNS3 --------MNWLCRNQDPNPPPQPEELTSSLHAFKNKAFKK-SKVCGVCKQIIDGQGISCRACKYSCHKKCEAKVVIPCG------------VQVRLEQAPGSSTLSSSLCRDKPLRPVI 99 
TNS4  ------------------------------------------------------------------------------------------------------------------------ 
PTEN ------------------------------------------------------------------------------------------------------------MTAIIKEIVSRN 12 
 
TNS1 VSRTMEDSCELDLVYVTERIIAVSFPSTANEENFRSNLREVAQMLKSKHGGNYLLFNLS-ERRPDITKLHAKVLEFGWPDLHTPALEKICSICKAMDTWLNADPHNVVVLHNKGNRGRIG 175 
TNS2 LDPLMERRWDLDLTYVTERILAAAFPARPDEQRHRGHLRELAHVLQSKHRDKYLLFNLS-EKRHDLTRLNPKVQDFGWPELHAPPLDKLCSICKAMETWLSADPQHVVVLYCKGNKGKLG 239 
TNS3 LSPTMEEGHGLDLTYITERIIAVSFPAGCSEESYLHNLQEVTRMLKSKHGDNYLVLNLS-EKRYDLTKLNPKIMDVGWPELHAPPLDKMCTICKAQESWLNSNLQHVVVIHCRGGKGRIG 218 
TNS4 ------------------------------------------------------------------------------------------------------------------------ 
PTEN KRRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTG 132 
 
TNS1 VVIAAYMHYSNISASADQALDRFAMKRFYEDKIVPIGQPSQRRYVHYFSGLLSGSIKMNNKPLFLHHVIMHGIPNFESKGGCRPFLRIYQAMQPVYTSGIYNIPGDSQTSVCITIEPGLL 295 
TNS2 VIVSAYMHYSKISAGADQALATLTMRKFCEDKVATELQPSQRRYISYFSGLLSGSIRMNSSPLFLHYVLIPMLPAFEPGTGFQPFLKIYQSMQLVYTSGVYHIAGPGPQQLCISLEPALL 359 
TNS3 VVISSYMHFTNVSASADQALDRFAMKKFYDDKVSALMQPSQKRYVQFLSGLLSGSVKMNASPLFLHFVILHGTPNFDTGGVCRPFLKLYQAMQPVYTSGIYNVGPENPSRICIVIEPAQL 338 
TNS4 ------------------------------------------------------------------------------------------------------------------------ 
PTEN VMICAYLLHRGKFLKAQEALDFYGEVRTRDKK--GVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFS-GGTCNPQFVVCQLKVKIYSS---------------------- 227 
 
TNS1 LKGDILLKCYHKKFRSPARDVIFRVQFHTCAIHDLGVVFGKEDLDDAFKDDRFPEYGKVEFVFSYGPEKIQGMEHLENGPSVSVDYNTSDPLIRWDSYDNFSGHRDDGMEEVVGHTQGPL 415 
TNS2 LKGDVMVTCYHKGGRGTDRTLVFRVQFHTCTIHGPQLTFPKDQLDEAWTDERFPFQASVEFVFSSSPEKIKGS-TPRNDPSVSVDYNTTEPAVRWDSYENFNQHHEDSVDGSLTHTRGPL 478 
TNS3 LKGDVMVKCYHKKYRSATRDVIFRLQFHTGAVQGYGLVFGKEDLDNASKDDRFPDYGKVELVFSATPEKIQGSEHLYNDHGVIVDYNTTDPLIRWDSYEN------LSADGEVLHTQGPV 452 
TNS4 -MSQVMSSPLLAGG---------------------------------------------------------------------------------------------------------- 13 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
 
TNS1 DGSLYAKVKKKDSLHGSTGAVNATRPTLSATPNHVEHTLSVSSDSGNSTASTKTDKTDEPVPGASSATAAHVNGGALASERETDILDDELPNQDGHSAGSMGTLSSLDGVTNTSEGGYPE 535 
TNS2 DGSPYAQVQRPPR---------QTPPAPSPEP-PPPPMLSVSSDSGHSSTLT----TEPAAESPGRPPPTAAERQELDR--------------------------LLGGCGVASGGRGAG 558 
TNS3 DGSLYAKVRKKSSSDPGIPGGPQAIPATNSPD-HSDHTLSVSSDSGHSTASARTDKTEERLAPGTRRGLSAQEKAELDQ--------------------------LLSGFGLEDPGSSLK 545 
TNS4 HAVSLAPCDEPRR---------TLHPAPSPSL-PPQCSYYTTEGWGAQALMA----PVPCMGPPGR------------------------------------------------------ 65 
PTEN ---NSGPTRRED------------------------------------------------------------------------------------------------------------ 236 
 
TNS1 ALSPLTNGLDKSYPMEPMVNGGGYPYESASRAGPAHAGHTAPMRPSYSAQEGLAGYQREGPHPAWPQPVTTSHYAHDPSGMFRSQSFSEAEPQLPPAPVRGGSSREAVQRGLNSWQQQQQ 655 
TNS2 RETAILDDEEQPTVGGGPHLGVYPGHRPGLSRHCSCRQGYREPCGVPNGGYYRPEGTLERRRLAYGGYEGSPQGYAEASMEKRRLCRSLSEGLYPYPPEMGKPATGDFGYR-----APGY 673 
TNS3 EMTDARSKYSGTRHVVPAQVHVN-GDAALKDRETDILDDEMPHHDLHSVDSLGTLSSSEGPQSAHLGPFTCHKSSQNSLLSDGFGSNVGEDPQGTLVPDLGLGMDGPYERERTFGSREPK 664 
TNS4 ---------------------------------------------------------------------------------------------LQQAPQVEAKAT--------------- 77 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
 
TNS1 QQQQPRPPPRQQERAHLESLVASRPSPQPLAETPIPSLPEFPRAASQQEIEQSIETLNMLMLDLEPASAAAPLHKSQSVPGAWPGASPLSSQPLSGSSRQSHPLTQSRSGYIPSGHSLGT 775 
TNS2 REVVILEDPGLP--------------------------ALYPCPACEEKLALPTAALYGLRLEREAGEGWASEAGKPLLHPV------RPGHPLPLLLP-------------ACGHHHAP 748 
TNS3 QPQPLLRKPSVS--------------------------AQMQAYGQSSYSTQTWVRQQQMVVAHQYSFAPDGEARLVSRCPADNPGLVQAQPRVPLTPTRGTSSRVAVQRGVGSGPHPPD 758 
TNS4 ---CFLPSPGEK--------------------------ALGTPEDLDSYIDFSLESLNQMILELDP--------------------------TFQLLPP-------------GTGGSQAE 129 
PTEN ---------------------------------------------------------KFMYFEFP------------------------------------------------------- 244 
 
TNS1 PEPAPRASLESVPPGRSYSPYDYQPCLAGPNQDFHSKSPASSSLPAFLPTTHSPPGPQQPPASLPGLTAQPLLSPKEATSDPSRTPEEEPLNLEGLVAHRVAGVQAREKQPAEPPAPLRR 895 
TNS2 MP-------------------DYSCLKPPKA---GEEGHEGCSYTMCPEGRYGHPGYPALVTYSYG-------------------------------GAVPSYCPAYGRVPHSCGSPGEG 815 
TNS3 TQ-------------------QPSPSKAFKPRFPGDQVVNGAGPELSTGPSPGSPTLDIDQSIEQLNRLILELDPTFEPIPTHMNALGSQANGSVSPDSVGGGLRASSRLPDTGEGPSRA 859 
TNS4 LA-------------------QSTMSMRKKE---ESEALDIKYIEVTSARSRCHDG------------------------------------------------------PQHCSSP--- 170 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
TNS1 RAASDGQYENQSPEATSPRSPGVRSPVQCVSPELALTIALNPGGRPKEPHLHSYKEAFEEMEGTSPSSPPPSGVRSPPGLAKTPLSALGLKPHNPADILLHPTGVTRRRIQPEEDEGKVV 1015 
TNS2 RGY-------PSPGAHSPRAG-----------------SISPGSP-----------PYPQSRKLSYEIPTEEGGDRYPLPGHLASAGPLASAES--------LEPVSWREGPSGHS---- 888 
TNS3 TGR-------QGSSAEQPLGG-----------------RLRKLSLGQYDNDAGGQLPFSKCAWGKAGVDYAPNLPPFPSPADVKETMTPGYPQD--------LDIIDGRILSSKES---- 943 
TNS4 --------------SVTPPFG-----------------SLRSGG-----------------LLLSRDVPRETR----------SSSESLIFSGN--------QGRGHQRPLPPSEG---- 220 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
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TNS1 VRLSEEPRSYVESVARTAVAGPRAQDSEPKSFSAPATQAYGHEIPLRNGTLGGSFVSPSPLSTSSPILSADSTSVGSFPSGESSDQGPRTPTQPLLESGFRSGSLGQPSPSAQRNYQSSS 1135 
TNS2 -------------------TLPRSPRDAPCSASSELSGP------------------STPLHTSSPVQGKEST-------RRQDTRSPTSAPTQRLSPGEALPPVSQAGTGKAPELPSGS 964 
TNS3 -------------------MCSTPAFPVSPETPYVKTALR-----------------HPPFSPPEPPLSSPAS-------QHKGGREPRSCPET-LTHAVGMSESPIGPKSTMLRADASS 1019 
TNS4 -------------------LSPRPPNSPSISIPCMGSKA------------------SSPHGLGSPLVASP----------RLEKRLGGLAPQR----GSRISVLSASPVSDVSYMFGSS 289 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
 
TNS1 PLPTVGSSYSSPDYSLQHFSSSPESQARAQFSVAGVHTVPGSPQARHRTVGTNTPPSPGFGRRAINPSMAAPSSPSLSHHQMMGPPGTGFHGSTVSSPQSSAATTPGSPSLCRHPAGVYQ 1255 
TNS2 GPEPLAPSPVSPTFPPSSPSDWPQERS----------------------------------------------------------PGGHSDGASPRSPVPT-------TLPGLRHA---P 1016 
TNS3 TPSFQQAFASSCTISSNGPGQRRESSSSAERQWV-----------------------------------------ESSPKPMVSLLGSGRPTGSPLSAEFSGTRKDSPVLSCFPPS---E 1095 
TNS4 ----------QSLLHSSNSSHQSSSRS----------------------------------------------------------LESPANSSSSLHSLGS-------VSLCTRPS---D 331 
PTEN ------------------------------------------------------------------------------------------------------------------------ 
 
TNS1 VSGLHNKVATTPGSPSLGRHPGAHQGNLASGLHSNAIASPGSPSLGRHLGGSGSVVPGSPCLDRHVAYGGYSTPEDRRPTLSRQSSASGYQAPSTPSFPVSPAYYPGLSSPATSPSPDSA 1375 
TNS2 WQGPRGPPDSPDGSPLTPVPSQ----------------------MPWLVASP--------------------EPPQSSPTPAFPLAASYDTNGLSQ------------------------ 1070 
TNS3 LQAPFHSHELSLAEPPDSLAPPSSQAFLGFGTAPVGSGLPPEEDLGALLANS--------------------HGASPTPSIPLTATGAADNGFLSHNFLTVAPGHSSHHSPGLQGQGVTL 1195 
TNS4 FQAPRNP-TLTMGQPRTPHSPP----------------------LAKEHASS--------------------CPPSITNSMVDIPIVLINGCPEPG------------------------ 384 
PTEN --------------------------------------------------------------------------------QPLPVCG--------------------------------- 251 
                                       
TNS1 AFRQGSPTPALPEKRRMSVGDRAGSLPNYATINGKVSSPVASGMSSPSGGSTVSFSHTLPDFSKYSMPDNSPETRAK-----VKFVQDTSKYWYKPEISREQAIALLKDQEPGAFIIRDS 1490 
TNS2 --------PPLPEKRHLPGPGQQ---PGPWGPEQA--SSPARGISH-----HVTFAPLLSDNVPQTPEPPTQESQSN-----VKFVQDTSKFWYKPHLSRDQAIALLKDKDPGAFLIRDS 1167 
TNS3 PGQ-----PPLPEKKRASEGDRS---LGSVSPSSSGFSSPHSGSTI-----SIPFPNVLPDFSKASEAASPLPDSPGDKLVIVKFVQDTSKFWYKADISREQAIAMLKDKEPGSFIVRDS 1302 
TNS4 --------SSPPQRTPGHQNSVQ---PGAASPSNP--CPATRSNSQ-----TLSDAPFT-----TCPEGPARDMQPT-----MKFVMDTSKYWFKPNITREQAIELLRKEEPGAFVIRDS 476 
PTEN --------------------------------------------------------------------------------------DIKVEFFHKQNK-------MLKKDKMFHFWVN-T 277 
 
TNS1 HSFRGAYGLAMKVSSPPPTIMQQNK-KGDMTHELVRHFLIETGPRGVKLKGCPNEPNFGSLSALVYQHSIIPLALPCKLVIPNRDPTDESKDS--SGPANSTADLLKQGAACNVLFINSV 1607 
TNS2 HSFQGAYGLALKVATPPPSAQPW---KGDPVEQLVRHFLIETGPKGVKIKGCPSEPYFGSLSALVSQHSISPISLPCCLRIPSKDPLEETPEAPVPTNMSTAADLLRQGAACSVLYLTSV 1284 
TNS3 HSFRGAYGLAMKVATPPPSVLQLNKKAGDLANELVRHFLIECTPKGVRLKGCSNEPYFGSLTALVCQHSITPLALPCKLLIPERDPLEEIAESSPQTAANSAAELLKQGAACNVWYLNSV 1422 
TNS4 SSYRGSFGLALKVQEVPASAQSR---PGEDSNDLIRHFLIESSAKGVHLKGADEEPYFGSLSAFVCQHSIMALALPCKLTIPQR---ELGGADGASDSTDSPASCQKKSAGCHTLYLSSV 590 
PTEN FFIPGPEETSEKVENGSLCDQEIDSICSIERADNDKEYLVLTLTKNDLDKANKDK----------------------------------------------ANRYFSPNFKVKLYFTKTV 351 
 
TNS1 DMESLTGPQAISKATSETLAADPTPAATIVHFKVSAQGITLTDNQRKLFFRRHYPLNTVTFCDLDPQERKWMKTEGGAPAKLFGFVARKQGSTTDNACHLFAELDPNQPASAIVNFVSKV 1727 
TNS2 ETESLTGPQAVARASSAALSCSPRPTPAVVHFKVSAQGITLTDNQRKLFFRRHYPVNSITFSSTDPQDRRWTNP-DGTTSKIFGFVAKKPGSPWENVCHLFAELDPDQPAGAIVTFITKV 1403 
TNS3 EMESLTGHQAIQKALSITLVQEPPPVSTVVHFKVSAQGITLTDNQRKLFFRRHYPVNSVIFCALDPQDRKWIK--DGPSSKVFGFVARKQGSATDNVCHLFAEHDPEQPASAIVNFVSKV 1540 
TNS4 SVETLTGALAVQKAISTTFERDILPTPTVVHFKVTEQGITLTDVQRKVFFRRHYPLTTLRFCGMDPEQRKWQK--YCKPSWIFGFVAKSQTEPQENVCHLFAEYDMVQPASQVIGLVTAL 708 
PTEN EEPSNPEASSSTSVTPDVSDNEPD------HYRYSDT-----------------------TDSDPENEPFDEDQHTQITKV--------------------------------------- 403 
 
TNS1  MLNAGQKR 1735 
TNS2  LLGQRK-- 1409 
TNS3  MIGSPKKV 1548 
TNS4  LQDAERM- 715 
PTEN  -------- 
Fig. 20: Clustal amino acid sequence alignment of the Tensin protein family and PTEN. ClustalW analysis of the four Tensins and PTEN show sequence 
homology, the C1 domain is indicated in red, the PTPase/C2 domain in green, the SH2 domain in blue and the PTB domain in purple. PTEN shares 
homology with Tensins 1-3 with the PTPase/C2 domains being homologous to the entire PTEN protein (92). 
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1.3.2. The Tensin family proteins 
The Tensins are a family of four homologous proteins with similar domain 
patterns but with distinct expression patterns and also potential functions (Fig. 
21 and Clustal analysis Fig. 20, Ensembl analysis 16-19 Table 5).  
Fig. 21: A schematic of the Tensin protein family. The Tensin -1, -2 and -3 molecules are larger than 
Tensin4, which is due to their extra possession of N-terminal C1, PTPase and C2 domains which Tensin4 
lacks. The domains are colour coded as follows: red: C1 domain; green: PTPase/C2 domains; blue: SH2; 
purple: PTB domain.  
Table 5: ClustalW analysis of degree of homology amongst various Tensin isoforms within the 
Tensin protein family. Each protein was compared against each other and assigned a score, 
with a higher score meaning greater homology between two proteins (92).  
First 
Tensin 
aa 
length 
Second 
Tensin 
aa 
length Score 
TNS1 1735 TNS3 1548 42 
TNS2 1409 TNS3 1548 38 
TNS1 1735 TNS2 1409 35 
TNS3 1548 TNS4 715 34 
TNS1 1735 TNS4 715 31 
TNS2 1409 TNS4 715 30 
TNS1 1735 PTEN 403 26 
TNS3 1548 PTEN 403 25 
TNS2 1409 PTEN 403 23 
TNS4 715 PTEN 403 3 
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1.3.2.1. The domain compositions of Tensin proteins 
All four of the Tensin molecules contain similar C-terminal regions containing an 
adjacent pairing of a Src homology 2 (SH2) domain and a phosphotyrosine-
binding (PTB) domain (93). In addition, Tensins 1-3 also contain tandem protein 
tyrosine phosphatase (PTPase) and C2 domains at their N-termini, whereas 
Tensin 4 lacks this region (94). Furthermore, specific isoforms of Tensin2 and 
Tensin3 additionally contain N-terminal C1 domains (Fig. 17, 18 and 21).  
The SH2 domain of all four Tensins is approximately 100 amino acids in length 
(Fig. 21). SH2 domains are distinct tertiary structural entities within many 
intracellular proteins that recognise and bind docking sites in other proteins that 
contain the modified amino acid phosphotyrosine (pTyr) (95). They mediate this 
protein-protein interaction for many proteins with a wide range of functions (95). 
For example, through phosphotyrosine-binding they can activate many protein 
tyrosine kinases (PTKs), which regulate many intracellular pathways involved in 
aspects of cellular communication. However, more recently, it has become 
apparent that several SH2 domains may bind other proteins in a pTyr-
independent manner (96), and the SH2 domains of Tensins may qualify as one 
such subtype of these domains. The structural characteristics of the SH2 
domain of Tensin2 was analysed by nuclear magnetic resonance (NMR) by Dai 
et al., and compared with the SH2 domain of SAP, which interacts with ligands 
in a pTyr-independent way (96). Although these two SH2 domains share low 
sequence identify, at the tertiary structural level, they both have typical SH2 
folds, with five central β strands flanked by two α helices at either side. This 
indicates that the SH2 domains are structurally conserved.  
Following the discovery of SH2 domains in the early nineties, other distinct 
protein motif-binding domains were also identified and described, including the 
PTB domain (97). In all four Tensin proteins, the PTB domain is located very 
close to, and virtually directly following the SH2 domain at the C-terminal. The 
PTB domains of Tensins have been shown to bind to various proteins, including 
β-integrins (98) and RTKs (84). The PTB domain of Tensin1, however, was 
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shown not interact to with tyrosine-phosphorylated proteins (99). However, the 
individual PTB domains of the other Tensins have not been assessed. PTB 
domains share generally similar structural and binding partner characteristics, 
however, there is a significant variety in their specific molecular features (100). 
For example, NMR structural analysis of the PTB domain of Tensin1 identified it 
as similar to the PTB domain of X11 protein (101). X11 is part of a multidomain 
protein family with a conserved PTB domain; this was used as a template for 
structural comparison in the NMR analysis (102). It was also noted that that it 
was structurally related to pleckstrin homology (PH) domains as both types of 
domains contain two β-sheets almost at right angles to each other, both being 
generally organised as three- and four-stranded, and also both domain types 
contain a C-terminal helix. Furthermore, Tensin1’s PTB domain contained an 
additional N-terminal helix which was found between β1 and β2 of the PTB 
domain. Moreover, it was shown that this domain is able to interact with 
phospholipids, specifically phosphatidylinositol (4,5)- bisphosphate 
(PtIns(4,5)P2) and phosphatidylinositol 4-phosphate (PtdIns(4)P), in a pocket 
that is distinct from the integrin binding site (101). Therefore, this further 
supports the dual nature of the Tensin PTB domain as both PTB-like and PH-
like.  
The C1 domain, which is found at the N-termini of isoforms of Tensin2 and 
Tensin3, is a small domain of around 50 amino acids length and is found in 
many proteins. The C1 domain of protein kinase C is the first characterised and 
best described of all, being able to bind to phorbol esters/diacylglycerol, a 
property that is important for both normal and aberrant PKC-mediated signalling 
pathways for cell growth and tumourigenesis respectively (103). By comparison, 
however, the C1 domains of Tensin2 and -3 are ‘atypical’, as they are shorter 
than 50 amino acids in length and as a consequence are also predicted to be 
non-phorbol ester binding (104). All full-length isoforms of Tensin2 (with or 
without a C1 domain) display the same localisation pattern within cells, i.e. one 
of punctate localisation in the cytoplasm and not in the nucleus (94). However, 
expression of the C1 domain alone in cells leads to its almost exclusive 
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presence in the nucleus. Moreover, smaller, N-terminal fragments of Tensins 
that possess a C1 domain are also partially located in the nucleus. Therefore, it 
is suggested that the C1 domain may serve to localise the Tensin, either the 
whole molecule or a fragment of it, into the nucleus under certain conditions, 
e.g. apoptosis, where proteolytic cleavage of Tensin into shorter fragments may 
occur (94).  
Tensins -1, -2, and -3 also contain a PTPase-C2 domain pairing, sometimes 
designated as a single domain, while Tensin4 lacks this domain pair altogether. 
The PTPase-C2 domain is homologous to almost the entire PTEN molecule, 
PTEN being a major tumour suppressor protein. The phosphatase activity in 
PTEN is predominantly that of a lipid phosphatase, with the main substrate 
being phosphatidylinositol (3,4,5)-trisphosphate (PtIns (3,4,5)P3), the 
dephosphorylation of which represents the major mechanistic element of the 
function of PTEN. This is because PTEN reverses the phosphorylation of PtIns 
(4,5)P2 to PtIns (3,4,5)P2 by PI3K, a major kinase that activates growth-
promoting intracellular signalling following e.g. growth factor receptor activation.  
The secondary and predicted tertiary structural similarity between the PTPase 
domains of Tensins -2 and -3 and PTEN therefore suggest that these Tensins 
may too possess similar lipid phosphatase activity (94). The potential for 
phosphatase activity in the PTPase domain of Tensin1 is excluded as it lacks 
certain crucial amino acid residues necessary for catalytic activity (105). 
Specifically, while both Tensin2 and Tenisn3 contain an essential catalytic 
cysteine residue in the PTPase domain, Tensin1 contains an asparagine in its 
place. However, sequence differences do exist between Tensin2 and Tensin3 
which also may affect their potential phosphatase activities as well as their 
substrate specificities. When modelling the Tensin2 PTPase domain, PtdIns 
(3,4,5)P3 as a substrate fits well into the binding site and all the essential 
residues are present, as is the case with PTEN, suggesting that Tensin2 may 
be an active phosphatase. However, molecular modelling of the PTPase 
domains suggests otherwise for Tensin3. Specifically, the “WPD loop” is 
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important in catalysis by protein tyrosine phosphatases (106); however, the 
Tensin3 PTPase domain has a small insertion in the “WPD” loop, which would 
sterically clash with PtdIns (3,4,5)P3 as substrate and therefore modify its 
potential catalytic activity (107) (Fig. 22). Moreover, Tensin3 has a smaller 
binding pocket with fewer hydrogen bond donors and acceptors as well as less 
hydrophobic probes. Therefore, this evidence suggests that Tensin3 is less 
capable of binding a potential substrate ligand than Tensin2 or PTEN (107).  
Fig. 22: Structural analysis of PTPase domains of Tensin2 and Tensin3 as well as PTEN. The 
molecular surface of the PTPase domains are shown, in green, with their active sites occupied 
by the head group of PtdIns (3,4,5)P3, inositol ring in grey, phosphates in orange. The P loop 
containing the putative catalytic Cyst residue is shown by a white arrow (107).  
Furthermore, Lo et al. have proposed an actin-binding domain (ABD) to be 
present at the N-terminal of the Tensin molecule, which overlaps with the N-
terminal PTPase and C2 domains (108). The PTPase/C2 domain is from amino 
acids 63-369, while the ABD domain is located from 1-463 amino acids. 
However, these regions in the other Tensins have not been experimentally 
determined to be actin-binding, and are designated as such due to sequence 
homology to Tensin1, which has been studied in greater molecular detail.  
 
1.3.3. Expression of Tensins in human tissues 
The different Tensins have distinct expression profiles in the body. As observed 
by northern blotting, Tensin1 mRNA is most prominently expressed in the heart, 
skeletal muscle, kidney and lung (109) (Fig. 23 A), while Tensin2 is 
predominant in the heart, kidney and liver (84) (Fig. 23 B). Tensin3 expression 
64 
 
is prominent in the kidney, placenta as well as in the thyroid (86, 110) (Fig. 24 
A), while Tensin4 expression is greatest in the placenta and the prostate (89) 
(Fig. 24 B). The most common feature amongst all four Tensins is their 
presence in the kidney, although to different extents. Tensin3 was shown to be 
present almost exclusively at the proximal tubular epithelium in normal human 
kidney (111). A study assessing the Tensins in mouse kidney found that 
Tensins 2-3 were expressed in the glomeruli, while Tensin1 was only weakly 
expressed there, and Tensin4 was not expressed at all (112).  
Fig. 23: Tensin1 and Tensin2 distribution in human tissues by northern blot analysis. A. 
Tensin1; top panel, long exposure, middle panel, short exposure, bottom panel reprobing with 
B-actin. (107). B. Tenisn2, top panel Tensin2 variant 1, middle panel all tensin2 variants and 
bottom panel reprobed with B-actin (84). Both; Lanes: 1, brain; 2, heart; 3, skeletal muscle; 4, 
colon; 5, thymus; 6, spleen; 7, kidney; 8, liver; 9, small intestine; 10, placenta; 11, lung and 12, 
peripheral blood leukocyte.  
Fig. 24: Northern blot analysis of Tensin3 and Tensin4 in human organs. A. Tensin3; the kidney 
and placenta have higher levels of Tensin3 mRNA compared to other human tissues however 
low levels of Tensin3 can be detected in other tissues, bottom panel reprobed with β-actin (9).B. 
Tensin4; bottom panel reprobed with β actin. Lanes: 1, brain; 2, heart; 3, skeletal muscle; 4, 
colon; 5, thymus; 6, spleen; 7, kidney; 8, liver; 9, small intestine; 10, placenta; 11, lung; 12 
peripheral blood leukocyte; 13, prostate; 14 testis and 15, ovary (89).  
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1.3.4. Functions of the Tensin proteins 
As all four Tensins are expressed in the kidney, it is therefore reasonable to 
hypothesise that they play roles in normal kidney development and function. A 
study on Tensin1 knockout mice, found the mice appear initially normal at birth; 
however, after 2 months they had significant abnormalities in the kidneys, which 
were pale and with a granular appearance, and displayed other defects 
including cysts and defects and glomerular abnormalities (113). However, 
despite this, the Tensin1 null mice often appeared clinically normal and did not 
exhibit any abnormalities that might manifest themselves as kidney failure. This 
absence of a clear abnormal kidney phenotype may however have been due to 
compensation from the presence of other members of the Tensin family (113). 
Nishino et al. studying the mouse strain ICGN, which is a model for 
glomerulosclerosis, found that the aberrant phenotype was caused by a natural 
deletion of the Tensin2 gene (Tenc1) (114).  
In a study of knockout mice that were generated lacking the Tensin3 gene, 
other phenotypes were displayed including: growth retardation, defects in small 
intestine development, lungs with enlarged distal air spaces and bone defects, 
with many of the mice dying within 3 weeks of birth. However, the cause of 
death in these mice was not clear; it was likely due to a combination of defects 
in the intestine, lungs and bones which lead to incomplete development of those 
organs (115). In 2008, a study reported on a prematurely born child, who was 
described with a complex syndromic phenotype, presenting with renal agenesis, 
low kidney function, neutropenia, recurrent pulmonary infections and growth 
and developmental delays (116). Genetic analysis of the patient revealed the 
presence of a balanced chromosomal translocation involving reciprocal fusions 
of parts of the TNS3 gene and another gene, EXCO6B. The translocation 
breakpoints gave rise to fusion transcripts TNS3-EXOC6B and EXOC6B-TNS3. 
The multiple clinical features mentioned above for the patient indicates a 
possible role for Tensin3 in at least kidney and lung development and function, 
although the same could equally apply for ExoC6B.  
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Further similarities in terms of molecular functionality exist amongst the Tensins 
in that both Tensin1 and Tensin4 have been shown to be cleaved by caspases. 
Tensin1 was shown to be cleaved by caspase-3, which could be prevented by a 
general caspase inhibitor as well as specific caspase-3 inhibitors. Tensin1, 
moreover, was lost from focal adhesion sites during etoposide-induced 
apoptosis (117). Tensin4 was also shown to be cleaved by caspases-3 
specifically, after undergoing a screen of potential cleaving enzymes including 
many other caspases. Furthermore, it was shown that a caspase-3 cleavage 
site lay between the SH2 and PTB domains, with cleavage giving rise to two 
fragments, Tensin4 without the PTB domain (1-570) and the PTB domain alone 
(571-715) (118). These studies therefore suggest that the Tensins may 
potentially be effectors of apoptotic signalling through being cleavage 
substrates of caspases, and their cleavage products potentially being able to 
relocate inside the cells and influence downstream outcomes. These could for 
example be affected by translocation of fragments that contain a C1 domain to 
the nucleus to influence gene expression, or removal of a cleaved Tensin from 
a previous location within focal adhesions.  
 
1.3.4.1 Tensins and their role in focal adhesions 
Focal adhesion proteins are important for linking the actin cytoskeleton to 
integrins and thereby the extracellular matrix (ECM). Focal adhesion complexes 
are able to mediate the link between the ECM and actin, and in this way are 
able to regulate cell growth and cell motility (Fig. 25). The disruption of focal 
adhesion complexes has been implicated in diseases such as cancer, which 
feature altered cell cytoskeletal dynamics and consequent aberrant cell motility 
and migration (119). A number of proteins have been identified over the years 
that reside in focal adhesion complexes and are able to act as direct bridges 
between the ECM and the cytoskeleton; these include Tensin, Talin, Filamin 
and α-actinin, while others link to other proteins before binding to actin or 
integrins (119).  
67 
 
Fig. 25: An example of a focal adhesion complex, the focal adhesion proteins in green bind to 
each other, to integrins and to actin. Tensin is depicted as also interacting with DLC1/2, a 
tumour suppressor and well-studied binding partner. Through these links, the focal adhesion 
proteins are able to active signalling pathways that regulate cell migration, adhesion, invasion, 
proliferation and apoptosis (120).  
The Tensins are believed to be involved in the interaction between integrins and 
the actin cytoskeleton through their interactions in focal adhesion complexes; 
however, only Tensin1 has so far been convincingly shown to exhibit this role. 
Tensin1 was first studied for its ability to bind actin, within three distinct actin 
binding domains (ABD) were identified, two located in the N-terminal and one 
located in the central “unknown” portion of the protein. Through those actin 
interactions, it was shown that Tensin1 was able to slow the rate of actin 
polymerisation and reduce F-actin elongation (108), both of two processes 
being important for cell motility (121). Further analysis of the ABD located in the 
unknown region revealed a 103-amino acid fragment which selectively 
eliminated ECM contacts, indicating that Tensin1 may be important in these 
structures. Furthermore, cells which overexpressed Tensin1 were unable to 
translocate integrins out of focal contacts (FC) (122). It was later found that 
Tensin1 mainly associates with fibrillar adhesions, which are usually found in 
more central locations in the cell, but which also can move slowly along cell 
margins in focal contacts (123). Therefore, it is through their placements and 
roles in focal adhesions that the Tensins may exert major influences on cell 
shape and stability, and conversely, impairment of Tensin expression/function 
may result in aberrant cell motility and migration.  
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1.3.4.2 Tensins and cell motility 
Due to the Tensins ability to bind to integrins and to actin, suggesting that they 
may be involved in cell migration. Tensin1 and Tensin2 (isoform 3) were shown 
to increase cell migration when overexpressed in HEK293 cells (83). Another 
study also showed this isoform of Tensin2 to increase migration of human 
hepatocellular carcinoma cells (85). Furthermore, cells isolated from Tensin1 
null mice migrate significantly slower than cells from wildtype mice (83).  
Fig. 26: The effects of Tensin1 and Tensin2 isoform3 on HEK293 cell migration. Cells were 
analysed using a transwell assay. Both Tensin1 and Tensin2 were shown to increase cell 
migration compared with empty GFP vector alone (83).  
However, another study using a similar approach of overexpression in HEK293 
cells showed that another Tensin2 isoform, one that possessed a C1 domain 
(as opposed to isoform 3, which lacks a C1 domain), decreased cell migration 
versus non-expressing cells (Fig. 27.) (124). Therefore, taking the results of 
these two similar studies together, it appears that the C1 domain plays a role in 
the cytoskeletal signalling effects of Tensins. This would have implications in 
pathologies such as cancer, where aberrant cell migration features, depending 
on specifically which Tensin isoform is altered in the cancer cell.  
69 
 
Fig. 27: The effect of Tensin2 (C1-TEN) on cell migration of HEK293. A transwell migration 
assay was conducted with cells transfected with Tensin2 isoform 1; this caused a reduction in 
cell migration as compared to mock-transfected cells (124).  
Furthermore, Tensin2 has been shown to negatively regulate the Akt pathway 
which is involved in cell survival, cell migration and metabolism (124). Tensin2 
has also been shown to reduce intracellular PtdIns (3,4,5)P3 levels, possibly 
through phosphatase activity of its PTPase domain that is similar to PTEN. As 
the Akt pathway is activated by increased membrane PtdIns (3,4,5)P3 levels, 
therefore this may be the mechanism through which Tensin2 inhibits the Akt 
pathway. This appears to be a unique property amongst the Tensin family, 
where in contrast to Tensin2, Tensin1 lacks the necessary sequence for 
phosphatase activity (105), whilst Tensin3, although containing an essential 
cysteine residue in its catalytic domain, is however incapable of binding 
PtdIns(3,4,5)P3 (107); lastly, Tensin4 lacks a PTPase domain altogether. It is 
therefore possible that Tensin2 exerts its suppressive effects on cell migration 
effects through its inhibition of the PI3K/Akt signalling pathway, although the 
molecular link between this pathway and the cytoskeleton is unclear. Alongside 
integrins, Tensin2 has also been shown to interact with RTKs such as Axl. Axl is 
involved in cell survival, proliferation and cell migration, and its overexpression 
has been reported in several cancers (125). Tensin2 was shown through 
immunoprecipitation to interact with Axl, and this interaction occurred via both 
the SH2 and PTB domains of Tensin2. As Axl is a kinase that mainly regulates 
cell migration and adhesion, it is equally possible that Tensin2 is able to 
regulate cell migration by mediating the signalling downstream of RTKs such as 
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Axl (84). When studying the effects of individual domain of Tensin2 on cell 
migration, Hafizi et al. found that the SH2-PTB pairing and the isolated PTB 
domain caused significant increases in cell migration (Fig. 28), highlighting the 
C-terminal region of Tensin2 (and possibly the other Tensins as they are 
homologous) to play a key role in cell migration (94). This gives further weight to 
the idea that Tensin4, the shortest Tensin, which lacks the N-terminal region of 
other, longer, Tensins, may induce increased cell migration through its ability to 
bind to integrins but not concomitantly to the actin cytoskeleton, as the PTB 
domain has been shown to bind to integrin β subunits (98).  
Fig. 28: The effect of C-terminal domains and full length Tensin2 on cancer cell migration. 
DU145 transfected with the individual C-terminal domains SH2 and PTB and the tandem SH2-
PTB domain as well as full length Tensin2 underwent a transwell assay analysis. Cells 
containing the PTB domain including the SH2-PTB showed an increased rate of migration 
compared with the full length Tensin2 isoform 2, indicating that the PTB helps to promote cell 
migration in these cells (126).  
Initial studies also suggested that Tensin3 plays a role in the suppression of cell 
migration. Using a similar overexpression model, Tensin3 was also shown to 
have a negative effect on cell migration in HEK293 cells (Fig. 29). Also, siRNA 
knockdown of Tensin3 in human melanoma cells resulted in increased cell 
migration (Fig. 29) (111).  
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Fig. 29: Overexpression of Tensin3 in HEK293 cells. M1-3 are mock cells (HEK293) while T1-3 
are HEK293 transfected with Tensin3, these were then analysed by a transwell assay. The 
tensin3 transfected cells migrate significantly less than the mock cells, *** denotes P<0.001 for 
mock cells vs. Tns3 (ANOVA with Bonferroni adjustment). 
In contrast, a study by Qian et al. in two non-small cell lung cancer (NSCLC) 
cell lines showed that Tensin3 positively regulated cell migration and 
anchorage-dependant growth (93). Also, Tensin3 knockdown in these cells by 
siRNA caused a decrease in cell migration compared to the knockdown of the 
other Tensins. The contrasting results from these different studies could be due 
to the use of different cell lines in the different studies, the first using non-cancer 
cells whilst the latter used cancer cells.  
Interestingly, a study found that overexpression of the microRNA miR200 
caused a reversal in epithelial-mesenchymal transition (EMT) in metastatic lung 
adenocarcinoma derived from mice and also featured an upregulation of 
Tensin3 (127). Conversely, Tensin4 was shown to increase EMT, with cells 
expressing Tesin4 having a more spindle-like morphology (128). EMT leads to 
degradation of cell-cell and ECM interactions which leads to the release of 
epithelial cells from the surrounding tissue; also, the cytoskeleton is reorganised 
to allow for the movement of cells and a new transcriptional paradigm is 
induced to maintain the mesenchymal phenotype (126). EMT is an important 
mechanism during development but one that can also be hijacked in cancer.  
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Ectopic expression of Tensin4 has been shown to cause an increase in 
migration of two colon carcinoma cell lines (128). Also, Tensin4 knockdown in 
the mammary epithelial cell line MCF10A caused a decrease in cell migration. 
Furthermore, while siRNA control transfection with no EGF stimulation 
produced very little cell migration, EGF stimulation stimulated an increase in 
migration. However, the EGF effect did not take place when Tensin4 has been 
knocked out; these results therefore indicate that Tensin4 plays a role in EGF-
driven migration of these cells (Fig. 30).  
Fig. 30: MCF10A cells transfected with siRNA against Tensin4. Cells were analysed by 
transwell assay. siRNA knockdown of Tensin4 (CTEN); without EGF, there is little migration 
after siControl, however, after EGF treatment the migration of the siControl cells increases, 
whilst the Tensin4 knockdown, the migration does not increase indicating that EGF driven 
migration involves Tensin4. Modified from Katz et al. (129). 
Additionally, Katz et al. showed that EGF stimulation of the cervical cancer 
cells, HeLa caused an increase in Tensin4 mRNA (red) whilst simultaneously 
Tensin3 mRNA expression decreased over the same time period (blue) (Fig. 
31) 
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Fig. 31: The expression of the 4 different Tensins in HeLa cells after EGF treatment. HeLa cells 
were stimulated with EGF over 500 min. The expression of the different Tensins was measured 
by oligonucleotide arrays. Tensin3 (blue) is shown to decrease over time, whilst Tensin4 (red) is 
shown to increase, there is no change in Tensin2 (brown/green) or Tenisn1 (bright green) (129).  
Katz et al. observed that this concomitant up- and downregulation of two related 
genes was linked to an increase in cell migration, proposing a model where 
Tensin4 competed for the integrin binding site usually occupied by the Tensin3 
C-terminal (Fig. 32).  
Fig. 32: A model of the function of Tensin4 and Tensin3 following stimulation with EGF. In 
normal resting cells stress fibres anchor to focal adhesion sites through Tensin3 or other 
binders simultaneously binding actin. Following EGF stimulation, Tensin3 is downregulated 
concomitantly as Tensin4 is upregulation, causing Tensin3 displacement from integrin, leading 
to breakdown of actin stress fibres and initiation of cell migration (129). 
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Tensins are also phosphoproteins in that they can be post-translationally 
modified through phosphorylation. One clear indication that this process occurs 
is interactions between the Tensin family and multiple RTKs. For example, 
Tensin3 was shown to be phosphorylated by EGF stimulation in breast cancer 
cells (86). The increase in phosphorylation appeared to be dependent on Src 
kinase, which was the first tyrosine kinase described as well as initially being 
described as a proto-oncogene (130). The reason for the EGF stimulation effect 
on Tensin3 particularly in the breast cancer cells studied was likely due to 
overexpression of EGF receptors (EGFR), as occurs often in breast cancer 
(93). An earlier study by Cui et al. showed that Tensin3 phosphorylation was 
also dependent on autophosphorylation by the EGFR as well as on Src in 
breast cancer cell lines (86). Both studies showed that Tensin3 phosphorylation 
was required for it to interact with focal adhesion kinase (FAK) and p130Cas, 
both of which are involved in focal adhesions. It was further shown that these 
interactions occur through phosphorylation of the SH2 domain (93).  
Table 6: Overview of migration studies for all four Tensins. 6 different cell lines were used in 5 
different studies, these were HEK293, kidney cell line; H1299, human non-small cell lung 
carcinoma cell line; WM793, melanoma cell line; MCF10A, mammary epithelial cells and 
HCT116 and SW480, both colon carcinoma cell lines.  
 Increase migration Decrease migration 
Tensin1 HEK293 (83).   
Tensin2 HEK293 (83).  HEK293 
Tensin3 H1299 (93) HEK293 (111) 
WM793 (111) 
Tensin4 MCF10A (129) 
HCT116 (128) 
SW480 (128) 
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1.3.4.2.1 Tensins as effectors of DLC1 tumour suppressor gene 
Deleted in liver cancer 1 (DLC1) is a tumour suppressor gene that was originally 
identified as being dysregulated in liver cancer, hence the name ascribed to it 
(131). DLC1 is a GTPase-activating protein (GAP) for the Rho family GTPases, 
particular RhoA-C. As these are involved in cell migration and cytoskeleton 
regulation, it was therefore hypothesised that DLC1 dysregulation would affect 
such cellular behaviours. Yam et al. first identified Tensin2 as a DLC1 binding 
partner from a yeast two-hybrid screen of human liver cDNA (132). They then 
localised the interaction site between the two proteins to lie within the PTB 
domain of Tensin2 and within the central region of DLC1 (375-509 aa, full 
length, 1090 aa).  
Interestingly, Liao et al. also showed Tensin4 to also be an interaction partner 
for DLC1 through co-immunoprecipitation experiments (133). However, in 
contrast to the results of Yam et al., it was the Tensin4 SH2 domain that 
appeared to be most important in the interaction. This was further supported by 
the effects of mutations within the Tensin4 SH2 domain, where DLC1 did not 
localise to focal adhesion complexes.  
When studying Tensin1, Qian et al. found DLC1 to bind to both SH2 and PTB 
domains, with stronger binding to the SH2 domain (134). Furthermore, Kawai et 
al. found that the N-terminal of DLC1 was able to bind to Tensin2 but not the 
SAM domain of DLC1 alone. Furthermore, they further found an interaction 
between the Tensin2 PTB domain and the FAT domain of DLC1 (135). In yet 
another study, Chan et al. also found the Tensin2 PTB domain to be 
responsible for the binding of DLC1 (136) (Fig. 38). Taken together, all of these 
studies clearly show that DLC1 is a major and common binding partner to all 
four Tensins, and moreover the interaction takes place with the C terminal end 
of Tensins, containing the SH2 and PTB domains.  
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Fig. 33: A model of how DLC1 binds to focal adhesion complexes. DLC1 is able to bind to 
Tensin2 through PTB domain interaction and possible to other Tensin proteins through 
interaction with the SH2 domain or both (136).  
The Tensin2 PTB domain as an isolated overexpressed protein has been 
shown to cause an increase in cell migration (94). Analysis of the effect of the 
Tensin-DLC1 interaction on cell migration showed that these interactions could 
be influenced by EGF stimulation. siRNA knockdown of DLC1 in the presence 
of EGF caused an increase in migration, which also occurred with knockdown of 
Tensin3. Conversely, Tensin4 knockdown caused a decrease in migration in the 
presence of EGF; therefore indicated that the EGF effect on migration is 
mediated through the DLC1/Tensin3 interaction (Fig. 34).  
Fig. 34: DLC1 and the Tensins affect cell migration. siRNA knockdown of MCF10A cells were 
stimulated with EGF and their affect on cell migration was measured compared to cells 
stimulated with EGF (137).  
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As previously stated, EGF caused a switch between Tensin3 and Tensin4; 
therefore, as DLC1 is able to bind to both, this suggests that EGF stimulation 
might regulate RhoA through modulating Tensin-DLC1 interaction. It was found 
that EGF was able to increase intracellular levels of RhoA-GTP in MCF10A 
cells, although the total RhoA levels were unchanged (137). Moreover, EGF 
stimulation also mobilised RhoA translocation from the nucleus out to the 
cytosol. Also, depletion of Tensin4 led to a reduction in RhoA activation while 
conversely, Tensin3 depletion led to a drastic increase in Rho-GTP levels. In 
addition, co-expression of Tensin3 and DLC1 lead to a marked decreased in the 
Rho-GTP levels indicating that Tensin3 is an activator of DLC1 GAP function. 
The GAP activity of DLC1 is thought to be controlled by its SAM domain, which 
functions as an autoinhibitory switch. Tensin3 was able to activate this activity 
through its N-terminal region, which explains why Tensin4 was unable to do the 
same, due to its lack of a similar region. Therefore, the alternatively designated 
“actin-binding domain” or “ABD”, which overlaps with the PTPase-C2 domains, 
is able to bind to the DLC1 SAM region, releasing the autoinhibition (Fig. 35).  
Fig. 35: The proposed mechanism for the Tensin3/Tensin4 DLC1 RhoA signalling pathway. 
Left: In the absence of EGF, Tensin3 binds to DLC1, activating its RhoGAP activity. This 
enables the conversion of RhoA-GTP to RhoA-GDP, which downregulates ROCK this leads to 
uncoupling of FA and cell rest. Right: In the presence of EGF, Tensin3 is downregulated and 
Tensin4 upregulated, Tensin4 binds to DLC1 but does not inactive the autoregulation by binding 
to the SAM domain, the RhoGAP is inactive, and RhoA-GTP cannot be converted to RhoA-
GDP, upregulating ROCK, which increases FA complexes and cell migration (137).  
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DLC1 Rho-GAP activity is important for the downregulation of Rho-Associated 
Coiled-Coil-Containing Protein Kinase (ROCK) which leads to the uncoupling of 
focal adhesion proteins and leads to cell rest/an immobile state. However, 
Tensin4 binding causes Rho-GAP inactivation in DLC1, leading to an increase 
in ROCK and through this an increase in focal adhesions and cell migration 
(Fig. 35) (137). The overall indication from the results of the studies on Tensins 
and DLC1 is that Tensin3 activates DLC1 in its role as a Rho-GAP and that 
Tensin4 inactivates this RhoGAP activity, which is mediated by EGF.  
 
1.3.5. Tensins and their role in cancer 
The Tensins’ role in cell migration, as well as their dysregulation in various 
cancer types, has been observed in a number of studies. Broadly, Tensins 1-3 
have been shown to be downregulated in a number of cancers (111, 129, 138-
141), whilst Tensin4 conversely is mainly upregulated in cancer (89, 128, 142-
145). Tensin3, having been shown in one of the earlier studies to be 
preferentially expressed in the thyroid, was shown to be downregulated in 
thyroid cancers (Fig. 36) (110).  
Fig. 36: Tensin3 mRNA expression in clinical samples from patients with different types of 
thyroid cancer. The Tensin3 mRNA expression was normalised against GAPDH housekeeping 
gene, Tensin3 was shown to be downregulated compared to normal thyroid tissue. *P<0.005, 
**P<0.01 (110). 
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However, a distinction was observed depending on which type of thyroid tumour 
was studied; while Tensin3 was downregulated in most thyroid carcinomas and 
non-functioning thyroid follicular adenomas, the Tensin3 expression level in 
functional adenomas was very similar to that of normal tissue (146). 
Investigation of the complete Tensin family in human kidney cancer by 
Martuszewska et al. found expression of all four Tensins to be downregulated in 
kidney tumours (Fig. 37).  
Fig. 37: Tensins 1-4 mRNA expression in human kidney cancer. A, C: 223 RCC patients were 
grouped according to their tumour type and compared with 48 normal samples by qRT-PCR 
analysis for mRNA expression of Tensin2 and Tensin3. B, D: mRNA expression of Tensin1 and 
Tensin4 were measured in 134 RCC samples and 21 kidney cortex samples (normal). In panel 
D, n=123 refers to the number of tumour samples with no Tensin4 expression. Expression is 
relative to the housekeeping gene B2M. ***P<0.001 (111). 
This study also found that the reduction in Tensin1 and Tensin3 expression 
correlated with a higher tumour grade. Additionally, immunohistochemical 
staining of Tensin3 at the plasma membrane correlated with increased patient 
survival (Fig. 38). Indicating that both Tensin1 and Tensin3 suppression plays 
an important role in the development of more aggressive renal tumours (111).  
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Fig. 38: Kaplan-Meier survival curve of 88 patients with ccRCC. Patients with Tensin3 staining 
in the cytoplasm (n=72) had a lower survival rate than those who also showed staining at the 
plasma membrane (n=16) (111).  
However, while Tensin2 is downregulated in kidney cancer, in hepatocellular 
carcinoma (HCC), Tensin2 isoform 3 has been shown to be associated with 
aggressive tumour behaviour (85). Furthermore, Tensin2 isoform 3 was shown 
to be overexpressed in 43% of HCC compared with normal liver samples which 
may relate to the increase in cell migration seen with overexpression of this 
isoform 3. The difference between these could be due to the different isoforms 
under study; isoform 3 lacks a C1 domain, and leads to a more aggressive 
cancer type, rather than being involved in tumour suppression as the other 
isoforms are. This ties in with what is observed in in vitro studies on cultured 
cells, with isoform 3 causing an increase in cell migration while the others 
decrease it.  
Tensin4 is now the most extensively researched Tensin family member due to a 
larger number of reports of its dysregulation, most frequently an upregulation, in 
various human cancers. It was originally identified as being predominantly 
expressed in the prostate, as well as being downregulated in prostate cancer 
cell lines and some clinical samples (89). Sasaki et al., however, found that in 
lung cancer patients there was no difference between Tensin4 expression 
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levels in lung tumour versus normal lung samples; however, Tensin4 
expression level did positively correlate with increased tumour status (Fig. 39) 
(147).  
Fig. 39: Tensin4 mRNA expression according to the tumour status of lung cancer. Tumour 
status is derived from the TNM grading system, there is statistical significance between T1 vs. 
T4 and T2 vs. T4, indicating that this is a later stage event (147).  
This study used a larger cohort of patient samples than the study in prostate 
cancer, which could account for the differences in expression as Lo’s study only 
had 3 patient samples compared to 89 samples in the lung cancer study. 
However, different mechanisms may also have taken place as these were also 
distinct types of cancers, particularly as Tensin4 is normally expressed in the 
prostate. A study by Sasaki et al. on 45 clinical samples with thymoma also 
found little difference in Tensin4 expression between tumour and the normal 
samples. However, as observed in the lung cancer study, Tensin4 expression 
did positively correlate with tumour stage. Those observations indicate the 
potential for Tensin4 to be a greater player in more advanced stages of the 
disease, where cell motility is a more prominent feature. Furthermore, in a study 
in gastric cancer on 114 matched tumour and non-tumour normal samples, 
Tensin4 mRNA expression was very significantly increased in the tumour 
samples.  
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Furthermore, the patients with higher level of Tensin4 expression also displayed 
a poorer histological grade, deeper invasion into the serosa and more positive 
lymph node metastasis, as well as an increased risk of cancer-related death 
(Fig. 40).  
Fig. 40: Kaplan-Meier survival curve of patients with gastric cancer. Those patients with higher 
TNS4 expression had shorter survival after surgery than those with lower expression 
(P=0.0034, log-rank test) (148).  
This was furthermore observed in colorectal cancer by Albasri et al. where 
patients with a higher expression of Tensin4 had a poor survival chance than 
those with lower Tensin4 levels (143). Moreover, Tensin4 appeared to be 
regulated through integrin-linked kinase (ILK) signalling in colon cancer cells. 
siRNA knockdown of ILK after forced Tensin4 expression still removed the 
motility-inducing effects of Tensin4 (143). In a similar study in breast cancer by 
the same authors, Tensin4 was also found to be upregulated in tumour tissues 
and patients with increased Tensin4 expression had significantly shorter 
survival as well as shorter metastasis-free survival time (149). Furthermore, 
another study in colon cancer found upregulation of Tensin4 mRNA expression 
in 91% of tumour samples analysed. It was also shown by co-
immunoprecipitation that Tensin4 interacted with β-catenin, a player in Wnt 
signalling. Knockdown of Tensin4 by siRNA lead to reduced colony formation, 
anchorage-independent growth cell invasion, to levels comparable to those in β-
catenin-depleted SW480 colon cancer cells. This suggests that Tensin4 
regulates colon cancer cell tumourigenic behaviour through the β-catenin 
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dependent pathway (145). Al-Ghamdi et al. showed that Tensin4 may also be a 
downstream target of Kras, the initiator of the proliferative ERK/MAP kinase 
signalling pathway, and that Tensin4 may be the mediator through which Kras 
regulates cell motility. It was shown that knockdown of Kras in cells 
overexpressing Tensin4 led to suppression of the cell motility-inducing effects of 
Tensin4 (150). As these studies increasingly put forward Tensin4 as an 
oncogene in various human cancers, Li et al. investigated the role of Tensin4 in 
modulating sensitivity to the anti-cancer therapeutic agent paclitaxel (Taxol) in 
prostate cancer (151). Paclitaxel disturbs the cell cycle through stabilising 
microtubule polymers; however, although treatment is often well received 
initially, resistance often develops rapidly (152). In that study, overexpression of 
Tensin4 in paclitaxel-resistant prostate cancer cell lines was able to partially 
restore their paclitaxel sensitivity (151). That study, suggested that Tensin4 is 
partially responsible for paclitaxel action in these cancer cells, and that 
downregulation of Tensin4 helps to prevent paclitaxel from exerting its effect on 
prostate cancer cells.  
Therefore, the evidence is now convincing that the Tensins appear to play 
important roles in cancers of different types. The role played by Tensin4 in 
cancer is the most well-established, where it appears to mainly be upregulated 
in many cancers and also appears to facilitate progression of these cancers to a 
more aggressive phenotype. Tensin4 is normally expressed in the prostate and 
unlike in the majority of studied cancers where Tensin4 is upregulated, in 
prostate cancer Tensin4 is downregulated. Furthermore, restoring Tensin4 in 
prostate cancer cells, Tensin4 proved to be important in reinstating paclitaxel 
sensitivity. The role of Tensin1 has been little studied in cancer. While Tensin2 
has shown mixed results depending on the isoform under study, with isoform 3 
being linked with more aggressive hepatocellular carcinoma (85). This 
aggressiveness could be linked to the data suggesting that Tensin2 isoform3 
causes an increase in cell migration, which could lead to a cancer being more 
metastatic through increased cell motility (83).  
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Tensin3 was shown to be downregulated in RCC along with the other Tensins 
(111). Furthermore, it was shown to be altered in its expression as part of a 
reciprocal EGF-driven switch, whereby Tensin4 is upregulated and competes 
with the downregulated Tensin3 for integrin binding, which leads to an increase 
in cell migration (129). It was further shown that the tumour suppressor DLC1 
exerts its effects through Tenisn3 binding, while Tensin4 inhibits DLC1 Rho-
GAP activity and enables a cell to become more migration-prone, this pathway 
also being controlled through this EGF-driven switch (137). It is therefore, highly 
likely that the Tensins’ effects in cancer cells are down to their roles as focal 
adhesion proteins and consequently their influence on cytoskeletal dynamics 
and thereby cell migration, which has implications for tumour metastasis. 
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1.4 Aims  
As previously stated, Tensin3 has been shown to be downregulated in RCC 
(111). However, the molecular mechanism behind this downregulation is 
unknown, including at which stage the expression is lost, e.g. pre-transcriptional 
or post-transcriptional. As described above, epigenetic mechanisms such as 
hypermethylation play important roles in the downregulation of some genes, 
and this has indeed been shown to be the case for the VHL gene, which is 
especially significant in kidney cancer. Therefore, the main aim of this PhD 
project was to identify whether an epigenetic mechanism, specifically gene 
promoter hypermethylation, exists to account for the observed downregulation 
of Tensin3 in RCC. To achieve this overall aim, the objectives of the project 
were to:  
1. Identify a functional promoter for the human TNS3 gene and a potential CpG 
island within it. 
2. To quantitatively determine the methylation level of the TNS3 CpG island in 
human RCC tumours versus adjacent non-tumour and normal samples. 
3. A further objective was to explore the potential for pharmacological 
manipulation of DNA methylation in human kidney cells and its potential to 
restore Tensin3 expression.  
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Materials and Methods 
2.1. Bioinformatics 
2.1.1. Identification of the region incorporating a human TNS3 
gene promoter 
As the TNS3 gene promoter region had not previously been identified, 
bioinformatic analyses were carried out, mostly using the European 
Bioinformatics Institute (EBI) Ensembl genome database (53). The identification 
of the target region for the methylation analysis was based on the location of the 
CpG island located upstream of exon 1 of transcript TNS3-012. Firstly, a search 
for the TNS3 gene within the human genome using the Ensembl genome 
browser identified 14 distinct Tensin3 transcripts (Fig. 41).  
Fig. 41: A screenshot of the human TNS3 gene region from Ensembl. Including 14 transcripts 
which included protein coding transcripts (red), processed transcripts (blue) and retained introns 
(blue), individual vertical lines indicate exon locations. The TNS3 gene is located on the reverse 
strand and therefore 5’-3’ is right to left. Location: 7:47314752-47622156 (53). 
As promoter-associated CpG islands are usually located upstream of the first 
exons of many genes, this region was honed in on when examining sequences 
around the TNS3 gene variants (Fig. 42).  
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Fig. 42: The region on chromosome 7 surrounding exon 1 of 3 distinct Tensin3 transcripts, 
TNS3-001, TNS3-003 and TNS3-012. The %GC cut-off point is indicated by a red line, 
suggesting there is a CpG island located close to the start of these transcripts; location 
7:47599881-47641000.  
The region around exon 1 was targeted as it appeared to have a higher level of 
%GC, which appeared consistently above the cut-off line (in red-Fig. 42). The 
target region was selected and the sequence was downloaded (Location: 7: 
47619521-47623871); this sequence was then analysed through EBI’s 
CpGPLOT programme to identify CpG islands within it (Fig. 43) (153).  
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The default settings were selected which were based on Gardiner-Garden and 
Frommer (GC content ≥50%, Obs/Exp ≥0.6, and length of CpG island ≥200 bp) 
(58).  
Fig. 43: The results of CpGPLOT analysis. An 826 bp was identified within the target region. 
The upper most panel displays the setting used, the next panel down shows the observed vs. 
expected ratio, in CpG islands this should be over 0.6, the percentage is displayed in the next 
panel and a combination of both in the last panel (153). Location 7: 47619521-47623871. 
The results indicated an 826 bp CpG island within the target region located 
upstream and running into exon 1 of one of the transcripts TNS3-012 (Fig. 43). 
Primers were designed around this region for the purposes of post-bisulphite 
conversion amplification (see below).  
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2.1.1.1. Primer design for bisulphite sequencing PCR  
Specific oligonucleotide primers were designed to indiscriminately anneal to 
both methylated and unmethylated DNA in order to amplify the desired TNS3 
region from both methylated and unmethylated samples following bisulphite 
conversion. These primer sequences were designed with the aid of the program 
MethPrimer (154) and are provided below (Table 7).  
Fig. 44: A screenshot of the data input page of the online MethPrimer program. The program 
designed primers for bisulphite sequencing PCR using the Garden-Gardiner and Frommer 
criteria.  
Using the MethPrimer software, primers were designed for “bisulfite sequencing 
PCR”, and “CpG island prediction” was used for primer selection, using the 
criteria set by Garden-Gardiner and Frommer (58). Due to low yields after 
bisulphite conversion (as described in Chapter 4), nested PCR was conducted, 
inner PCR primers were also designed using the MethPrimer program (Fig. 44).  
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Table 7: The primers used for pyrosequencing. Including the outer and inner PCR primers and 
the sequencing primers used.  
Primers for 
Pyrosequencing 
Forward Primer (5’-3’) Reverse Primer (5’-3’) Size 
Outer nested 
PCR- 
pyrosequencing 
GGGTTGTTTAATGGGTTTGATAA
T 
 
ACCTACCCATTAAAACCCCAACT 
 
902 bp 
Inner for cluster 1 TTGTATTGTTAGGGTGATGAGGT
TAG 
Biotin-
CCCAATACCTAAAAAAACCTAAA
AC 
217 bp 
Inner for Cluster 2 TGGGGAGAGTATAGAGATTTGGA
G 
 
Biotin-CCCAAACCCAACCAATCA 258 bp 
Sequencing 
primer 1 (cluster 
1) 
GATGAGGTTAGGTGATT 
 
  
Sequencing 
primer 2 (cluster 
1) 
GTAGTTAGTTAGGA 
 
  
Sequencing 
primer 3 (cluster 
2) 
GGAGGAATTTAGGTTAGGGA 
 
  
 
Fig. 45: Screenshot of primer selection result in the online MethPrimer program. For the TNS3 
gene region under study, 5 different primer sets were designed, the first primer set was chosen. 
The program identifies the CpG island, indicated by the blue shaded portion of the sequence, 
the primer pairs are indicated by red boxes joined by blue lines (154). 
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The MethPrimer search returned 5 designed primers sets, with the first primer 
set being chosen as it amplifies a section with a greater number of CpGs within 
it compared to the others (Fig. 45).  
Within the CpG island, there were two groups of dense CpG dinucleotides, two 
sets of primers were designed to encompass these two clusters, cluster 1 and 
cluster 2. Then, sequencing primers were designed manually to be used for the 
pyrosequencing analysis, using the amplified 218 bp inner PCR product of 
cluster 1 and the 258 bp inner PCR product of cluster 2 as templates (Fig. 46). 
Primers were designed to contain no CpG dinucleotides and were between 14 
and 20 bp long. The template being double the length of usual pyrosequencing 
templates, two sequencing primers were therefore designed for cluster 1, as on 
average the pyrosequencing machine is able to measure 10 CpG dinucleotides 
in one reaction. However, with one sequencing primer 17 CpG dinucleotides 
were measured, therefore another primer was designed to be able to sequence 
the remaining 12 CpGs in cluster 1. In addition, one sequencing primer was 
designed for cluster 2 PCR product which was able to measure 14 CpGs. Thus, 
the potential total number of CpG dinucleotides that could be detected within 
these two separate PCR reactions using these 3 pyrosequencing primers came 
to 43. 
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Fig 46: The two clusters within the Tensin3 CpG island. Closer analysis of the CpG island 
revealed two areas with a higher number CpG dinucleotides, named cluster 1 and cluster 2, the 
primers are in bold. 
 
2.1.1.2. Primer design for the luciferase reporter assay  
Oligonucleotide primers were designed for the luciferase reporter assay of gene 
promoter activity. These would anneal around the target region that included 
part of exon 1 of one of TNS3 transcript TNS3-012. To explore sequence and 
length-dependence of this region as a potential promoter, different forward 
primers were used that annealed increasingly further upstream of exon 1, each 
time using the same reverse primer, in order to PCR amplify the region with 
increasing product lengths of up to 2000 bp away from the exon 1 (Fig. 47). 
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Fig. 47. Luciferase assay PCR design. Primers were designed for increasing lengths of product 
including exon 1 of TNS3-012 transcript origin, the primers contained restriction sites which 
enabled the products to be cloned into the promoterless pGL4.10 [Luc] vector, the products 
were cloned upstream of the luciferase gene.  
 
The primers were designed with restriction digestion sites incorporated into 
them, the forward primers contained a KpnI restriction site and the reverse 
primers contained a HindIII restriction site and therefore were able to be 
directionally cloned into the promoterless pGL4.10 [Luc] vector. 
 
Table 8: Primers used in the generation of fragments for the luciferase assay.  
Primers for 
Luciferase 
Assay 
Forward Primer (5’-3’) Reverse Primer (5’-3’) Size 
(bp) 
500 bp GACTGGTACCGGGGAGCGCGGAGA
CAGA 
CTCGAGTGGTCCTGCGCCCCAGCC
AGTCC 
 
458 
1000 bp CGGCGGTACCGAACCTGCAAGCCT
CCAG 
CTCGAGTGGTCCTGCGCCCCAGCC
AGTCC 
 
954 
2000 bp GGGGGGTACCAATGACACTACCTTC
CAG 
CTCGAGTGGTCCTGCGCCCCAGCC
AGTCC 
1962 
3000 bp GGTACCGGGTGTGGGTAGCAGTTT
G 
CTCGAGTGGTCCTGCGCCCCAGCC
AGTCC 
3209 
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2.2 Analysis of promoter activity in the TNS3 CpG 
island region 
2.2.1. DNA cloning 
2.2.1.1. Blunt cloning 
Initially, a 3000 bp fragment encoding the wider region of interest was amplified 
using Pfu enzyme from SNB-19 gDNA and cloned into a blunt cloning vector 
(pJET1.2, Fermentas, Loughborough, UK, Fig. 48) due to cloning difficulties. 
This was then confirmed by Sanger sequencing, following which all subsequent 
PCRs for sticky cloning used this as a template. Primers were then designed 
containing restriction enzyme digestion sites in the forward primer (KpnI) and 
the reverse primer (HindIII).  
The proof-reading polymerase enzyme Pfu was used (Fermentas) according to 
manufacturer’s conditions: 
 
5 µl Pfu Buffer + MgSO4 
5 µl dNTPs, 2. 5mM 
1 µl Forward primer, 25pmol/µl 
1 µl Reverse primer, 25pmol/µl 
0.5 µl Pfu enzyme (1.25 u) 
1124 ng Template 
X µl Nuclease-free water 
2.5 µl DMSO 
50µl Total 
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These PCRs were done under conditions:  
 
95°C 2 min  
95°C 1 min  
60°C 1 min  40 cycles 
72°C 7 min  
72°C 15 min  
 
5 µl of the PCR reaction product was analysed by 1% agarose gel 
electrophoresis prior to purification (GeneJet PCR purification kit, Fermentas). 
All gel electrophoresis was conducted using TAE buffer (0.04 M Tris-acetate 
and 0.001 M EDTA) unless otherwise stated.  
 
Fig. 48: Blunt cloning vector, pJET1.2/blunt, Fermentas. The vector contains a blunt cloning site 
and is ampicillin resistant.  
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For the blunt cloning, after purification of the 3000 bp PCR product, the 
fragment was incubated in a 10 µl ligation reaction together with 1 µl of 
pJET1.2.  
 
10µl 2x Reaction Buffer 
2µl PCR product  
1µl pJET1.2 (50 ng) 
6µl Nuclease-free water 
1µl T4 DNA Ligase 
20µl Total 
 
The ligation mix was incubated for 20 min at room temperature before being 
transformed into competent cells.  
All of the ligation mix (10 µl) was added to 100 µl of DH5α competent E. Coli 
bacterial cells. Competent cells were prepared in-house by a chemical 
competence protocol using CaCl2 (155). The DNA-competent cell mix was kept 
on ice for 30 min, and then heat shocked at 42°C for 40 sec in a water bath, 
immediately chilled on ice again for 2 min, following which 1 ml of LB medium 
was added to it. This mixture was then transferred to a shaking incubator at 
37°C, shaking at 220 rpm for 1 h. After this time, the competent cell suspension 
was gently spun down and resuspended in 200 µl LB medium, which was then 
all spread onto an LB agar plate containing 50 µg/ml ampicillin, to be incubated 
overnight at 37°C. The next day, colonies were picked and inoculated into 3-4 
ml of LB medium containing 50 µg/ml of ampicillin; these were then incubated 
overnight at 37°C, shaking at 250 rpm. The following day, the cell suspensions 
from colonies were centrifuged at 4500 x g for 10 min, the supernatants 
discarded, the pellets lysed and DNA extracted from them using a DNA 
miniprep kit according to the manufacturer’s protocol (GeneJet, Fermentas). LB 
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agar (tryptone, 10g; yeast extract, 5g; NaCl, 15g; and agar, 15g) plates were 
prepared by autoclaving before 50 µg/ml of ampicillin was added, the plates 
were poured then stored at 4°C. LB medium (tryptone, 10g; yeast extract, 5g; 
and NaCl, 10g) was autoclaved before being stored at room temperature. 
To assess whether the product had been successfully ligated, 5 µl of the 
purified product was digested with the appropriate restriction enzymes found in 
the cloning vector either side of the blunt cloning site (XbaI and XhoI) and 
analysed by 1% agarose gel electrophoresis.  
 
5 µl Purified vector  
0.5 µl XbaI (5 u) 
0.5 µl XhoI (5 u) 
1 µl 10x fast digest buffer 
2 µl Nuclease free water 
10 µl Total 
DNA samples that visibly contained the expected size insert were sent for 
verification by sequencing prior to scaling up. For this, 5 µl of purified miniprep 
DNA product was transformed into competent cells as above; however, the cells 
were this time added at 200 µl volume directly into 200 ml of LB medium in a 
culture flask containing 50 µg/ml ampicillin, and this was then incubated 
overnight at 37°C, shaking at 250 rpm. The following day, the cell suspension 
was centrifuged at 4500 x g for 10 min, the supernatant discarded, and DNA 
extracted from the pellet and purified according to the manufacturer’s 
instructions (GeneJet Midiprep kit, Fermentas).  
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2.2.1.2. Sticky “end” cloning 
Using the above 3000 bp fragment as a master template, differently-sized DNA 
fragments encoding the region around the putative TNS3 promoter were then 
amplified by PCR using specific primer pairs containing cut sites for the 
restriction enzymes HindIII and KpnI to enable directional cloning. The purified 
PCR products (GeneJet, Fermentas) obtained were first analysed by agarose 
gel electrophoresis. For the cloning preparation, correct products were digested 
using HindIII and KpnI, the digestion being carried out first with KpnI in KpnI 
buffer (Fermentas) overnight at 37°C, followed by digestion with HindIII in R 
buffer (Fermentas) for 3 h at 37°C. The entire doubly digested DNA was then 
run on an agarose gel and the DNA fragment at the expected size was cut out 
of the gel using a scalpel over a UV and extracted and purified according to the 
manufacturer’s instructions (GeneJet gel purification kit, Fermentas).  
 
In parallel, the pGL4.10 vector was also digested and purified in the same way 
(Fig. 49). Then 2 µl of the digested vector and 4 µl of the digested inserts were 
mixed together in a 10 µl ligation reaction: 
2 µl Digested vector pGL4. 10  
4 µl Digested insert  
0.5 µl T4 DNA Ligase (fermentas) (2.5 u) 
1 µl Ligase buffer (fermentas) 
2. 5 µl Nuclease-free water 
10 µl Total 
 
The reaction was allowed to take place at room temperature for approximately 
2.5 h, after which the whole 10 µl mix was transformed into competent cells, as 
described above (2.2.1.1.).  
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Fig. 49: Luciferase assay vector pGL4.10 [luc2], a promoterless vector which contains the firefly 
luciferase gene luc2 as well as an ampicillin resistance gene.  
 
2.2.3. Human cell lines used in gene promoter analysis 
For the luciferase promoter assay, a cultured human cell line was sought that 
naturally expressed Tensin3. Thus, the human glioma cell line SNB-19 and 
kidney cell line HK2 were analysed by western blot for Tensin3 protein 
expression. These cells were lysed in a homemade cell lysis buffer (Tris-HCl, 
50 mM; NaCl, 150 mM; Triton X-100, 1%; NP-40, 0.5%; EDTA, 1 mM; Na4P2O7 
10 mM) containing a cocktail of protease inhibitors (Fisher Scientific) .  
 
2.2.3.1. BCA protein quantitation assay 
Prior to western blotting, the total protein concentration of cell lysates was first 
determined using the bicinchoninic acid (BCA) protein assay, according to the 
manufacturer’s conditions (Sigma). A standard curve was derived using bovine 
serum albumin (BSA) as protein standard, diluted to 5 µg/ml, 10 µg/ml, 15 
µg/ml, 20 µg/ml, 30 µg/ml, 40 µg/ml and 50 µg/ml, in protein lysis buffer 
containing protease inhibitor and water. Cell lysates were diluted in lysis buffer 
and water 1:10 and 1:50. 25 µl of protein sample was added to 200 µl of BCA 
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working reagent (1:50 reagent B: reagent A) in a 96 well plate. The plate was 
then incubated for 30 min at 37°C, then the absorbance read at 592 nm. The 
concentration of the sample was then calculated based on the standard curve.   
  
2.2.3.2. Western blot 
Having determined the total protein content of each cell extract, equal amounts 
of total protein from the samples, 60 µg, was mixed with water and SDS-PAGE 
loading (“Laemmli”) buffer (4x buffer: Tris-HCl 3.04 g; SDS 8 g; glycerol 40 ml; 
bromophenol blue 0.4 g; water 100 ml) with added DTT (5 mM). This mix was 
boiled for 5 min on a heating block at 94°C and briefly vortexed before being 
loaded onto a 10% polyacrylamide SDS-PAGE gel.  
The gel was run at 100 V in running buffer (Tris base, 25 mM; glycine, 190 mM; 
SDS, 0.1%; pH 8.3) until the bromophenol blue dye front in the samples had 
entered the main/running gel, after which it was the voltage was increased to 
200 V; the current was then allowed to run until the dye had exited the bottom of 
the gel. The separated proteins in the gel were then transferred onto an 
activated PVDF membrane using a wet transfer method (wet transfer buffer: 
Tris base, 25 mM; glycine, 200 mM; SDS, 0.04%; methanol, 20%). Wet transfer 
was carried out under a constant current of 250 mA for 2 h at 4°C. Following 
transfer, the membrane was initially blocked by incubation in blocking buffer 
(5% milk powder in TBS-Tween (Tris-HCl, 20 mM; NaCl, 150 mM; Tween-20, 
Running Gel 8%  Stacking Gel   
Protogel (30:8)                ml 2.68  Protogel (30:8)                 ml 1.2  
2.0 M Tris pH 8.8             ml 2  0.5 M Tris pH 6                 ml 1.4  
60% Sucrose                   ml 2  60% Sucrose                    ml 2  
20% SDS                         µl 25  20% SDS                          µl 25  
TEMED                            µl 5  TEMED                              µl 10  
Make up with water to   ml 10  Make up with water to    ml 10  
10% APS (fresh- freezer) µl 25  10% APS (fresh- freezer)   µl 25  
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0.005%, pH 7.6) for 1 h at 32°C, followed by incubation with the primary 
antibody (in-house antibody rabbit anti-human Tensin3, 1:500 dilution) for 2 h at 
32°C. The membrane was washed in three changes of TBS-Tween for 5 min 
each, after which it was incubated with secondary antibody (HRP-conjugated 
anti-rabbit IgG, 1:7500 dilution) for 1 h at 32°C. After a final wash with TBS-
tween of 3 x 5 min, the membrane was developed for chemiluminescence 
detection by incubation in Luminata Forte HRP reagent (Millipore) in the dark for 
2 min before imaging in the dark in a CCD camera (Syngene). The exposure 
time was set at 4 min and 6 images were successively taken and accumulated 
together over 25 min. The same membrane was then washed in TBS-Tween 
before being incubated with the primary anti-actin antibody (Sigma antibody, 
rabbit anti-human Actin, 1:10000 dilution) overnight at 4°C. The next day, the 
membrane was then washed 3 times for 5 min each in TBS-Tween before being 
incubated with the secondary antibody (HRP-conjugated anti-rabbit IgG, 1:7500 
dilution) for 1 h at 32°C. The membrane was then reimaged as above.  
 
2.2.4. Transfection 
The luciferase assay involved transfection of the cell lines with the plasmid 
under test, using a cationic lipid reagent. The cell lines acting as hosts for the 
expression assay were SNB-19 for their natural Tensin3 expression and HK2 
and HEK293 as human kidney cell lines. 5x104 cells in 500 µl complete medium 
were seeded into wells of a 24-well plate and allowed to adhere overnight. The 
following day, 750 ng of the reporter plasmids containing promoter fragments 
and a 1:200 dilution of the positive transfection control (pGL4.74[hRluc/TK] 
vector expressing Renilla luciferase, Promega) were mixed with JetPrime 
transfection reagent according to the manufacturer’s protocol (Polyplus, 
Nottingham) and added to the cells. After 4 h incubation at 37°C, the 
transfection medium was replaced with fresh medium, and expression was 
allowed to occur at 37°C for a further 48 h. After this, cells were passively lysed 
in luciferase assay lysis buffer and analysed for luciferase levels and activity.  
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2.2.5. Luciferase reporter assay and data analysis 
After lysis, 20 µl of crude cell lysates were added to 100 µl LARSII solution 
(luciferase assay substrate in luciferase assay, for firefly luminescence) and the 
luminescence level measured for 10 sec using a luminometer (1450 microbeta, 
Perkin Elmer, Waltham, MA). Shortly after this, 100 µl Stop and Glo reagent (for 
Renilla luminescence) was added, and the luminescence read again (Luciferase 
Assay System, Promega) (Fig. 50).  
Fig. 50: Steps in the luciferase assay. First firefly luminescence is measured followed by the 
addition of Stop and Glo to enable renilla luminescence measurement. These steps are then 
repeated for each sample. Image modified from Dual-Luciferase Reporter Assay Quick Protocol 
(156). 
The luminescence values measured were subtracted from background readings 
(untransfected control lysates) and then normalised against the Renilla 
luciferase positive transfection control (pGL4.74 [hRluc/TK]).  
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2.3 Bisulphite-Specific PCR 
2.3.1 Samples 
Clinical samples for this study were obtained through collaboration with Prof. 
Börje Ljungberg of the Department of Urology, Umeå University Hospital, 
Umeå, Sweden. Samples from tumour-bearing kidneys in patients with 
histologically verified RCC were collected from nephrectomy procedures carried 
out between 1988 and 2003. The study was approved by the Umeå University 
ethical committee and the institutional review board (Appendix I); and informed 
consent was obtained from each patient. Samples were purified in Sweden 
using the Qiagen DNeasy Blood & Tissue Kit. 
Normal (disease-free) DNA samples were from cell lines derived from 
peripheral blood lymphocytes of healthy blood donors (HRC1, Health Protection 
Agency, Salisbury, UK).  
 
2.3.2. Bisulphite conversion 
Bisulphite conversion is used to identify the difference between non-methylated 
and methylated CpGs. The sodium bisulphite conversion process converts non-
methylated cytosines to uracils (following which PCR converts those to 
thymines), whilst 5-mC is protected as that reaction occurs at a much slower 
rate (Fig. 51). In this study, 350 ng of sample genomic DNA was bisulphite 
converted according to the manufacturer’s instructions (EZ-96 DNA 
Methylation-Gold™ Kit, Zymo, California) under the following conversion 
conditions: 
1. 98°C for 10 min  
2. 64°C for 3.5 h 
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Samples were then immediately purified using the Zymo-Spin™ IC Column and 
eluted in 10 µl of M-Elution buffer (Zymo) before undergoing PCR.  
 
 
Fig. 51: Sodium bisulphite conversion. Sodium bisulphite, through a series of reactions including 
desulphonation, converts non-methylated cytosines to uracils. However, this reaction takes 
place much more slowly for methylated cytosines and so these are not converted. This provides 
a way of assessing the difference between methylated and non-methylated cytosines. Image 
modified from Huang, 2012 (157). 
 
2.3.3. Nested PCR 
A technical problem with bisulphite treatment of genomic DNA is that it yields 
both low amounts and poor quality DNA to be used for subsequent analysis. 
Therefore, a two-step protocol, nested PCR, was employed to provide a 
sufficiently high level of good quality DNA from the converted samples for the 
subsequent analyses. The primers used for the outer PCR, anneal to a larger 
region than required, within which the inner PCR primers anneal to amplify the 
desired DNA product (Fig. 52).  
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Fig. 52: Nested PCR. The original template is used for the outer PCR which undergoes 50 
cycles, and then the outer PCR is used as the template for the inner PCR, producing from little 
starting material, a sufficient amount of template available for the second round of (inner) PCR, 
which increasing the amount of desired product.  
Following bisulphite conversion, 3 µl out of 10 µl of this DNA (possible 
maximum 115 ng) was amplified by nested PCR using Truestart Taq 
polymerase (a “hotstart” polymerase) as described in the manufacturer’s 
protocol; 2.5 µl of DMSO was also added to the reaction to aid with loosening 
DNA secondary structures in the bisulphite-converted DNA (158). 
5 µl dNTPs, 2. 5mM 
5 µl Truestart Buffer 
3 µl MgCl2, 25 mM 
1 µl Forward primer 25 pmol/µl 
1 µl Reverse primer 25 pmol/µl 
2.5 µl DMSO 
0.5 µl Truestart Taq polymerase 
3 µl Bisulphite-treated DNA 
29 µl Nuclease free water 
50 µl Total 
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The outer PCR was carried out under “touchdown” conditions; all PCR reactions 
were carried out in a peqSTAR 96 Universal thermocycler (PEQLabs, Sarisbury 
Green, UK):  
95°C 2 min  
92°C 1 min  
60°C to 48°C 
Every 3rd cycle reducing by 1°C 
 
1 min 
 
 36 cycles 
72°C 1 min  
92°C 1 min  
47°C 1 min  14 cycles 
72°C 1 min  
72°C 15 min  
 
 
Then, 2 µl of the outer reaction product was carried forward into the inner PCR 
reaction, with five inner reactions carried out simultaneously for each sample, 
using the specific cluster inner primers, under normal cycling conditions  
 
92°C 2 min  
92°C 1 min  
47°C 1 min  50 cycles 
72°C 1 min  
72°C 15 min  
 
The 5 inner PCR reaction products were then pooled together and purified 
using the GeneJet PCR purification kit (Fermentas) and analysed by 3% low 
melting agarose gel electrophoresis prior to undergoing processing for 
pyrosequencing. The PCR product for cluster 1 had an expected size of 217 bp 
and cluster 2 had an expected size of 245 bp.  
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2.3.4. Pyrosequencing 
Pyrosequencing is a technology that is able to detect with quantitative accuracy 
single nucleotide polymorphisms (SNPs), including those arising from 
modification of gDNA to identify single nucleotide modifications such as 
methylation of a cytosine in CpG dinucleotides. The pyrosequencing platform 
requires DNA samples to be analysed to have one strand that is biotinylated; 
this is the strand that acts as template for the sequencing reaction. The biotin 
on the DNA strand, arising from biotinylation of one of the two inner PCR 
primers in the nested PCR, enables that strand to be affinity purified utilising the 
extremely high affinity and specificity binding chemistry between streptavidin 
and biotin (Fig. 53).  
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Fig. 53: Affinity purification using streptavidin beads and biotinylated strands. The biotinylated 
strand of DNA (arising from the biotinylated primer) will bind to the streptavidin beads which will 
remain on the filter of the vacuum purification system. This can then be purified and made 
single stranded for the pyrosequencing reaction.  
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DNA samples that were prepared from nested PCR in Portsmouth, and deemed 
to be of sufficiently high amount and quality, were then transported to Barts and 
the London Genome Centre, London, for the subsequent affinity purification and 
pyrosequencing. The purification was performed on a PyroMark vacuum station, 
and all reagents used were part of the PyroMark Gold Kit (Qiagen). Of the 50 µl 
taken, 30 µl of the sample to be pyrosequenced (purified nested PCR product) 
was added to 37 µl of binding buffer and 3 µl of binding beads, and then shaken 
for 10 min on a shaker (1400 rpm). In a separate tube, 1.5 µl (10 µM) of a 
sequencing primer was added to 43.5 µl of annealing buffer. After this time, the 
samples were purified on the vacuum station. The DNA sample was aspirated 
through the filter, with the beads containing the biotinylated strand remaining on 
the filter; this was then washed with 70% ethanol to remove any contaminants. 
This was followed by washing in 0.2 M NaOH, which denatures the product to 
make it single stranded with the biotinylated strand remaining on the beads; and 
a subsequent wash in Qiagen Wash Buffer removed non-biotinylated strands 
and any excess NaOH followed lastly by double distilled water, before the 
vacuum was switched off. The beads were then placed into the annealing buffer 
containing the sequencing primer. The sequencing plate was then heated to 
80°C for 2 min. During this time the pyrosequencing cartridge was prepared 
with the dinucleotide triphosphates, the enzyme and substrate for the reaction. 
Following the pyrosequencing reaction, the product was “stripped”, by adding 
additional binding buffer to the plate and repurifying it, before adding it to 
annealing buffer with a different sequencing primer. Through this “stripping” 
procedure, we were able to detect a total of 43 individual CpG dinucleotides 
across two products (cluster 1 and 2).  
Pyrosequencing works by adding one dNTP at a time then reading the level of 
light produced (Fig. 54). At each dNTP being incorporated, a pyrophosphate is 
released that is then converted to ATP, which drives the luciferase-mediated 
conversion of luciferin to oxyluciferin, producing light which can then be 
detected. The dNTPs are broken down by apyrase which then allows for the 
addition of alternate dNTPs on the DNA product which was being generated 
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through extension of the sequencing primer. From the intensity of light produced 
the software is able to determine whether one or more dNTPs were added. This 
allows for accurate single base pair recognition along with the ability to 
determine the percentage of dNTPs that were added to the same point i.e. 
whether 50% of the strands contained a C and 50% contained a T (Fig. 54)  
Fig. 54. The chemistry of the pyrosequencing reaction. Pyrosequencing is able to detect SNPs 
and methylation differences through its ability to determine the amount of individual dNTPs 
incorporated into the new strand through the detection of light produced through the reaction . 
The nucleotides are added in sequences, when they are incorporated pyrophosphate is 
released, which is converted to ATP by sulfurylase, which in turn is used to mediate the 
conversion of luciferin to oxyluciferin which produces light, which is detected by the machine, 
the apyrase breaks down any excess nucleotides and the process repeats. (159)  
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2.4 Cell culture 
2.4.1. Human cell lines  
The human kidney cell line HK2 (160) and the prostate cancer cell line DU145 
(161) were used for demethylation experiments followed by qRT-PCR. 786-O 
(renal cell carcinoma cell line) and SK52 (skin fibroblast cell line) were also 
initially tested in the demethylation experiments. The human glioma cell line 
SNB-19 (162) and HK2 cells were used in luciferase assays of promoter 
activity. The human kidney cell line HEK293 (163) and SNB-19 were used as a 
source of genomic DNA for control pyrosequencing experiments.  
 
2.4.2. Cell culture conditions 
All cell culture was carried out under sterile culture conditions using good 
laboratory practice, with all sterile work carried out in a Class II biological safety 
cabinet (Herasafe, Heraceus, Thermo Scientific). All hardware items which 
entered the hood were first sprayed and wiped with 70% ethanol. All 
contaminated solid waste (e.g. plastics) was autoclaved, while liquid waste was 
aspirated into a flask containing a working concentration of Virkon.  
All cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% foetal bovine serum, 20 mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 37°C in a humidified atmosphere of 5% 
CO2 in air. Cells were passaged every 7 days. The medium was aspirated and 
cells briefly rinsed with 2 ml PBS, which was aspirated and 2 ml trypsin-EDTA 
was added and incubated at room temperature for 5 min. A new T25 flask (25 
cm2 surface area) was prepared with 6 ml complete medium; 40 µl of the 
trypsin-EDTA containing the cells was added to this (1:50 split).  
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2.5. DNA demethylation treatment of cells with 5-aza-2’-
deoxycytidine  
2.5.1. Cell viability (MTS) assay 
Firstly, to determine an optimal concentration of 5-aza-2’-deoxycytidine (5-aza, 
Sigma) for cell demethylation treatment that was non-toxic, a colorimetric cell 
viability assay was employed to test the effect of different concentrations of the 
agent on 786-O human RCC cells. At the same time, four other antineoplastic 
agents were also assessed for comparison: etoposide, temozolomide, 
acetaminophen and apigenin. The principle of the MTS assay is based on the 
reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-
sulfophenyl)-2H-tetrazolium (MTS) in the presence of phenazine methosulphate 
(PMS) to formazan, in viable cells, which causes a colour change that can be 
measured at 490 nm; thus, the colour change is representative of the number of 
viable cells (164). Cells were seeded into a 96-well plate at 5x103 cells in 100 µl 
per well, and incubated overnight to allow for adherence. The next day, various 
concentrations of the 5-aza between 0.04 µM to 40 µM were added to the cells 
and incubated for 96 h. After this period, 10 µl of MTS+PMS solution mix was 
added to each well and left for 3 h at 37°C, followed by reading the OD490nm of 
each well on a microplate reader (Synergy, Biotek, Potton, UK).  
 
2.5.2. Incubation of cells with 5-aza for gene expression 
analysis 
Cells from the human kidney cell line HK2 were incubated with 5-aza in order to 
demethylate their genomic DNA followed by TNS3 gene expression analysis. 
HK2 cells were first seeded into a 24-well plate in complete medium and 
allowed to adhere overnight at 37°C. The next day, cells were treated with 40 
µM of 5-aza (which was determined to be non-toxic to the cells in the MTS 
assay). Initially, 3 different dosing patterns were carried out over a period of 96 
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h, with cells being lysed every 24 h: 1. 5-aza was added at 0 h; 2. 5-aza was 
added at 0 h and added again after 72 h; 3. 5-aza was added at 0 h and again 
every 24 h. After 96 h, gene expression analysis was carried out by qRT-PCR 
as described below. It was determined that condition 1 provided the most 
consistent results with cells only being lysed at 96 h. Five different cell lines 
were tested under condition 1 to determine the most appropriate cell line to use: 
DU145, SNB-19, HK2, SK52 and 786-O.  
 
2.5.3. Real-time quantitative RT-PCR  
Cells treated with 5-aza were subsequently analysed for TNS3 gene expression 
by real-time, quantitative reverse transcription PCR (qRT-PCR) (Fig. 55).  
Fig. 55: Flow chart of steps involved in RT-qPCR. Cells were lysed and total RNA extracted; the 
RNA is then reverse transcribed into cDNA, which undergoes qPCR using Taqman primers and 
probes.  
Total RNA was extracted from the lysed cells (GeneJet kit, Fermentas) followed 
by reverse transcription using M-MLV reverse transcriptase (New England 
Biolabs, Hitchin, UK) according to the manufacturer’s instructions.  
1 µl oligo dT (Fermentas) 5 pmol/µl 
1 µl dNTPs, 2.5 mM 
1 µl Reverse Transcriptase 
2 µl M-MLV 10x buffer 
0.5 µl Ribolock (Fermentas) 
4 µl Purified RNA 
10.5 µl DEPC treated water 
20 µl Total 
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The reverse transcription mix was incubated at 37°C for 2 h. Multiplex real-time 
quantitative RT-PCR (qRT-PCR) was performed on the samples to analyse 
simultaneous expression of both the TNS3 (Hs00994939_m1) and TENC1 
(Hs00539247_m1) genes and the endogenous control gene β-2-microglobulin 
(B2M) (Hs00984230_m1). B2M gene encodes a protein which is found on the 
cell surface of many cells and is ubiquitously expressed, therefore is often 
chosen as a housekeeping gene. A primer/probe-based system was used for 
real-time detection of PCR amplification (Taqman, Applied Biosystems, Paisley, 
UK).  
 
2 µl cDNA 
6 µl Nuclease free water 
1 µl TNS3/TENC1 primer (900 nM) and probe (5 µM) 
1 µl B2M primer (225 nM) and probe (5 µM) 
10 µl 2x Maxima mastermix (Fermentas) 
20 µl Total 
 
The probes for TNS3/TENC1 and B2M genes were labelled with FAM and VIC 
fluorophores, respectively. The qPCR was performed under the following 
cycling conditions: 50°C for 2 min, 95°C for 10 min and 40 cycles of 95°C for 15 
sec and 60°C for 60 sec (ABI PRISM 7900HT system, Applied Biosystems). 
The relative standard curve method was used for quantitative determination of 
amount of TNS3 mRNA generated, using serial dilutions of cDNA from the 
SNB-19 cell line, which naturally expresses Tensin3, to generate a standard 
curve. Each measurement was performed in duplicate and the duplicate Cts 
were converted into ng RNA from linear regression analysis of the standard 
curve (Excel, Microsoft). Each determined RNA value was then normalised 
against the endogenous control gene level within the same well.  
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2.6. Alternative methods used for DNA methylation 
analysis 
2.6.1. Methylation-Specific PCR (MSP) 
Methylation-specific PCR (MSP) is a PCR-based technique designed to amplify, 
in two different reactions, either methylated or unmethylated DNA after 
bisulphite conversion (Fig. 56).  
Fig. 56: Methylation-Specific PCR primer design. Two sets of primers are designed which 
include CpG dinucleotides in the primers will cover the region and are designed to discriminate 
between methylated and unmethylated regions.  
 
Primers for MSP were designed using the MethPrimer software (154). As a 
potential positive control for seeing clear methylation differences between 
tumour and non-tumour DNA samples. 
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Table 9: MSP primers for TNS3  
 Forward primer 5’3’ Reverse primer 5’3’ Size 
(bp) 
TNS3 
Methylated 
GTAGTTAGTTAGGAGGACGGGTTC CCAATACCTAAAAAAACCTAAAACG 103 
TNS3 
Unmethylated 
GTAGTTAGTTAGGAGGATGGGTTTG CCCAATACCTAAAAAAACCTAAAAC 104 
All gDNA samples underwent bisulphite conversion as described above, before 
3 µl out of 10 µl, a maximum amount (115 ng), was added to each MSP 
reaction (methylated and unmethylated). All PCR reactions were carried out 
using “Truestart” hotstart Taq polymerase (Fermentas). These were carried out 
under variable conditions as described in Chapter 4. 
 
2.6.2. Restriction digestion-based qPCR analysis of 
differentially methylated DNA 
The EpiTect methyl II qPCR assay works by digesting DNA samples with two 
different restriction enzymes in three different combinations. These restriction 
enzymes are able to digest methylated and unmethylated DNA; one enzyme 
being methylation-sensitive whilst the other is methylation-dependent. The 
system is able to detect the remaining intact DNA after cleavage and is 
therefore able to quantitatively determine the level of methylation within the 
target region (165) (Figure 57).  
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Fig. 57: EpiTect Methyl II PCR assay. Samples are digested, before they are added to SYBR 
green qPCR mastermix containing the individual TNS3/TENC1 primers, and underwent qPCR 
followed by analysis using the spreadsheet provided by Qiagen (166).  
Samples were set up according to manufacturer’s conditions (EpiTect Methyl II 
qPCR assay, Qiagen). For each sample, 250 ng of patient gDNA sample was 
added into each reaction, which was split into the four tubes containing the 
different restriction digestion combinations: 1. Control digest (no digestion); 2. 
Methylation sensitive digest, 3. Methylation-dependent digest; 4 Both enzymes. 
These were then incubated at 37°C overnight. The qPCR was then immediately 
set up the next day, using RT2 SYBR Green qPCR mastermix (Qiagen) and 
EpiTect Methyl II PCR primers for Tensin3 (cat #. EPHS113148-1A) and 
Tensin2 (EPHS103156-1A).  
2.6.3. Ethanol precipitation  
It is important that all solutions are kept on ice, 1/10 of the volume of the sample 
of 3 M sodium acetate (pH. 5.2) and mixed thoroughly, to which was added 2.5 
times the sample volume of cold 100% ethanol with further thorough mixing; the 
mixture was then kept at -20°C for minimum 30 min, after which it was 
centrifuged in a cold microfuge at maximum speed (approximately 20000 x g). 
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Following this, the supernatant was then decanted and the pellet (which may 
not have been visible) briefly washed in 70% ethanol, which was then removed 
and the pellet dried and resuspended in the appropriate volume of TE buffer. 
2.6.4. Homemade bisulphite conversion protocol 
SNB-19 DNA (1 µg) was either digested with EcoRI (as there were no EcoRI cut 
sites in the TNS3 promoter region) for 1h or heat-denatured for 5 min at 100°C 
to allow for the bisulphite solution penetrate all CpG dinucleotides. The 1 µg 
DNA was then diluted up to 48 µl with nuclease free water and incubated with 2 
µl of 5M NaOH solution at 37°C for 15 minutes, this process denatures the DNA 
making it single stranded. Then 550 µl of bisulphite/hydroquinone solution was 
added and incubated at 55°C in a water bath, overnight, in the dark. After this, 
the sample either underwent purification according the Zymo kit, the Qiagen kit 
or underwent ethanol precipitation as described above.  
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Results 
The results shown within this chapter address 3 main research aims: firstly, the 
identification and experimental validation of a functional promoter for the human 
TNS3 gene; this was a crucial initial aim, as no such gene regulatory region for 
TNS3 had been characterised to date. As part of this effort, a key sub-aim was 
to also identify a CpG island located with proximity to the putative TNS3 
promoter. Secondly, the work lead to addressing the core aim of the project, 
which was to uncover an epigenetic mechanism behind Tensin3 downregulation 
in RCC patients, as has previously been shown by our group (111). Specifically, 
efforts were directed towards quantifying the degree of cytosine methylation in 
CpG dinucleotides within the CpG island of the identified TNS3 promoter. 
Thirdly, experiments were performed to determine whether Tensin3 expression 
in cultured human kidney cells could be manipulated by treatment with a 
pharmacological demethylating agent, which in this study was 5-aza. These 
results would functionally support the preceding experiments if they were to 
show that there was a significant difference in TNS3 promoter methylation 
between RCC and non-tumour DNA.  
 
3.1 Bioinformatic identification of a CpG island close to 
the human TNS3 gene 
3.1.1 The human TNS3 gene  
As the human TNS3 gene promoter region had not previously been identified, 
bioinformatic analysis was carried to identify one such region. The human TNS3 
gene is located on the short arm of chromosome 7 (7p 12.3) on the reverse 
strand (ENSG00000136205) (Fig. 59). Analysis of the Ensembl database 
identified 14 transcripts. This study focussed on the region surrounding one set 
of transcripts, as the region surrounding these has characteristic promoter 
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features (Fig. 58). There are two regions of exon 1 locations, those near TNS3-
201 and TNS3-001.  
Fig. 58: TNS3 putative promoter region located near TNS3-001 transcript origin. The three 
TNS3 transcripts located closest to a CpG island and a number of regulatory elements. The 
exons are displayed as open boxes in dark red. The area in which the CpG island is located is 
indicated by a red box. Two of the three first exon 1s are located within this CpG island region 
(53).  
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Fig 59: Screenshots of bioinformatic analysis of the TNS3 gene from the Ensembl database. A. The TNS3 gene is located on chromosome 7 on the short arm at 7p12.3 on the reverse strand. B. 
screenshot of 7p12.3, also located on p12.3 are the genes IGFBP1 and IGFBP3 in close proximity to TNS3. C. An expanded image of the TNS3 region, the TNS3 gene is in the middle shown in 
orange. D. There are 14 Tensin3 transcripts; there are two full length transcripts, TNS1-001 and TNS3-201, which start in different locations. The majority of the other transcripts are truncated.   
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Fig. 60: CpG island locator for TNS3 putative promoter region. A large section including the 
exon 1 of three transcripts was analysed through EBI’s CpG island locator. This located an 826 
bp CpG island. Location 7: 47619521-47623871 
Analysis of the region upstream of TNS3-012 exon 1 revealed an 826 bp CpG 
island (EMBOSS CpGPLOT(153), criteria based on Gardiner-Garden and 
Frommer: GC content ≥50%, Obs/Exp ≥0.6, and length of CpG island ≥200 bp 
(58)) (Fig 60). Within this CpG island were two sub-regions with a higher 
number of CpG dinucleotides clustered together; these were designated cluster 
1 (contains 29 CpGs) and cluster 2 (contains 14 CpGs) (Fig. 61).  
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Fig. 61: The TNS3 CpG island identifying cluster 1 and cluster 2. An 826-bp CpG island was 
located upstream of exon 1 encoding one of the alternatively spliced transcripts of Tensin3 
(TNS3-012). The exons are indicated by small bars, the first exon is located on the right. Closer 
analysis of the CpG island revealed two stretches with a higher concentration of CpG 
dinucleotides (Cluster 1 and 2). These clusters were subsequently analysed for alternative 
methylation by pyrosequencing.  
Within this region were also identified a number of regulatory features including 
Yy1, CTCF and E2F1. Furthermore, there is a separate, smaller CpG island 
located after the start of the first exons of two other full length transcripts TNS3-
201 and TNS3-202 (Fig. 62).  
Fig. 62: A screenshot of the Ensembl database localised to the start site of the other TNS3 
transcripts, including full length transcripts TNS3-201 and TNS3-202. The red box indicates the 
approximate location of the CpG island. Location: 7: 47,575,292-47,581,189.  
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Fig. 63: CpG island locator for the other Tensin3 transcripts. A large section including the exon 
1 of six transcripts was analysed through EBI’s CpG island locator. This identified a 380 bp CpG 
island and 513 bp CpG island that are 47 bp apart.  
 
The EMBOSS CpGPLOT identified two small CpG islands 380 bp and 513 bp 
which were 47 bp apart. These were located approximately 1500 bp after the 
start of exon 1 of transcript origins TNS3-201 and TNS3-202 (Fig. 63).  
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Fig. 64: Encyclopaedia of DNA Elements (ENCODE) database image for TNS3. The DNaseI 
hypersensitivity of the region indicates that there is an open chromatin state which would 
normally be associated with active transcription. A. Also in this region are two identified histone 
marks, H3K4Me1 and H3K4Me3. B. In build Hg19 of ENCODE, identified H3K27Ac marks also.   
(167).  
 
Analysis of the Encyclopaedia of DNA Elements (ENCODE) database identified 
a number of histone modifications in the region surrounding the 826 bp CpG 
island (indicated by a green cube), including H3K4Me1, H3K4Me3 (Fig 64 A) 
and H3K27ac (Fig 64 B), as well as DNaseI hypersensitive clusters within the 
region surrounding exon 1 of the set of transcripts (167). These bioinformatic 
results together (CpG island and promoter/enhancer associated histone marks) 
therefore strongly indicate the identification of a TNS3 gene promoter region.  
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3.1.2. The genes for Tensins -1, -2 and -4 
Bioinformatic analysis of the other three Tensin genes was also carried out to 
determine whether they may also be regulated by a CpG island. Bioinformatic 
analysis of the region upstream of the human TENC1 gene (gene encoding 
Tensin2) revealed a 1004 bp CpG island, which included within it TENC1-001, 
and was also approximately 1000 bp upstream of TENC1-002 (Fig. 65). 
Furthermore there were a number of regulatory elements within this region 
including: Yy1, Erg1, CTCT, Max, cMyc and Nrsf. 
Fig. 65: A screenshot from the Ensembl database of the 5’ end of the human TENC1 gene, 
which contains one CpG island of 1004 bp in length. This CpG island covers exon 1 of TENC1-
001 and is approximately 1000 bp upstream of TENC1-002. Location: 12: 53,440,211-
53,445,231. 
 
Fig. 66: A screenshot from the Ensembl database of the 5’ end of the human TNS1 gene. There 
is no CpG island directly upstream of exon 1 of TNS1-002; however, around 8000 bp away 
there are two CpG islands of 412 bp and 361 bp length which are 17 bp apart. Location: 
2:218866725-218875615 
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Bioinformatic analysis of the human TNS1 gene revealed that there are no CpG 
islands located immediately upstream of transcript origin TNS1-002. However 
approximately 8000 bp upstream of the first exon, there are two CpG islands 
which are 17 bp apart, of 412 bp and 361 bp in length. However, in contrast to 
the TNS3 and TENC1 genes, analysis of the Ensembl database did not identify 
any regulatory elements within the region upstream of this exon (Fig. 66). 
However, downstream of this exon (TNS1-002) but upstream of the first exon of 
TNS1-013, there is located another adjacent pair of CpG islands, of 264 bp and 
275 bp length, with 22 bp separating them (Fig. 67).  
Fig. 67: A screenshot of the Ensembl database highlighting the Tensin1 transcript TNS1-013 
has two small CpG islands located within this region. They are 264 bp and 275 bp in length and 
are 22 bp apart indicated by a red box. Location: 2: 218,807,587-218,846,058 
No regulatory features were identified near this CpG island either. However, 
further downstream, a CTCF-binding motif was identified located immediately 
upstream of exon 1 of another full length transcript TNS1-001. Therefore, 
further bioinformatic analysis also revealed a potential CpG island-containing 
TENC1 gene promoter to exist; it is moreover likely that, based on analyses of 
upstream regions of all four Tensin genes, that Tensins 2 and 3 are the only 
Tensins whose expression may be regulated via a CpG island.  
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3.2 Functional promoter analysis of the TNS3 CpG 
island region 
To confirm whether the putative TNS3 promoter identified by bioinformatic 
analysis was a functional element, a luciferase reporter assay was employed. 
To begin with, western blot analysis of SNB-19 total protein lysates revealed 
expression of Tensin3 protein in these cells, while no Tensin3 was detected in 
HK2 cells (Fig. 68). The SNB-19 cell line was then used for the luciferase assay 
because it naturally expressed Tensin3. HK2 cells were also used, however, as 
Tensin3 is normally expressed in the proximal tubule epithelium of the kidney, 
and there is therefore a possibility that the promoter could be functionally active 
under certain conditions.  
Fig. 68: Western blot detection of Tensin3 protein in SNB-19 and HK2 cells. Upper blot, a 
specific Tensin3 antibody was used to detect the Tensin3 protein band at approximately 150 
kD. Lower blot, actin control, the blot was reprobed with the actin antibody.  
PCR-amplified DNA fragments of 500 bp, 1000 bp and 2000 bp in length, 
covering the TNS3 CpG island region were cloned into a promoterless firefly 
luciferase reporter plasmid. This was then transiently expressed in SNB-19, 
HEK293 and HK2 cells, followed by quantitation of luciferase expression 
through luminescence detection in the cell lysates. In the SNB-19 cells, the 500 
bp fragment yielded higher luminescence above background levels, indicating 
promoter activity. However, this was abolished with the presence of the 1000 bp 
fragment; the luciferase activity was then restored with the presence of the 
longest, 2000 bp fragment (Fig. 69). A similar pattern was seen in HEK293, 
however the 2000 bp fragment yielded much greater luciferase activity than 
even the 500 bp fragment within this system (Fig 70).  
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Fig. 69: Luciferase reporter assay of promoter function of 2 kb region upstream of exon 1 of 
TNS3 gene in SNB-19 cells. Three different length fragments of this region, approximately 500 
bp, 1000 bp and 2 kb, were cloned into pGL4.10 plasmid upstream of the luciferase reporter 
gene, and transfected into SNB-19 cells along with a co-transfection control. The lysates were 
subsequently analysed for luminescence as readout of luciferase expression driven by the 
fragments. The obtained values had background levels subtracted from them and then were 
normalised against the transfection control [FLuc/RLuc]. Bars represent ±SEM (n=3). *** 
denotes P<0.0001 for 500 bp vs. 1000 bp fragments and for 2000 bp vs. 1000 bp fragments.  
Fig 70: Luciferase reporter assay of promoter function of 2 kb region upstream of exon 1 of 
TNS3 gene in HEK293 cells. The lysates were subsequently analysed for luminescence as 
readout of luciferase expression driven by the fragments. The obtained values had background 
levels subtracted from them and then normalised against the transfection control [FLuc/RLuc]. 
Bars represent ±SD, one representative experiment shown (n=3) ** denotes P<0.001 for 500 bp 
vs. 1000 bp fragments and for 500 bp vs 2000 bp; *** denotes P<0.0001 2000 bp vs. 1000 bp 
fragments. 
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Furthermore, a similar observation was made in the human kidney cell line HK2, 
the 500 bp fragment showing higher luminescence above background, which 
was absent in the case of the 1000 bp fragment (Fig 71).  
Fig. 71: Luciferase reporter assay of promoter function of 1 kb region upstream of exon 1 of 
TNS3 gene in HK2 cells. Two different length fragments of this region, approximately 500 bp 
and1000 bp, were cloned into pGL4.10 plasmid upstream of the luciferase reporter gene, and 
transfected into HK2 cells along with a co-transfection control. The lysates were subsequently 
analysed for luminescence as readout of luciferase expression driven by the fragments. The 
obtained values had background levels subtracted from them and then normalised against the 
transfection control [FLuc/RLuc] (n=1).  
 
Therefore, the luciferase reporter assay in these experiments enabled 
confirmation of the location of a minimal promoter element upstream of the 
TNS3 gene, which houses part of the CpG island. Nevertheless, further analysis 
should be conducted to determine the cause of the suppression of luciferase 
expression seen with 1000 bp to determine whether this is an experimental fault 
or negative regulatory element.  
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3.3 Bisulphite sequencing PCR and pyrosequencing 
To determine whether the downregulation of Tensin3 in these patient samples, 
as previously observed and reported by our group (111), was caused by 
differential methylation in the TNS3 gene promoter region, pyrosequencing 
analysis was employed to determine this quantitatively.  
3.3.1. RCC patient samples  
In total, 48 matched genomic DNA sample pairs were obtained from RCC 
patients. However, only 14 of these patient samples yielded results; their 
clinicopathological variables are shown in Table 10.  
Table 10: Patient information and clinicopathological variables relating to DNA samples 
analysed for DNA methylation.  
RCC type   pRCC/ccRCC 2/12 
Patient sex (%)   male/female 57.1/42.85 
Patient age range   (medium) 47-80 (66.5) 
TNM stage   I/II/III/IV 4/5/1/3 
Nuclear grade   1/2/3/4 0/4/9/2 
Tumour size   (medium) 25-130 (90) 
Vein invasion  (no/yes) 12/2 
Capsule invasion   (no/yes) 12/1 
Survival   median/ % 5 yr 64.5/ 64.28 
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3.3.2. Pyrosequencing  
3.3.2.1. Pyrosequencing control analysis 
Genomic DNA from HEK293 cells was treated with the CpG methyltransferase 
M.Sssi to be used as near fully methylated control DNA, while SNB-19 gDNA 
was used an unmethylated control. These control gDNA samples were used to 
validate the accuracy and robustness of the pyrosequencing approach to 
quantifying DNA methylation within the putative TNS3 promoter region. The 
Pyromark software is able to give a percentage of methylation for each CpG 
dinucleotide (Fig. 72).  
Fig. 72: Pyromark pyrograph readout. A. gDNA from HEK293 cells treated with the CpG 
methyltransferase M. Sssi to produce fully methylated control DNA. B. SNB-19 cell DNA served 
as negative control with negligible methylation. The full methylated control has two peaks, whilst 
the unmethylated control only has one peak at thymine, the % methylation indicated in blue 
squares at the top of each CpG is calculated based on the height of the peak relative to other 
peaks from the same nucleotide.  
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The assay was able to detect both high and low methylation levels with 
considerable accuracy. Pyrosequencing analysis of cluster 1 revealed that M. 
Sssi-treated HEK293 DNA to be highly methylated within the putative TNS3 
promoter, with a mean methylation of 83%±3.59 (n=34). SNB-19 gDNA, on the 
other hand, was almost completely unmethylated in the same region, with 
0.87%±0.29 methylation across the 17 CpGs (n=34) (Fig. 73). Therefore, this 
experiment verified the sensitivity and detection range of the pyrosequencing 
method, and was therefore a prelude to using the method for analysis of the 
RCC patient samples.  
 
Fig. 73: Validation of pyrosequencing analysis of putative TNS3 promoter in methylated and 
unmethylated control DNA. Genomic DNA from the HEK293 cell line was treated with the CpG 
methyltransferase M. SssI to produce fully methylated control DNA, whilst the SNB-19 cell DNA 
served as negative control with negligible methylation. Both gDNA samples underwent 
pyrosequencing in duplicate; bars represent mean±SD of methylation level (%) for each CpG 
dinucleotide within cluster 1.  
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3.3.2.2. Pyrosequencing analysis of patient samples  
The methylation level was then determined in the kidney gDNA samples from 
the RCC and normal/control samples for cluster 1 (12 tumour, 3 non-tumour 
and 12 normal samples) (Fig. 74) and the RCC samples for cluster 2 (8 tumour 
and 2 non-tumour) (Fig. 75). Moreover, in the first 17 CpG of cluster 1, there 
was a significantly higher methylation level in the tumour samples compared to 
the normal control (P<0.001), additionally there was also a significantly higher 
methylation between non-tumour compared to normal control (P<0.01) (Fig. 
76). Furthermore, a third of tumour samples had a median methylation level 
over 5% compared with 0% of both non-tumour and normal DNA. 
Fig. 74: Pyrosequencing analysis of RCC patient and normal control samples for cluster 1. RCC 
patient kidney gDNA samples were analysed by pyrosequencing. The cluster 1 region was 
sequenced from one PCR product, using two different sequencing primers that enabled 
coverage of 29 CpG dinucleotides. Dots/triangles represent the methylation level (%) of an 
individual sample at each CpG dinucleotide, with blue dots denoting RCC tumour samples 
(n=12), red dots denoting adjacent non-tumour kidney samples (n=3) and green triangles 
denoting normal control samples (n=12).  
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Overall, there was a significantly higher level of methylation in tumour vs. non-
tumour samples across all CpGs sequenced (cluster 1, P<0.001 and cluster 2, 
P<0.05). Therefore, these results together revealed for the first time quantitative 
differences in DNA methylation at the site of the putative TNS3 promoter 
between tumour and non-tumour samples.  
 
Fig. 75: Pyrosequencing analysis of RCC patient samples for cluster 2. The cluster 2 region was 
sequenced from one PCR product, using one sequencing primer that enabled coverage of 14 
CpG dinucleotides. Dots/triangles represent the methylation level (%) of an individual sample at 
each CpG dinucleotide, with blue dots denoting RCC tumour samples (n=8), red dots denoting 
adjacent non-tumour kidney samples (n=2).  
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Fig. 76: RCC patient samples and normal control samples for the first 17 CpG dinucleotides of 
cluster 1. Line is median methylation *** Denotes P<0.0001, ** denotes P<0.01. 
The overall difference in methylation was mostly seen at two individual 
dinucleotides, CpG 2 and CpG 8 of cluster 1. These showed significant 
differences between their methylation levels and that of the remaining CpGs in 
the tumour samples, as analysed by a Kruskal Wallis H test followed by post 
hoc Dunns test. The CpG dinucleotides that were significantly different to CpGs 
2 and 8 as identified by the Kruskal Wallis H test were pooled and analysed for 
significant differences by a Mann-Whitney test (Fig 76). The level of methylation 
in CpG 2 was 10.69% compared to 1.72% in most remaining CpGs (P<0.0001 
CpG 2 (n=12) vs. multiple CpGs (n=80), Mann-Whitney test) (Fig. 77 A). The 
methylation level in CpG 8 was 13.01% compared with 2.75% in most 
remaining CpGs (P<0.0001, CpG 8 (n=12) vs. multiple CpGs (n=122), Mann-
Whitney test) (Fig. 77 B). 
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Fig. 77: Methylation level of specific CpG dinucleotides within the tumour sample set were 
compared against each other. Two CpG dinucleotides in cluster 1, CpG 2 (A) and CpG 8 (B), 
showed a significantly higher methylation level compared to the remaining CpGs in the sample 
pool (multiple). Boxes represent mean±SEM of % methylation. *** Denotes P<0.0001 for CpG 2 
vs. multiple and CpG 8 vs. multiple; Mann-Whitney test.  
In addition, CpG 2 and CpG 8 were also individually compared against the 
entirety of the remaining CpG dinucleotides, including those which were not 
highlighted as significant through the Krustal Wallis H test. This analysis also 
showed each of the two specific dinucleotides, CpG 2 and 8, to be highly 
significantly different from the rest (Fig. 78). Therefore, these results show that 
quantitative differences in methylation levels between samples, over a given 
DNA stretch, can be predominantly on specific dinucleotides, rather than evenly 
spread across all CpGs in that DNA stretch.  
Fig. 78: Methylation level of two specific CpG dinucleotides in cluster 1, CpG 2 (A) and CpG 8 
(B), within the tumour sample set as compared against the rest (all other CpG dinucleotides). 
Both CpG 2 and CpG 8 showed a significantly higher methylation level compared to all 28 other 
CpGs in the sample pool (Rest). Boxes represent mean±SEM of % methylation. *** Denotes 
P<0.0001 for CpG 2 and CpG 8 vs. “Rest”; Mann-Whitney test. 
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To determine whether the increase in methylation was due to the age of the 
patient; correlation analysis between overall methylation and patient age was 
conducted (r value -0.515, P value 0.087); no significant correlation was made.  
Table 11: Correlation between clinicopathological parameters, in RCC patients, and CpG 
dinucleotides 2 and 8.  
 CpG 2 CpG8 
 r value P value r value P value 
Tns3 mRNA in tumour -0.779 0.0047** -0.328 0.325 
Tumour size 0.053 0.870 -0.551 0.063 
Age -0.095 0.770 -0.455 0.137 
Tumour grade -0.063 0.846 0.111 0.731 
Tumour stage 0.189 0.557 -0.385 0.216 
r value, significant values in bold; (2) P value; **P<0.005.  
Fig. 79: Scatter plots showing the correlation between methylation and Tensin3 mRNA. A. The 
percentage methylation in CpG dinucleotide 2 was correlated with relative Tensin3 expression 
from the same patient tumour sample. B. The percentage methylation in CpG dinucleotide 8 
was correlated with relative Tensin3 expression from the same patient tumour sample. n=11. 
R
2
= coefficient of determination. 
Correlation analysis was also carried out to evaluate a relationship between the 
methylation levels on CpG 2 and CpG 8 and the clinicopathological parameters. 
Interestingly, a significant negative correlation was present between the 
methylation level in CpG 2 and Tensin3 mRNA in tumours, although this was 
not significant in the case of CpG 8 (Table 11). However, there were no 
significant correlations between methylation at CpG 2 and 8 and any of the 
other clinicopathological parameters.  
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Thus, analysis of the CpG island in RCC samples identified two CpG 
dinucleotides whose methylation changes were more pronounced than in those 
around them. The significance of this was furthermore more apparent from the 
observation that the methylation level of CpG 2 negatively correlated with 
Tensin3 mRNA expression in the same patient samples. Together, these data 
suggesting that methylation of the TNS3 gene CpG island could be a possible 
mechanism for the downregulation of Tensin3 seen in RCC patients.  
 
3.4 Effect of demethylation treatment with 5-aza and 
Tensin3 expression in cells 
To determine whether there was a functional role for alternate methylation of 
the TNS3 gene promoter in controlling its expression, human kidney cells 
underwent pharmacological DNA demethylation treatment with 5-aza followed 
by qRT-qPCR analysis of Tensin3 expression.  
Firstly, to determine the optimal concentration of 5-aza to use, an MTS/survival 
assay was carried out, testing 5 different concentrations of 5-aza (0.004 µM- 40 
µM). None of the concentrations tested caused a reduction in cell survival (Fig. 
80 and 81). Simultaneously, 4 other drugs were also tested for their effect on 
survival. Acetaminophen (P<0.05), etoposide (P<0.05) and temolozomide 
(P<0.05) all caused a decrease in cell survival at their highest concentrations, 
while apigenin was non-toxic at all concentrations tested. In relation to 5-aza, it 
was therefore determined that 40 µM was suitable for the expression 
experiments. The results on the other drugs, although not directly relevant to 
this project, nevertheless inform on the sensitivity of RCC cells to such agents, 
each of which is relevant to anticancer therapy.  
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Fig. 80: MTS assay of a dose response of 5 different drugs on 786-O cells.786-O cells in serum 
free medium were incubated with 5 different drugs at 5 different concentrations for 72 h. MTS 
formazan dye was added after and incubated for a further 2 h, following which medium 
OD492nm was read. * denotes P <0.05 vs. lowest concentration.  
Fig. 81: Effect of 5-aza on cell viability. Human 786-O kidney cancer cells in serum free medium 
were incubated with different concentrations of 5-aza at for 72 h. Conversion of the MTS 
formazan dye was used as an index of cell viability. No significant difference in viability was 
observed at any of the treatments; bars represent mean±SEM % cell viability (n=3).  
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Five different cell lines were treated with 5-aza for 4 days, following which 
Tensin3 expression in them was determined by qRT-PCR. As Tensin3 is 
predominately expressed in the kidney, 786-O and HK2 cells were chosen as 
they were both kidney-derived cell lines. Also, as this study was focussed on 
cancer, the cancer cell lines SNB-19 and DU145 were also used. The cell lines 
786-0, SNB-19 and SK52 all showed little change in expression between 
treated and untreated (Fig. 82). However, there was a change in expression 
between treatments in both DU145 and HK2 cells, and so further analysis on 
these two cell lines was carried out. Although Tensin3 was detected in HK2 
cells here but not by western blot, the Tensin3 protein was likely present in HK2 
cells but its band intensity was under the detection limit of the western blot in 
Fig. 68, relative to the clear band seen in SNB-19 cells. However, it is difficult to 
correlate mRNA expression with protein expression (168). 
Fig. 82: Different cell lines were treated with 5-aza (40 µM), and incubated for 4 days. 5 different 
cells lines were incubated with 5-aza for 4 days, lysed and underwent qRT-PCR. Tensin3 
expression was normalised against the housekeeping gene B2M. T=5-aza treatment, U= 
untreated control.  
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DU145 prostate cancer cells were treated with 40 µM of 5-aza for 4 days, 
before being lysed and undergoing qRT-PCR. Although there was a small 
increase in Tensin3 expression after 5-aza treatment, this was not significant 
(Fig. 83).  
Fig. 83: DU145 cells were treated with 40 µM of 5-aza for 4 days. The cells were then lysed and 
underwent qRT-PCR. Tensin3 expression was normalised against the housekeeping gene 
B2M. Error bars represent ±SEM, n=3.  
 
The kidney HK2 cell line was treated with 5-aza over 4 days; qRT-PCR analysis 
showed there to be a statistically significant increase in Tensin3 expression in 
the 5-aza treated cells over untreated control (P=0.0068) (Fig. 84). However, 
the level of methylation was not assessed by pyrosequencing analysis after 5-
aza treatment and therefore, it is unclear whether this is a direct effect on the 
Tensin3 CpG island or an indirect effect, affecting another gene which is 
upregulating Tensin3.  
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Therefore, in at least 2 cell lines tested, demethylation treatment with 5-aza did 
result in an upregulation of Tensin3 expression, suggesting that removal of 
methylation can allow for positive gene transcription effect to take place.  
 
Fig. 84: The effect of 5-aza treatment on Tensin3 mRNA expression in HK2 cells. HK2 cells 
were treated with 40 µM 5-aza for 96 h, and RNA extracted from cell lysates underwent qRT-
PCR analysis. Tensin3 mRNA amounts were determined using the relative standard curve 
method, with normalisation against the housekeeping gene B2M. Bars represent mean±SD of 
gene expression relative to untreated control;** denotes P<0.01 (n=3, representative 
experiment).  
 
 
3.4.1. Effect of demethylation treatment and Tensin2 expression 
As the human TENC1 gene also contains a CpG island in proximity to its first 
exons, Tensin2 mRNA expression after 5-aza was also analysed. HEK293 cells 
were treated over 4 days with 5-aza, after qRT-PCR analysis of Tensin2 
expression found an 8-fold increase was seen compared to untreated control 
(P=0.0058) (Fig. 85).  
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Fig. 85 The effect of 5-aza treatment on Tensin2 mRNA expression in HEK293 cells. HEK293 
cells were treated with 40 µM 5-aza for 96 h, and RNA extracted from cell lysates underwent 
qRT-PCR analysis. Tensin2 mRNA amounts were determined using the relative standard curve 
method, with normalisation against the housekeeping gene B2M. Bars represent mean±SD of 
gene expression relative to untreated control;** denotes P<0.01 (n=3, representative 
experiment).  
 
The results from this section of the project indicate that suppression of Tensin3 
may be reversible using the pharmacological demethylating agent 5-aza, 
although it is unclear whether this is a direct effect on Tensin3 or indirectly 
upregulating another gene with in turn upregulates Tensin3. This was also 
observed with the TENC1 gene, indicating that Tensin2 expression may also be 
regulated via epigenetic mechanisms.  
 
 
3.5 Summary 
Bioinformatic analysis identified CpG islands located in close proximity to the 
human genes TNS3 and TENC1. Therefore, it is likely that Tensin2 is the only 
other Tensin whose expression may be regulated by a CpG island, as the TNS1 
gene CpG island(s) are located at a much greater distance away than those for 
the TNS3 and TENC1, whilst the TNS4 gene appears to lack such CpG island 
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regulation control altogether. The luciferase reporter assay identified a minimal 
functional promoter element with 500 bp of the TNS3 promoter. However, 
analysing a larger region up to 1000 bp upstream of the first exon did not drive 
luciferase expression, and so further research is required to determine the exact 
cause of this lack of an effect. For example; the 1000 bp fragment could be re-
cloned into the pGL4.10 vector and multiple clones analysed to rule out any 
experimental problems before assessing the role of the regulatory sites within 
this region such as the CTCF and YY1 binding motifs. Pyrosequencing analysis 
identified two specific CpG dinucleotides, CpG 2 and 8, that were methylated at 
significantly higher levels within the RCC cancer samples. Furthermore, CpG 2 
methylation negatively correlated with Tensin3 expression. In addition, Tensin3 
expression was able to be restored in cultured cells after pharmacological 
demethylation treatment with 5-aza.  
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Chapter 4 
 Investigation of alternative methods for DNA 
methylation analysis  
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Investigation of alternative methods of DNA methylation 
analysis 
This chapter describes the employment of three different methodologies that 
were explored for their usefulness in determining methylation levels in the RCC 
patient samples. These included (i) methylation-specific PCR (MSP), which 
enables the detection of one CpG dinucleotide with a region; (ii) the EpiTect 
qPCR methylation assay which is able to quantitatively determine the 
methylation level within a region and lastly, (iii) BSP-pyrosequencing which was 
able to quantitatively determine the methylation level at individual CpG 
dinucleotides. This enable a clear comparison to be made between these three 
different experimental approaches and their usefulness in this study. 
Furthermore, this chapter describes the process of development and 
optimisation of the BSP-pyrosequencing methodology.  
4.1. Methylation-Specific PCR (MSP) for Tensin3 
Methylation-specific PCR (MSP) is a PCR-based technique designed to amplify, 
in two different reactions, either methylated or unmethylated DNA after 
bisulphite conversion (Fig. 65- Chapter 2). 200 ng of patient sample was taken 
for bisulphite conversion as described above (Chapter 2), before undergoing 
PCR with Truestart Taq polymerase.  
 
5 µl Buffer 10X 
0.5 µl Truestart Taq (2.5 u) 
1 µl dNTP, 10 mM 
2 µl MgCl2 
1 µl Forward primer (25 pmol/µl) 
1 µl Reverse primer (25 pmol/µl) 
1 µl Bisulphite converted DNA 
38.5 µl Nuclease free water 
50 µl Total 
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Two different annealing temperatures were initially tried, 50°C or 55°C to 
determine the optimal temperature to obtain specific bands. 
 
 
 
95°C 3 min  
94°C 1 min  
55°C or 50°C 1 min 35 cycles 
72°C 1 min  
72°C 10 min  
 
Following MSP, 5 µl of the samples were analysed using 2% standard agarose 
gel electrophoresis, which was run at 100 V for 30 min (Fig. 86).  
 
 
Figure 86: The difference between two different annealing temperatures in MSP. MSP PCR was 
initially carried out at two different annealing temperatures, 50°C and 55°C. At 55°C bands were 
visualised at below 100 bp, while no bands were detected in the 50°C condition.  
 
The higher annealing temperature for this MSP reaction, 55°C, gave clear 
bands, which were absent when running at the lower annealing temperature of 
50°C. Furthermore, the bands were sharp; however, they did appear smaller 
than the expected sizes of the methylated band (103 bp) and the unmethylated 
band (104 bp). Nevertheless, all further MSP reactions were carried out at this 
temperature. To help clarify the bands under more suitable conditions for such 
small bands, a 3% agarose gel was run in both Tris-Acetate EDTA (TAE) and 
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Tris-Borate EDTA (TBE- 0.045 M Tris-borate and 0.001 M EDTA) buffers. 
However, this did not improve the appearance of the bands (not shown). 
Following this, an 8% polyacrylamide gel was attempted, run at 20 V; however 
as seen in Figure 87, the bands were no clearer and they also appear to be too 
low in size to be the specific product.  
 
Fig.87. An 8% polyacrylamide gel was at run at 20 V. Bands should be around 103-104 bp, 
these bands appear much lower than this. The numbers indicate the sample ID while, M and U 
describe the primer type, methylated (M) or unmethylated (U). 
 
Lastly, a 3% low-melting agarose gel was run to analyse the MSP reactions. 
Although the bands were weak, the resolution appeared to be sharper than in 
the polyacrylamide gel (Fig. 88). 
 
Fig.88. A 3% low-melting agarose gel. The gel was run at 100 V for 45 minutes, although the 
bands are very weak, although the ladder was sharp (whole ladder not shown on image-100 bp 
highlighted by arrow). The numbers indicate the sample ID while, M and U describe the primer 
type, methylated (M) or unmethylated (U). 
 
Therefore, it was decided that 3% low-melting agarose (fisher) gels should be 
used from then on. However, with each sample that was run post-PCR, it was 
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very difficult to accurately determine whether the bands seen were specific as 
every band was only weakly visible on the gel. Furthermore, MSP primers did 
not appear to recognise and amplify the correct target region, however there 
was only one band seen on the gel. Thus, it was concluded that a different 
methodological approach should be taken in order to reliably analyse the DNA 
methylation status of the TNS3 promoter region  
 
4.2. Restriction digestion-based qPCR analysis of 
differentially methylated DNA 
The EpiTect qPCR (Qiagen) technique provides a quantitative alternative to 
MSP, although not as accurately and comprehensively quantitative as 
pyrosequencing. Nine patient samples (8 tumour and 1 non-tumour) were 
assessed for their methylation status in the TNS3 promoter (Fig. 89 A) and 4 
samples (3 tumour and 1 non-tumour) were analysed for methylation in the 
TENC1 promoter (Fig. 89 B). The level of methylation across both groups was 
generally low for both TNS3 and TENC1 gene promoters; however, only a small 
number of samples were assessed. In the TNS3 assay the level of methylation 
in the tumour samples is marginally higher with a range from 0.01-6.81%; 
however, with only 1 non-tumour sample analysed, it is difficult to draw 
conclusions from this data. In the Tensin2 assay the tumour samples had a 
range from 0.47-6.01%, there was also only 1 non-tumour sample analysed.  
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Fig. 89: EpiTect analysis of TENC1/TNS3 CpG island. RCC gDNA samples were digested 
according to the manufacturer’s protocol, before undergoing qPCR with SYBR green. A. 
Analysis of TNS3 CpG island, 8 tumour and 1 non-tumour samples were analysed. Median 
methylation is denoted by the bar.  B. analysis of TENC1 promoter, 3 tumour and 1 non-tumour 
were analysed. The bar denotes median methylation.  
 
4.3. Bisulphite-Specific PCR 
4.3.1. Overview 
Bisulphite specific PCR (BSP) can be the starting point for a number of different 
types of analysis. In this study, it was the prelude to pyrosequencing analysis; 
however, other types of sequencing can also be employed. BSP differs from 
MSP in the primer design, where BSP primers are designed to not discriminate 
between the methylated and unmethylated DNA and should therefore be 
unbiased.  
Fig. 90: Workflow employed in this study for quantitative DNA methylation analysis, from 
bisulphite conversion to pyrosequencing, including BSP,  
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4.3.2. Bisulphite conversion protocols 
Three different bisulphite conversion methods were assessed: homemade 
bisulphite reagents (chapter 2), EZ DNA Methylation-Gold™ Kit (Zymo) and 
EpiTect Bisulphite Kit (Qiagen) to determine best choice for bisulphite 
conversion in these samples. Firstly, the Zymo kit and the Qiagen kit were 
compared, using as source material, 350 ng of methylated control DNA 
(HEK293 gDNA treated with M. SssI) and unmethylated control DNA (untreated 
SNB-19 gDNA). These were treated with either the Zymo kit or the Qiagen kit 
following the manufacturer’s conditions. Following the purification of the 
samples using the kits’ own components, the purified Qiagen kit samples were 
finally eluted in 15 µl of elution buffer whilst the purified Zymo kit samples were 
finally eluted in 10 µl of elution buffer. The concentrations of the samples were 
then assessed on the nanodrop spectrophotometer (Nanodrop, Thermo 
Scientific) (Fig. 91).  
Fig. 91: Nanodrop spectrophotometer readings for purified bisulphite-converted DNA using 
Zymo vs. Qiagen kits. A) methylated and unmethylated DNA readings after bisulphite 
conversion using the Qiagen kit. B) Methylated and unmethylated DNA after bisulphite 
conversion using the Zymo kit. The concentration indicated by the pink box, is calculated based 
on the absorbance at 260 nm (RNA), the samples were blanked against the elution buffer.  
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Although it appears that there may be more DNA in the Qiagen kit spectra, the 
readings for DNA concentrations of both kits were inaccurate as they indicate 
there to be a higher yield of DNA than was originally input into the conversion 
method. The properties of the reaction may have been preventing accurate 
measurements, making it difficult to determine from this analysis which was the 
better product. Furthermore, all the samples had high 260/280 ratios over 2, the 
Qiagen kit samples had 260/280 ratios over 3, indicating contamination in the 
sample from substances that also absorb at the 260nm wavelength e.g. certain 
phenolic compounds and/or alcohols. This overestimation of the amount of 
nucleic acid and contamination in the sample could then possibly impair the 
accuracy of the downstream application. For this reason, the post-bisulphite 
converted samples were instead compared directly only at the later, PCR stage, 
using 3 µl of each sample as template for the outer reaction of the nested PCR; 
0.5 µl of DMSO was also added to improve the amplification of the GC rich 
region.  
5 µl dNTPs, 2.5 mM 
5 µl Truestart Buffer 
3 µl MgCl2, 25 mM 
1 µl Forward primer 25 pmol/µl 
1 µl Reverse primer 25 pmol/µl 
0.5 µl DMSO 
0.5 µl Truestart Taq polymerase 
3 µl Bisulphite-treated DNA 
31 µl Nuclease free water 
50 µl Total 
 
The outer PCR reaction was then run using an annealing temperature of 50°C 
for 40 cycles. Then, 1 µl of the outer reaction product was carried forward into 
the inner PCR reaction, with three inner reactions carried out simultaneously for 
each sample, under the same conditions as the outer reaction.  
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95°C 2 min  
95°C 1 min  
50°C 1 min  40 cycles 
72°C 7 min  
72°C 15 min  
 
These were then pooled together before being purified. To assess the 
difference between the two kits, 5 µl of each sample was mixed with a 
bromophenol blue loading dye and analysed by 3% low-melting agarose gel 
electrophoresis at 100 V (Fig. 92).  
Fig. 92: Comparison of inner nested PCR reaction products using as starting material DNA 
treated with Zymo vs. Qiagen bisulphite conversion kits. PCR reactions included those on 
control methylated (M) as well as unmethylated (U) DNA; these were run on a 3% low-melting 
agarose gel.  
For both kits, the unmethylated control sample failed to give a band, although 
the reason for this is unclear, it could be due to the quality of the DNA before it 
entered the bisulphite conversion process. On the other hand, both kits 
provided a band for the methylated control sample, although it was not clear 
from the gel which kit was the more effective. However, when this was repeated 
from DNA, which has been bisulphite converted previously and frozen, from 
each kit, the Zymo DNA gave a band, indicating that the Zymo kit bisulphite 
converted DNA is more stable after storage (Fig. 93).  
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Fig. 93: The difference between DNA treated with Zymo (ZM) and Qiagen (QM) bisulphite 
conversion kits after storage at -20°C for 2 months. Samples underwent nested PCR and were 
analysed under 3% low-melting agarose gel electrophoresis, as described above.  
Therefore, the Zymo kit, although not appearing to give stronger bands than the 
Qiagen kit with control samples that were freshly converted, did appear to yield 
samples that were more stable after storage, enabling multiple analyses to be 
carried out from the same sample. Furthermore, more of the patient samples 
gave results using the Zymo kit than with the Qiagen kit (not shown). However, 
the yield and quality of DNA produced from each patient DNA sample was 
variable.  
To try and improve the yield and quality of DNA, a homemade bisulphite 
conversion protocol was also attempted, based on the method described by 
Tøst and Gut (169) (Chapter 2). This then underwent PCR according to the 
touchdown conditions described above. There were either little or no bands 
seen when analysed on a 3% low melting agarose gel. The homemade method 
was more time consuming and although it cost less, it did not work as well as 
the kit version which were much quicker than basic alternative.  
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4.3.3. Optimisation of BSP protocol 
4.3.3.1. Nested PCR and cycling conditions 
To increase the amount of product produced after PCR, nested PCR was 
employed. Initially, the conditions of the PCR were set as described in the 
protocol for the Zymo EZ DNA Methyl Gold kit protocol:  
95°C 2 min  
95°C 1 min  
55°C 1 min  35 cycles 
72°C 1 min  
72°C 15 min  
 
Although this worked well for the control samples from cell gDNA which had 
been freshly prepared, this was more problematic when using the patient 
samples that had been prepared previously and elsewhere. Therefore, to try to 
increase the template available after bisulphite conversion, nested PCR was 
used. Nested PCR employs two distinct sets of primers for two separate, 
sequential PCR reactions, an outer and an inner reaction, with the inner primer 
pair annealing to the product produced by the outer primer pair. The outer PCR 
essentially serves to increase the amount of template for what would otherwise 
be too little for a normal, single, PCR reaction. The PCR conditions were used 
as described below and 5 forward and 5 reverse primers were chosen, and 
used in 25 different combinations (Table 12) (Fig 94).  
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Table 12: Nested PCR outer primers. 5 different forward and reverse primers were designed 
around the CpG island and used in 25 different combinations.  
 Primer sequence 53 
Forward primer 1 TAGGATGGATAGTTAGGATGGATA 
Forward primer 2 TGTGATTTTTTTGGAGGAAGAGTAT 
Forward primer 3 AGGGTAGGATTTTAGGGTTG 
Forward primer 4 GAATAGGGTAGGATTTTTAGGGTTG 
Forward primer 5 TTTAGTTGTTTGGATTTTGGGG 
Reverse primer 1 TCTCTACTAACCCCACACCCTAATA 
Reverse primer 2 AAAAACACTACACCTCCATCT 
Reverse primer 3 AAAACCCAATACACCTCCATCT 
Reverse primer 4 ATACACAAACCAAAACCTCAAAAA 
Reverse primer 5 CCACCCTCAATAATACTCTCTACTAAC 
 
 
 
Fig 94: The location of the outer primers relative to the CpG island. 5 forward primers and 5 
reverse primers were designed outside of the CpG island. The largest PCR product was 2709 
bp and the smallest was 1524 bp.  
 
 
The expected size of these outer PCR fragments was between 1524 bp and 
2749 bp depending on the combination of primers used. Therefore, the 
extension time was set at 3 min with an annealing temperature of 55°C and the 
reaction undergoing 30 cycles. Then 4 µl of the outer PCR was taken as 
template for the inner reaction of the nested PCR, and run under the same 
conditions as above. Following this, 5 µl of the crude inner PCR was then 
analysed by 3% low melting agarose gel electrophoresis at 100 V.  
The majority of the primer combinations after the inner PCR reaction did not 
yield any products; however, 3 sets gave clear bands at the expected size, 
217bp (Fig. 95); these were:  
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18: Forward primer 3 and reverse primer 4, expected outer size 2364 bp 
22: Forward primer 4 and reverse primer 3, expected outer size 2065 bp 
25: Forward primer 1 and reverse primer 3, expected outer size 2260 bp 
Fig. 95: Analysis of the 25 different outer primer combinations after inner PCR. Control gDNA 
was bisulphite converted and then underwent the outer PCR with 25 different primer 
combinations then the inner reaction to assess which primer combination would yield a greater 
amount of product. Inner reaction shown; expected size 217 bp.  
The samples containing the expected size products after the inner PCR were 
purified using the GeneJet PCR purification and taken to Barts and the London 
Genome Centre for pyrosequencing analysis. However, all samples failed to 
provide clear results due to low yield. Therefore, to increase the yield, a greater 
number of inner PCR reactions were carried out for each nested PCR. Initially, 
5 inner PCRs were carried out on methylated and unmethylated controls using 
the same combinations of primers as above (Fig. 96). Sample 18 gave a strong 
band for the unmethylated control (S), but gave a weaker band for the 
methylated control (M). Only primer combination 22 gave strong bands for both 
methylated and unmethylated control DNA. All of these samples were analysed 
by pyrosequencing; this time primer combinations 19 (forward primer 2 and 
reverse primer 4) and 22 (Forward primer 4 and reverse primer 3), were 
suitable for pyrosequencing analysis.  
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Fig. 96: Analysis of multiple inner PCR reactions for the 5 primer pairs. Multiple inner PCR 
reactions were carried out. 5 inner reactions were carried out from one outer PCR product, 
these were pooled then purified using the GeneJet PCR purification kit (Fermentas). The 
number corresponded to the outer primer pair, S is SNB-19 (unmethylated control) and 
methylated control.  
As primer combination 22 gave the most consistent results, working in both 
PCR reactions, this primer pair was selected for the analysis of the patient 
samples in the main study. However, with patient samples, only weak products 
came from reactions that worked, with the majority of the samples failing. 
Therefore, to try and improve the PCR product yield so as to be sufficient for 
successful pyrosequencing, the number of cycles for the inner reaction was 
increased from 30 to 40. This modification improved the intensity of the bands 
upon electrophoresis, and also increased the number of samples that showed 
bands (Fig. 97). However, with prior experience, these bands were deemed not 
strong enough for pyrosequencing.  
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Fig. 97: Varying the cycles in the outer and inner PCR. A) The outer and the inner PCR had 30 
cycles in total 7 samples showed clear bands. B) The number of cycles was increased from 30 
to 40 cycles, the number of patient samples showing products with the expected bands 
increased to 15, doubling the number of patient samples which yielded a result. The number 
denotes number of the sample. 
Although the optimisation of the PCR, in particular the employment of nested 
PCR and improvement of cycling conditions, greatly improved the yield of DNA 
appropriate for pyrosequencing, the majority of samples still failed. This could 
have been due to the large length of the outer PCR amplicon (2065 bp). 
Therefore, two new outer PCR primers pairs were designed that would produce 
a much shorter amplicon, one which would cover only the CpG island (1000 bp) 
and the other only the half of the CpG which contained cluster 1 (500 bp) (Table 
13).  
 
Table 13: Redesigned outer PCR primers for the small amplicon were used in order to improve 
the efficiency of the outer PCR. Three primers were designed, one that was a common forward 
primer and two reverse primers, which together with the common forward primer would give 
different length products, one of 500 bp and the 1000 bp.  
 Primer sequence (5’3’) Size (bp) 
Forward primer GGGTTGTTTAATGGGTTTGATAAT  
Reverse primer 1 (500 bp product) CCCCAACTCCAAATCTCTATACTC 452 
Reverse primer 2 (1000 bp product) ACCTACCCATTAAAACCCCTAACT 902 
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Only the primers yielding the larger amplicon (1000 bp) product, that 
incorporated the whole CpG island, gave a strong band for the inner reaction, 
which was of the expected size (217 bp). Interestingly, when the crude outer 
PCR was run on a gel, the outer PCR for the smallest amplicon (500 bp) gave 
an expected size product (Fig. 98), indicating that perhaps they were efficient at 
amplifying that region from genomic DNA. However, this was not exploited as it 
was deemed to be of greater risk and with potential for greater variability when 
working with clinical samples.  
Fig. 98: The new outer primers, these amplified a much smaller region than the original outer 
primers. In the inner reaction there is a clear band for the 1000 bp primer pair and whilst in the 
500 bp there was only a weak product as well as non-specific bands. In the outer reaction, there 
was a clear band for the 500 bp product, indicating the outer PCR appeared to work, there was 
no specific band for the 1000 bp product in this reaction.  
Whilst the nested PCR improved the number of patient samples that worked, 
there were still a large number of patient samples that were “falling at the last 
hurdle”, i.e. pyrosequencing. Therefore, touchdown PCR was employed. This is 
a technique whereby the annealing temperature in the PCR is initially high, but 
successively lowered by 1°C every 3 cycles until remaining at an optimal 
annealing temperature for the remainder of the PCR cycles. During the initial 
cycle, the higher temperatures should only allow the specific binding of primers 
to the target sequencing, therefore increasing the amount of specific product to 
164 
 
be used as template for the later cycles. Therefore, this cycling approach helps 
to reduce non-specific binding and can increase the amount of PCR product as 
a result. Furthermore, it was expected to be particularly useful for this study due 
to the potential for greater non-specific annealing, owing to the fact that 
bisulphite treatment converts non-methylated cytosines to uracils/thymines, thus 
leaving large sections of DNA that are similar to each other (170).  
 
Two patient samples that had previously been bisulphite-converted were used 
under the new touchdown conditions, with 2.4 µl of the bisulphite-converted 
DNA being used in the outer PCR. The reaction was set up as described above 
and run under the following conditions:  
95°C 2 min  
95°C 1 min  
60°C48°C 1 min  3 cycles at each annealing temperature 
72°C 1 min  
95°C 1 min  
47°C 1 min  14 cycles 
72°C 1 min  
72°C 15 min  
 
Sample number 20 had previously failed under the non-touchdown PCR 
conditions while number 21 had worked, although yielding a weak product. The 
touchdown conditions improved the intensity of sample 21, whereas sample 20 
still failed to produce a result (Fig. 99). Therefore, the touchdown PCR cycling 
conditions were then used for the rest of the patient samples for production of a 
PCR fragment that was of sufficient yield and quality to pass stringent 
pyrosequencing process.  
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Fig. 99: Analysis of touchdown conditions for BSP. Touchdown conditions tried on two samples, 
20 which previously failed and 21 which was weak. The touchdown conditions improved the 
intensity of sample 21; however 20 still failed.  
However, as alluded to above, even under touchdown PCR conditions, samples 
often did not provide enough material for pyrosequencing analysis. Therefore, 
to improve on this, a variable number of inner reactions were compared 
following the outer reaction during the nested PCR. On gDNA from SNB-19 
cells, which was an unmethylated control sample, 1, 2 and 3 inner reactions 
were carried out before being pooled together and purified (GeneJet PCR clean 
up kit) (Fig. 100).  
Fig. 100: Multiple nested PCR reaction. Multiple inner reactions were carried out from the same 
outer reaction, these were either 1, 2 or 3 inner reactions which were then pooled and purified 
(GeneJet PCR clean up kit). It appears that there is no great difference between the number of 
inner reactions run, with both 1 and 3 reactions yielding a similar amount. 
Using control gDNA, any number of inner reactions can be carried out and the 
band intensity stays approximately the same (Fig. 100), however when patient 
samples were used, this was not the case. This difference could be due to the 
quality of DNA obtained from the patient samples after bisulphite conversion. 
With this limitation in mind, the minimum number of inner reactions necessary in 
order to have enough product for pyrosequencing was therefore deemed to be 
5.  
166 
 
4.3.4.2. Purification of post-BSP samples  
After bisulphite-converted DNA samples had undergone the PCR reactions, 
they were pooled together and purified to remove any contaminants and also 
reduce the volume and increase the concentration of the sample. However, 
there was a concern that the GeneJet PCR cleanup kit was reducing the yield of 
the sample too greatly. Therefore, two PCR product purification methods were 
compared: commercial kit or ethanol precipitation. Precipitation of DNA with 
ethanol allows for the DNA to be solubilised in a lower volume than the original 
volume, thus concentrating the solution (Appendix 1). Samples were either 
eluted or resuspended in 60 µl of TE buffer, and 5 µl was taken and analysed 
by 3% low melting agarose gel electrophoresis (Fig. 101).  
Fig. 101: Determination of the optimal purification technique for samples. One sample was 
purified by either ethanol precipitation or column purification (GeneJet PCR cleanup kit).  
There appeared to be no significant difference between the band intensity of the 
expected product emerging from either the precipitation or column purification 
processes. However in the precipitated sample, at around 50 bp primer dimers 
could be seen which would cause a problem for the pyrosequencing, as these 
likely contained the biotinylated primer. These would also bind to the 
streptavidin beads in the purification step of the pyrosequencing reaction and 
therefore cause low readouts from the pyrosequencer.  
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4.4. Conclusion 
BSP with pyrosequencing offers a more quantitative solution of methylation 
detection that the alternative methods. However it is entirely dependent on the 
effectiveness of the bisulphite conversion. Through this technique, 43 CpG 
dinucleotides within the TNS3 CpG island were detected and able to be 
individually quantified for their methylation level (Chapter 3). As the EpiTect 
qPCR assay does not involve the bisulphite conversion, this would be a good 
alternative to both MSP and BSP; although it does not offer the same level of 
quantitation as BSP. It was able to detect differences within tumour samples 
between 0.01-6.81%. Although the EpiTect qPCR assay is able to obtain 
percentage values of methylation, these percentages are accounting for more 
than one CpG dinucleotide and the exact location of these is unknown. 
However, for the BSP-pyrosequencing analysis, methylation levels are detected 
for individual CpG dinucleotides, enabling a clearer, more specific and 
comprehensive picture of the variable methylation within a CpG island. 
Therefore, although BSP has its failings, it was the method of choice for this 
study to give a more accurate and statistically comparable picture of the 
methylation differences in the TNS3 promoter region.  
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5.1 Bioinformatic analysis of the Tensin gene family  
5.1.1. CpG island surrounding the TNS3 gene 
The human TNS3 gene is located on chromosome 7, on the short arm. There 
appears to be 2 full length transcripts that code for different protein isoforms of 
Tensin3, as well as a number of shorter transcripts. Initial bioinformatic analysis 
of the TNS3 gene revealed an 826 bp CpG island that was located immediately 
upstream of and running into exon 1 of one of its various transcripts 
(ENST00000434451). In addition, another genomic DNA stretch was identified 
by the EMBOSS CpGPLOT analysis that contained two small CpG islands, one 
380 bp and the other 513 bp, separated by only a 47 bp stretch; however, it is 
more likely that they are part of the same unit. This CpG island is however 
located after the first exons of the second set of transcripts, approximately 2000 
bp downstream of exon 1 of ENST00000355730. This is, therefore, less likely to 
be involved in direct gene activation or repression of the TNS3 gene. CpG 
islands such as this one have been called “orphan” CpG islands as they do not 
associate with known transcriptional features. However, they have been shown 
to be important as promoters for ncRNAs, which themselves may function to 
regulate expression of either that gene or another gene nearby (49). 
Interestingly, studies have shown that these regions appear to be more 
methylated than those CpG islands located at the 5’ end of genes (171, 172). 
To investigate whether this CpG island may be important for regulation of 
Tensin3 expression, this CpG island could for example be analysed in a 
luciferase reporter assay such as the one that was employed, making sure to 
conserve the regional and sequence context in which the island resides in 
relation to the transcription start of the TNS3 gene or unknown lncRNA. It would 
also be worthwhile to determine the methylation status of this region as 
intragenic regions can often be more methylated.  
The general outcome of many molecular biological studies to date have 
together identified two types of promoter regions, those with highly conserved 
DNA sequence features such as TATA boxes and those with a high CG content 
(59). There are a large number of CpG islands within the human genome, 
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around 45,000 (173), with around 60-70% of transcriptional start sites of genes 
being found within CpG islands. Although it was initially believed that these 
were relevant for predominately housekeeping genes, it has since become clear 
that this is not the case, and that CpG islands regulate transcription of a larger 
number and wider variety of genes (174). Such CpG islands also appear to be 
fairly conserved in vertebrates, and moreover display a distinct lack of 
methylation within these regions in most species. Furthermore, in higher 
organisms, it is evident that the mouse and human genomes have a similar 
number of CpG islands, although in the mouse genome these are less CpG-rich 
(175). The similar positioning and number of these islands indicates their 
potential importance for gene regulation and furthermore the degree of 
conservation of such regulatory capability throughout evolution. In addition, 
CpG islands have been shown to preferentially bind CXXC domain-containing 
proteins which can recruit chromatin-modifying activities, including Cfp1, which 
is a subunit of an H3K4Me3 methyltransferase (176). Therefore, this suggests 
an important role for CpG islands in epigenetic gene regulation via not only 
DNA methylation but also indirectly via recruitment of histone-modifying 
enzymes.  
Further bioinformatic evidence for the putative TNS3 gene promoter region that 
was identified came through searching the ENCODE database (167). This 
revealed a number of histone marks, namely H3K4me1 (enhancer and 
promoter associated mark), H3K4me3 (promoter associated mark) and 
H3K27ac (regulatory associated mark), all of which were located upstream of 
exon 1 of transcript origin TNS3-003 (177). The H3K27ac histone acetylation 
mark, seen here near TNS3, is commonly believed to be an important enhancer 
mark that can distinguish between active and poised enhancers (178), while, 
trimethylated H3K4me3 is usually associated with an active promoter and, 
unlike H3Kme2, is almost exclusively found at the 5’ end of active genes (179). 
In addition, components of HAT complexes, such as Chd1, have been shown to 
specifically interact with H3K4me in Saccharomyces cerevisiae (180), while 
H3K4me1 has been shown to promote transcription through association with 
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the transcription factor E2A (181) as well as marking enhancers which have 
weak if any enrichment of H3K4me3 (182).  
Analysis of the Ensembl genome database further identified a CCCTC-binding 
factor (CTCF) motif also located upstream of the start of exon 1 of TNS3-012. 
The CTCF factor usually binds to CTCF insulator sequences, which are often 
located between an enhancer and promoter and prevents the enhancer from 
incorrectly switching on the promoter or activating the wrong promoter (87, 88). 
Methylation of these specific sequences can cause upregulation of genes, 
acting through preventing this inhibition (183).  
Also within this region there are two other regulatory features, Ying Yang 1 
(YY1) binding site, a regulatory transcription factor and E2F1 binding site, a 
transcription factor, which have both been shown to be involved in cancer 
dysregulation, for example through suppression of tumour suppressor genes or 
other regulatory genes (184, 185). YY1 can either repress or enhance genes 
depending on which cofactors are recruited; for example, among the cofactors 
of YY1 are HDACs and the methyltransferase Enhancer of zeste homolog 2 
(Ezh2), which represses transcription, whilst histone acetyltransferases p300, 
cyclic adenosine monophosphate response element binding (CREB binding 
protein (CBP), and P300/CBP-associated factor (PCAF) all increase 
transcription (185). Furthermore, both CTCF and YY1 have been shown to 
interact in particular in X chromosome inactivation (186). This was further 
shown to be important where the binding sites for these two proteins were close 
together, and therefore they were able to be co-immunoprecipitated. Through 
this interaction, CTCF-YY1 suppressed Tsix, which promotes the imprinting of 
the X chromosome (187). The transcription factor E2F1 also has differing 
effects depending on its binding partners, although it is usually associated with 
control of transcription of genes involved in cell proliferation, differentiation and 
apoptosis (188).  
As a means to confirm the validity and accuracy of these findings with regards 
to the putative TNS3 promoter that was identified, data was also sought on this 
region through analysis using alternative programs. It was found that the 
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bioinformatics software employed by commercial organisations that 
manufacture gene promoter sequence constructs for functional analysis also 
identified the same region that we identified as a putative TNS3 gene promoter 
(website: www.switchgeargenomics.com). Therefore, from this in-depth 
bioinformatic analysis, as well as that of others, there was a high degree of 
confidence that this region had many traits of being a genuine functional gene 
promoter. Therefore, this was the region which was focussed on as the putative 
TNS3 promoter region, and was therefore subsequently analysed for functional 
and epigenetic characteristics.  
 
5.1.2. Identification of CpG islands related to the genes coding 
for human Tensin1, -2 and -4 
In addition to TNS3, similar bioinformatic analyses were conducted for the 
genes for the other Tensin family members so as to gain an insight into 
potential relationships in epigenetic control. For the human Tensin2 gene, 
TENC1 (ENSG00000111077), which lies on chromosome 12; there are a 
number of transcripts identified, which all start around the same site. Lying 
downstream of the first exons of these transcripts is a 1004 bp CpG island 
which contains a number of regulatory elements within it, namely binding sites 
for neuron-restrictive silencer factor (Nrsf), CTCF and c-Myc. Nrsf is a tissue 
specific transcription factor usually associated with neuronal development (189). 
c-Myc is most relevant in embryogenesis as well as in adult tissues with high 
proliferative activity; for this reason it is often found to be dysregulated in a 
favourable manner for cancerous cells (190). Interestingly, it has been shown 
that c-Myc is less able to bind to its binding motif if there is methylation present 
in the binding site (191). As Tensin2 was also shown to be downregulated in 
RCC patients (111), it was therefore of interest to investigate this region for 
methylation level in RCC. The human Tensin1 gene, TNS1, located on 
chromosome 2, also gives rise to a number of transcripts, including 3 full length 
transcripts which start at different locations. However, no CpG islands were 
present immediately upstream of the alternative first exons. However, around 
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8000 bp upstream, there are two small CpG islands of 412 bp and 361 bp 
length, separated by a 17 bp stretch, as with the TNS3 intragenic CpG island, 
and are therefore also likely to constitute practically one CpG island. However, 
unlike the island close to the TENC1 and TNS3 genes, no regulatory elements 
were apparent within this CpG island as identified by Ensembl. Therefore, it is 
unclear whether this region is involved in regulating transcription. In addition, 
another CpG island was found, located closer to exon 1 of transcript origin 
TNS1-013, which also was composed of two CpG clusters of 264 bp and 275 
bp length, separated by a 22 bp stretch. This region, however, also does not 
contain any currently defined regulatory elements. As neither of these CpG 
islands appear to have identified regulatory elements within them, it is therefore 
less clear as to whether these regions are a part of a promoter region or 
whether the CpG islands located nearby are the actual regulatory features 
required for transcription of the gene in question. On the other hand, the human 
Tensin4 gene, TNS4 (ENSG00000131746), located on chromosome 17; is 
currently thought to give rise to only 1 full-length transcript. However, no CpG 
island was located upstream of the gene’s predicted first exon, although one 
isolated regulatory element, a binding site for c-Myc, was identified upstream of 
the gene. Recent analysis of TNS4 found there to be strong promoter activity 
within a 327-bp region surrounding the first exon, which was strongest in non-
malignant prostate cells (192); this supports the observation that Tensin4 is 
most strongly expressed in the prostate. Furthermore, the same study identified 
through ChIP-seq analysis that RNA polymerase II bound TBP (TATA binding 
protein) and TAFI (TBP-associated factors) in the same region (192). Therefore, 
the human TNS4 gene appears to be regulated in a more traditional manner, 
through sequence-directed transcription complex regulation, rather than 
perhaps through CpG island regulation within the region. Taking these 
observations together on all four human Tensin genes, it is therefore likely that 
Tensin2 is the only other Tensin whose expression may be regulated by a CpG 
island, as the Tensin1 CpG island(s) are located at a much greater distance 
away than those for Tensin2 and -3, whereas the TNS4 gene appears to lack 
such CpG island regulation control altogether.  
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5.2. Functional activity of the putative TNS3 gene 
promoter 
Although bioinformatic analysis identified a region to study for the alternative 
methylation status analysis, it was unclear whether this region possessed 
functional gene promoter activity. Therefore, a functional assay was employed 
to ascertain this. A human cell line that endogenously expressed Tensin3, the 
SNB-19 glioma cell line, was selected to be used as a suitable model for 
expression, and western blot analysis confirmed natural expression of Tensin3 
protein in these cells. In addition, the non-cancer human kidney cell line HK2, 
was also chosen for the promoter analysis due to its relevance for the organ 
under study for this thesis, and as the Tensins are predominately expressed in 
the kidney (111). Although, the Tensin3 protein was not detected in these cells; 
it was nevertheless thought worthwhile to include these cells in the assay as 
luciferase expression may still be induced with the aid of the cells’ natural 
machinery.  
Three DNA fragments of roughly 500, 1000 and 2000 bp in length were 
obtained by PCR. These fragments encoded a stretch of the DNA sequence 
lying upstream of the TNS3 gene including exon 1 of transcript origin TNS3-
012; these were cloned into a luciferase reporter plasmid and the cloning 
verified by sequencing. The results of the luciferase reporter assay showed a 
significant minimal promoter activity to be present in the smallest fragment 
analysed, which contains the beginning of the CpG island but which lacks all of 
the aforementioned regulatory elements. Interestingly, the promoter activity was 
absent when the analysed sequence was extended to 1000 bp length; this 
indicates the possible presence of a repressor element or regulatory feature in 
this longer stretch, which has been observed in the past for other genes 
promoters (193). Bioinformatic analysis confirmed this indication, showing that 
there are indeed regulatory elements present within this longer sequence, in the 
form of a CTCF motif, which may account for the observed shutdown in reporter 
gene expression. Using such luciferase assay models, binding to such CTCF 
motifs has been shown to be responsible for the suppression of enhancer 
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function (194). However, the other regulatory elements identified, E2F1 and 
YY1 are also located in this 1000 bp fragment; therefore, it is less clear which 
regulatory element is responsible for the repression seen and/or how usage of 
these regulatory sites may be coordinated to produce an overall repressive 
effect as was seen with this 1000 bp stretch.  
Furthermore, the promoter assay showed that activity was then restored in the 
largest fragment analysed, of 200 bp length. The same pattern of sequence 
length dependence was also observed when analysing reporter expression in 
the HEK293 kidney cell line. Here too, positive expression was observed driven 
by the 500 bp fragment, which was then lost with the larger 1000 bp fragment. 
Interestingly, the 2000 bp fragment yielded a much greater expression than 
seen in the 500 bp. The restorative effect of the longest stretch could be due to 
inclusion of additional regulatory elements that together contribute an overall 
positive promoter function. Alternatively, they could have also uncovered a 
distinct promoter for another TNS3 transcript or even for another gene. The 
Ensembl database did not reveal any further known regulatory elements within 
this region; therefore, there could be as yet unidentified binding motifs which 
bring about the restoration of the expression seen. Another possible mechanism 
for the observation made is that the repression observed with the 1000 bp 
fragment left out important regulatory sequences which may provide more fine-
tuned regulation of Tensin3 expression. Moreover, the longer sequence may 
also provide an adequate secondary structure that could also play a role in 
concerted regulatory protein binding. More detailed molecular work is required 
to determine specifically which elements of the DNA fragments analysed are 
actively contributing to promoter activity or else suppressing it. One approach is 
site-directed mutagenesis, which could introduce single nucleotide changes in 
selected locations in the putative promoter, e.g. the CTCF, E2F1 or YY1 motifs, 
and alter them, resulting in altered reporter gene expression as compared to the 
wildtype sequence.  
In conclusion, this part of the study confirmed that the putative TNS3 gene 
promoter region identified, containing a CpG island within it, possesses 
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functional promoter activity and so was suitable for further study by methylation 
quantification.  
 
5.3. Quantitative methylation variations in the human 
TNS3 gene in RCC 
Subsequent to confirming reporter activity for the CpG island-containing DNA 
sequence close to the TNS3 gene, the pyrosequencing method was established 
and methodological workflow optimised, in order to analyse in quantitative detail 
the level of methylation present within this region. Using pyrosequencing 
analysis, the methylation status of up to 43 individual CpGs dinucleotides was 
determined over two clusters by two individual PCR reactions.  
Prior to the actual quantification of TNS3 promoter methylation in tumour 
samples from RCC patients, the pyrosequencing workflow itself required 
methodological validation. As a means to exploring the methylation detection 
range of the pyrosequencing, firstly pyrosequencing of a distinct portion of the 
TNS3 CpG island, designated “cluster 1”, in genomic DNA samples that were 
either highly methylated or showed negligible methylation was carried out. The 
results demonstrated the range and sensitivity of the pyrosequencing 
quantification to be broad and of a sufficiently high level, with a composite mean 
of 83±3.59% methylation detected in DNA from methyltransferase-treated DNA 
versus 0.87±0.29% in negligibly methylated DNA. Therefore, this result showed 
the method which was optimised and employed to possess an adequate degree 
of robustness and sensitivity for subsequent measurement of clinical samples, 
as it contained little or no methylation bias and could detect both high and low 
levels of methylation accurately.  
Subsequent analysis of RCC DNA samples showed that overall there was a 
significantly greater degree of TNS3 CpG island methylation in the RCC DNA 
compared to adjacent non-tumour kidney samples. In addition, the RCC 
samples also showed significantly higher methylation levels when compared to 
normal control DNA, and at a greater significance level than when comparing 
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with non-tumour samples. RCCs had a median methylation level of 5.3%, non-
tumour adjacent of 0.9% and normal control of 0%. These results therefore 
point to promoter hypermethylation as being a possible cause for the 
downregulation of TNS3 gene expression in RCC that has been previously 
reported (111).  
An additional advantage of the pyrosequencing approach to analysing DNA 
methylation was that it possessed the specificity and sensitivity to enable one to 
pinpoint specific locations, at the individual CpG dinucleotide level, where there 
might be more pronounced methylation differences. Indeed, it was found that 
the greater methylation in the tumour samples was mostly due to more 
pronounced increases in methylation of specifically two CpG dinucleotides in 
cluster 1, CpG 2 and CpG 8. These two dinucleotides were methylated at 
significantly higher levels than the remaining CpGs around them, indicating that 
these specific CpGs may play more significant roles in regulating Tensin3 
expression. Furthermore, this enhanced role could be due to their close 
proximity to the regulatory elements CTCF, YY1 and E2F1 and/or proximity to 
modified histone binding sites where chromatin remodelling can occur. Alternate 
methylation levels at specific sites within a region has also been observed in a 
number of other cases. One study on chromosome 21 showed that, although 
methylation was not strictly site-specific as not all samples analysed contained 
that methylation, the methylation distribution was not random and did show a 
pattern within the region, with some CpG dinucleotides consistently containing 
higher methylation levels than others (195). Similarly, a study of the GREM1 
gene CpG island in ccRCC revealed hypermethylation variability within specific 
regions (196). Although the study was carried out using MSP and therefore was 
not site-specific but region specific, it at least gave a sufficient overview of small 
regions within the CpG island to detect such differences. Furthermore, site-
specificity of methylation level has also been observed in pathological scenarios 
other than cancer; for example, genomic analysis of mice in behavioural models 
showed methylation levels to change only at a specific CpG dinucleotide that 
was part of a transcription factor start site (197).  
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Interestingly, IGFBP1 and IGFBP3 have both been shown to be epigenetically 
dysregulated in RCC (198). Both of these genes are also located on 7p12.3 and 
are believed to be part of a duplication event with TNS3, as indeed all four 
Tensin genes are located in close proximity to an IGFBP gene. It has previously 
been noted that genes which are located in close proximity to one another are 
often dysregulated together in cancer; this has been noted on chromosome 3 in 
RCC with the VHL and RASS1A genes (21).  
Furthermore, the increase in methylation level at CpG dinucleotide 2 in RCC 
samples was negatively correlated with Tensin3 mRNA expression in those 
tumours, i.e. the increase of methylation correlates to a decrease in mRNA 
expression. This therefore indicates that CpG 2 may play a particularly 
significant role in the epigenetically-driven downregulation of Tensin3 in RCC. A 
number of studies have shown that as age increases, so does the level of 
overall methylation, and this has been taken to explain the increase in cancer 
risk with increasing age (199-201). To determine whether the age of the patient 
is responsible for the increase in methylation seen between RCC tumour DNA 
compared with non-tumour DNA, the average overall methylation level of cluster 
1 for each patient was correlated with their ages. However, no significant 
correlation was observed (R=-0.515, P=0.086), suggesting that it is unlikely that 
the increase in methylation, at least of this region, is related to age.  
There are a number of ways that methylation is believed cause downregulation, 
one of which is by preventing transcription factor binding if the methylation 
occurs on the motif that normally binds that transcription factor. For example, it 
has been shown that methylation blocks binding of some transcription factors 
such as c-Myc (191). This mechanism has also been shown to be important in 
imprinted genes; for example, a study assessing Peg3 found that YY1 was only 
able to bind to the unmethylated motif located on the paternal allele (202). 
Within this study, the CpG dinucleotide within the YY1 binding motif had a 
median methylation of 2.07% and this methylated level did not correlate with 
Tensin3 expression (R=0.536, P=0.137). Another mechanism by which 
methylation is able to downregulate genes is by recruiting histone modifying 
enzymes to promote a heterochromatin state. Many proteins which bind to CpG 
179 
 
islands such as ZF-CXXC proteins also have histone modification functions, 
although these predominately bind to unmethylated DNA (203). However, 
proteins such as MeCP2, a transcriptional repressor, have been shown to bind 
to methylated DNA, as well as co-precipitating as part of a HDAC complex 
(204). Although inhibition with an HDAC inhibitor Trichostatin A (TSA) did not 
fully reverse the repression, MeCP2 was further shown to have specific histone 
methylation activities for H3K9 as well (205). There has also been speculation 
that the methylation state is not the direct cause of a transcriptional repression 
but a way of permanently marking the downregulation subsequent to, and as 
result of, chromatin modifications having occurred. In particular, some genes 
have been shown to be repressed before methylation has occurred, and the 
methylation has then been detected distinctly after the initial repression had 
been induced. For example, this has been observed for genes as part of X 
chromosome inactivation during embryogenesis, where one X chromosome in 
females is silenced. This appears to occur through the action of XIST, a non-
coding RNA. Although the main route for the downregulation is through 
chromatin modifications, this is followed by DNA methylation that permanently 
silences XIST on the maternal allele (206). Nevertheless, regardless of which 
mechanism predominates for regulation of a particular gene, there is no doubt 
that DNA methylation correlates with the downregulation of genes that are 
particularly in close proximity to the methylation sites.  
Further correlation analysis revealed no other clinicopathological parameter to 
significantly correlate with the increased methylation seen on these two CpG 
dinucleotides, including tumour grade or TNM staging. This could indicate that 
the methylation changes occurred early on in tumour development and played 
less of a role in tumour progression. However, this is a tentative conclusion to 
make, as any methylation changes would only indirectly affect these parameters 
through their more direct effects on Tensin3 expression, and so awareness is 
required of the multiple other molecular changes that take place to induce and 
drive tumour progression through stages of tumour cell migration and tumour 
metastasis.  
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To determine whether the methylation seen on CpG 2 plays a direct role in the 
downregulation of Tensin3 in RCC patients through inhibition of the promoter 
region, mutagenesis analysis is one approach to take, where the cytosine within 
this pair is mutated to a thymine and the gene regulation effect is then 
measured. However, as CpG 2 is located within the 1000 bp fragment studied in 
the luciferase reporter assay, which showed no promoter activity, a better 
starting point would be to utilise the longer, 2000 bp fragment that did drive 
gene expression. Subsequently, the effect of this mutated 2000 bp fragment is 
then analysed for luciferase expression as directly compared to the wildtype 
sequence fragment.  
 
5.3.1. Methodological considerations  
It is worth noting that BSP is unable to determine the difference between 5-mC 
and 5-hydroxymethylcytosine (5-hmC) (207). Oxidation of 5-mC by the Ten 
eleven translation enzyme (TET) family of proteins leads to 5-hmC, which 
appears to be important in demethylation of DNA (208). It is believed that 5-
hmC is an intermediate in a demethylation pathway, as shown in Fig. 102 (209).  
Fig. 102: The oxidation of 5-mC to 5-hmC, this can then be further oxidised by TET to 5fC and 
5caC which is then converted back to cytosine. This is one possible pathway involved in 
demethylation (209).  
 
Interestingly, the 5-hmC modification is more commonly present in cell types 
found in the brain as part of a normal process where 5-hmC is believed to be a 
stable epigenetic mark (210). Furthermore, 5-hmC loss has been associated 
with melanoma due to the loss of TET (211). If 5-hmC is only part of pathway to 
cause demethylation, then this loss would cause 5-mC to become more stable.  
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5.4. Evaluation of alternative methods for DNA 
methylation analysis 
Three methods were assessed MSP, EpiTect qPCR assay and BSP. The MSP 
technique has its benefits as it is cheap and quick; however it only gives an 
overview of a region, usually only targeting one or two CpG dinucleotides. It 
also assumes that the methylation state is black and white, i.e. that the region is 
either methylated or unmethylated, when in reality not all of the CpGs that are 
covered in the primer are going to be methylated and so there may be some 
primer mismatch occurring, giving an incomplete picture from primer bias. 
Therefore, in order to avoid this it is preferable for primers to anneal to one CpG 
dinucleotide. However, this then limits the information gained to only one CpG, 
whereas it may be the whole region that is of interest. The EpiTect methyl II 
qPCR technique is quantitative it still has some of the limitations of MSP, 
including the fact that the primers only provide information about a few CpGs. 
Another limitation of this technique is that the sequences of the primers for 
analysis were designed and supplied by the company that produced the 
reaction components (Qiagen). This means the exact target region including the 
number of targeted CpGs was unknown, and therefore, it may be targeting a 
region which has little or no methylation, whereas another region of the CpG 
island may be more relevant to study for methylation changes. On the other 
hand, BSP offers a much more quantitative solution of methylation detection 
than the alternative methods. However, it is entirely dependent on the bisulphite 
conversion reaction, which through its many steps denatures the DNA, causing 
strand breakages. Following the observations made in this study, this may be 
the possible cause for the suspected low yields and poor quality DNA after 
bisulphite conversion which was much lower than reported by the kit. However, 
as there was no accurate way of measuring this in this laboratory, as the 
nanodrop is unable to determine an accurate readout of this type of modified 
DNA due to artificially high DNA contraction readouts. This is mostly likely due 
to high 260/280 ratios, indicative of contamination possible from phenol, alcohol 
or salts. Therefore, it is hard to determine that this is the cause of the problems 
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that were had when analysing the patient samples compared to control 
samples. As the EpiTect qPCR assay does not involve the bisulphite conversion 
treatment, this would be a good alternative to both MSP and BSP, however it 
does not offer the same degree and accuracy level of quantitation as BSP. 
Furthermore, as the kit used is proprietary, therefore the exacted location of 
these CpG dinucleotides analysed was unknown. Therefore, although BSP has 
its failings, it was the best method that was used in this study to give a clear 
picture of the methylation differences in the TNS3 promoter region. 
 
5.5. Pharmacological demethylation of DNA to affect 
Tensin3 expression 
Having measured quantifiable methylation differences between human RCCs, 
non-tumour and normal DNA, the effect of pharmacological demethylation of 
this region on Tensin3 expression was then determined experimentally. 
Treatment of human kidney cells with 5-aza, produced a 2.5-fold increase in 
Tensin3 expression, which demonstrates that Tensin3 expression can be 
manipulated by exogenously altering the methylation status of the TNS3 
promoter. This effect appeared however to be cell-line specific, for example, the 
prostate cancer cell line DU145 initially appeared to show a change in Tensin3 
expression, but subsequent experiments did not show this trend. Furthermore, 
the kidney cancer cell line 786-O also showed no effect of 5-aza treatment on 
expression. Pyrosequencing analysis showed there to be very low levels of 
methylation within the TNS3 CpG island of the cell lines that did not respond to 
5-aza. SNB-19 cells also had negligible methylation levels as measured by 
pyrosequencing, and they also showed little response to 5-aza. This could be 
due to the nature of the methylation status of the CpG island closest to Tensin3, 
with the different cell lines having different methylation states. However, the 
HK2 and DU145 cell lines were not analysed by pyrosequencing analysis. 
Therefore, further analysis should be conducted into the methylation status of 
the TNS3 CpG island in different cell lines. Furthermore, the methylation status 
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in cancer cell lines may not reflect the real methylation status of primary 
tumours in vivo as the levels of methylation may be altered during 
immortalisation of these cell lines (212). However, this is still a good model to 
use for measuring gene expression after treatment in a human system.  
In addition, Tensin2 expression was also measured after 5-aza treatment in 
HEK293 cells as, as previously mentioned, there is also a CpG island in close 
proximity to the first exons of the full length Tensin2 transcripts. 5-aza induced 
an 8-fold increase in Tensin2 expression as detected by qRT-PCR, indicating 
that Tensin2 may also be regulated via epigenetic mechanisms. Thus, this also 
warrants further analysis of the regulation of the TENC1 gene in RCC patient 
samples.  
The 5-aza effect could be a direct one on the TNS3 promoter through the 
inhibition of the methyltransferase DNMT1 or through replacement of 
methylated cytosines after replication. Alternatively, the effect could be indirect 
as 5-aza is indiscriminate in targeting hypermethylation (75); for example, the 
agent could be upregulating another gene which in turn targets Tensin3 for 
upregulation. However, the fact that there was little change in expression in cell 
lines that had little methylation, as shown by pyrosequencing analysis, points to 
the 5-aza effect as being direct. Nevertheless, this observation, taken together 
with the evidence that the region is alternatively methylated compared to 
adjacent non-tumour and normal control DNA, does strongly suggest that 
hypermethylation could play a role in suppressing the expression of Tensin3 
during RCC tumourigenesis.  
 
5.5.1. Analysis of other pharmacological agents  
A number of antineoplastic agents were assessed for their effects on the kidney 
cancer cell line 786-O in terms of viability. Three of these agents, 
acetaminophen, temolozomide and etoposide, caused a decrease in cell 
survival. Acetaminophen is more commonly known as paracetamol in the UK. A 
previous study had shown that acetaminophen was able to decrease the 
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expression of Tensin2 and Tensin3 mRNA in liver slices (213, 214). Etoposide 
is a topoisomerase inhibitor which causes a high level of DNA damage 
complexing DNA topoisomerase II and DNA, and has also been shown to 
activate cell-cycle check points that should lead to apoptosis (215). As Tensin1 
and Tensin4 have been shown to be cleaved by caspases (117, 118), it is 
possible that Tensin3 also has this action and therefore, its expression may be 
altered after etoposide treatment. Temozolomide is a derivative of dacarbazine 
(an alkylating agent) and has been shown to be an effective treatment in 
glioblastoma (216). In a similar way to dacarbazine, Temozolomide causes 
alkylation of DNA in tumour cells as well as normal cells which are fast 
replicating, which causes their death. The expression of Tensin3 using RT-
qPCR should be assessed after treatment of these agents at sub-toxic 
concentrations to determine their effects on Tensin3 expression as a potential 
route by which they inhibit cancer cells. Furthermore other agents which have 
shown to upregulate other Tensins should also be assess as potential therapies 
which may also target Tensin3. For example, resveratrol, which has been 
shown to be chemopreventive, it is a phytoalexin and is found in certain foods 
such as the skin of red grapes (217), was shown to induce Tensin1 and 
increase cell adhesion as well as altering the cytoskeleton. Given that Tensin3 
is also involved in focal adhesion complexes with DLC1, resveratrol may also 
target Tensin3, this should be further investigated (218).   
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5.6. Conclusions and future study 
In conclusion, this study has identified a TNS3 gene promoter region through a 
combination of bioinformatic and experimental approaches. The bioinformatic 
approach identified a CpG island which contained within it a number of 
regulatory elements. Subsequent experimental analysis identified a minimal 
functional promoter activity within the shortest, 500 bp fragment, which contains 
the beginning of the CpG island, along with a positive promoter effect of the 
largest, 2000 bp, fragment, which may potentially house enhancer function. 
Although the exact cause of the suppression in the 1000 bp fragment is 
unknown, further study should be carried out into the role of regulatory elements 
located here, such as the CTCF binding motif.  
Following identification of the TNS3 promoter region, a number of methylation 
analysis techniques were assessed, and the workflow involving BSP with 
pyrosequencing was selected for the analysis of the patient samples due to its 
superiority over the other methods for quantitation and robustness. Analysis of 
the CpG island in this region showed hypermethylation in RCC samples 
compared with adjacent non-tumour kidney cortex and normal control samples; 
this therefore suggests an epigenetic cause for the downregulation of Tensin3 
seen in RCC. This increase in methylation was particularly prominent on two 
CpG dinucleotides, CpG 2 and CpG 8, with CpG 2 hypermethylation negatively 
correlating with Tensin3 expression. Further analysis should focus on whether 
this CpG dinucleotide is directly responsible for downregulation through 
affecting the promoter region. 
Along with the data from the demethylation treatment, which saw an increase in 
Tensin3 expression after pharmacological demethylation of cells, it is indicated 
that hypermethylation of the TNS3 gene promoter region could be playing an 
important role in the downregulation of Tensin3 that has been previously 
reported in RCC (111). Tensin3 is an important protein involved in focal 
adhesion complexes, and its dysregulation has been observed in many 
cancers. These expression changes go hand in hand with other studies 
unravelling the normal biological role of Tensin3, particularly its role in cell 
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migration and EMT. The general trend of results points to dysregulation of 
Tensin3 as leading to an increase in cancer cell metastasis. Tensin3 and focal 
adhesion complexes in general would make a good target for therapeutic 
agents, including those which target epigenetic mechanisms. Moreover, at least 
in kidney cancer, the need for greater knowledge is equally applicable to 
Tensin2, as it is also downregulated in RCC and it too has a related CpG island 
that could have variable methylation. Therefore, future studies should identify 
whether methylation in the Tensin2 promoter is also playing a role in the 
downregulation seen in RCC.  
In summary, the work in this thesis has resulted in the identification a novel 
TNS3 gene promoter through a combination of bioinformatic and experimental 
approaches. Analysis of the CpG island in this region showed hypermethylation 
in RCC samples compared with non-tumour samples, suggesting a novel 
epigenetic mechanism behind the downregulation of Tensin3 in kidney cancer.  
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